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Abstract 
 
Natural killer (NK) cells are a key component of innate immunity and have been implicated in 
determining the outcome of HCV infection in both genetic and functional studies.  The last two 
decades have seen significant advances in the understanding of NK cell regulation with the discovery 
of a multitude of activating and inhibitory receptors.  CD94:NKG2A operates in tandem with the 
polymorphic killer cell immunoglobulin-like receptors (KIR) and Ly49 systems to inhibit NK cells, 
however it is not clear as to the benefits of having two distinct inhibitory receptor:ligand systems.  
Down regulation or modification of MHC class I expression is a key feature of NK cell recognition of 
virus infected cells.  However, viruses can subvert this mechanism of NK cell surveillance by 
encoding peptides that can bind to MHC class I.  The aim of this thesis is to further our understanding 
of the interaction between viral and host derived MHC class I binding peptides and their effect on NK 
cell inhibition. 
By using an MHC deficient cell line, we have shown that HCV core35-44 peptide is capable of 
enhancing cell surface expression of MHC class I (HLA-C and HLA-E).  Although this peptide 
stabilises HLA-E, the HLA-E:HCV core35-44 complex alone is insufficient to inhibit at NKG2A positive 
NK cells.  However, in the presence of HLA-E binding MHC class I signal peptides, HCV core35-44 has 
a synergistic effect in suppressing the NKG2A
+
 NK cell population.  Peptides derived from other 
viruses such as EBV and HIV, and the stress related peptide derived from heat shock protein 60 also 
augment inhibition of NKG2A
+
 NK cells, but only when in the presence of MHC class I signal peptides.   
This augmentation is caused by recruitment of the non-signalling CD94 molecule to the immune 
synapse in the absence of its inhibitory signalling partner NKG2A.  Thus CD94 can function 
independently as an enhancer of inhibition.   
The augmentation of inhibition of CD94:NKG2A by non-inhibitory peptides, contrasts with antagonism 
of inhibition of KIR by low affinity peptide:MHC complexes.  We also show that KIR
+
 and NKG2A
+
 NK 
cells respond with differing stoichiometries to MHC class I down-regulation. Thus peptide selectivity 
and MHC class I sensitivity of natural killer cell receptors provides a rationale for the evolution of two 
distinct inhibitory systems for MHC class I. 
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Chapter 1. Introduction 
 
1.1 HCV infection 
 
Hepatitis C virus (HCV) is a burgeoning worldwide public health problem with an estimated 170 million 
people currently believed to be infected (Lavanchy, 2009).  This small enveloped positive-stranded 
RNA virus belonging to the Hepacivirus genus of the Flaviviridae family was first identified in 1989 as 
the infectious agent responsible for human non-A, non-B hepatitis (Choo et al., 1989).  Phylogenetic 
analysis has since revealed HCV as a rapidly mutating virus with six major genotypes (along with 
numerous subtypes) which vary by up to 30% in nucleotide sequence.   This heterogeneity may 
facilitate HCV to escape the host immune response with the majority (75-85%) of exposed individuals 
developing chronic infection.  Chronic HCV carries the associated risks of cirrhosis, liver failure and 
hepatocellular carcinoma and is the leading indication for liver transplantation in Western countries 
(Hoofnagle, 2002).  The current cornerstone of treatment for chronic HCV consists of pegylated 
interferon alpha and ribavirin.  However, a significant number of patients who receive treatment are 
not cured or experience serious side effects.  Two new direct acting antivirals -NS3/ 4A protease 
inhibitors - have recently been integrated into standard therapy with improved response rates but with 
exacerbation of adverse effects. 
The factors associated with HCV clearance are incompletely understood. It is widely accepted that 
HCV-specific T cell responses are crucial for the spontaneous resolution of acute HCV infection and 
long-term immunity (Day et al., 2002; Thimme et al., 2001).  The innate immune system primes this 
virus-specific adaptive immune response.  Indeed in chronic HCV many of the shortcomings seen in 
adaptive immunity may be related to deficiencies in innate immune cells.  It is understood that natural 
killer (NK) cells, dendritic cells (DC) and T cells communicate with one another via cytokines and 
direct cell-to-cell contact (Mailliard et al., 2003).  This interplay has prompted immense interest in the 
role of NK cells, which may represent an interface between the innate and adaptive immune system, 
in determining the outcome of HCV infection. 
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1.2 Natural Killer cells 
 
Natural killer (NK) cells are one component of the immune response associated with the outcome of 
HCV infection.  They were first described in 1975 as a lymphocyte subset capable of cytotoxicity 
against leukaemia cells in vitro without previous sensitisation (Kiessling et al., 1975).  These bone 
marrow derived large granular lymphocytes comprise 5-20% of peripheral blood mononuclear cells 
but make up a substantially greater proportion (30-50%) of lymphocytes in the liver (Corado et al., 
1997).  Human NK cells are defined by the presence of surface markers CD56 and/or CD16 (the low 
affinity receptor for IgG Fc) and are CD3 negative. In contrast to T and B cells, NK cells do not require 
priming, enabling them to provide early protection against tumour transformation and intracellular 
pathogens such as viruses (Biron et al., 1999).  Their receptors do not show germ-line rearrangement 
and are not clonally distributed.   
 
1.2.1 Mechanism for NK cell activity against target cells 
NK cells possess a number of mechanisms to wield their effector functions on target cells. They can 
mediate direct cytotoxicity via the release of preformed lytic granules and by surface expression of 
ligands that activate death receptors on target cells.  Furthermore, they are early producers of 
cytokines, predominantly of the T-helper 1 (Th1) type, which may exert a direct antiviral effect and 
shape downstream immune responses (Figure 1.1).   
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Figure 1.1. NK cell activity against target cells 
Natural killer (NK) cells have several potential effector mechanisms.  Degranulation of cytotoxic 
granules containing perforin, granzyme and sulphated proteogylcans results in direct cytotoxicity to 
target cells.  Additionally, NK cell surface upregulation of Fas ligand (FasL) and tumour necrosis 
factor related apoptosis inducing ligand (TRAIL) can trigger death-receptor mediated apoptosis in 
target cells.  NK cells are also an important source of cytokines, such as IFN-γ and TNF-α, which 
have a direct antiviral effect and induce the adaptive immune response. 
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Equipped with this potent arsenal, NK cells must be tightly controlled to enable them to provide host 
defence whilst avoiding autoreactivity against healthy cells.  Regulation of NK cell activity is achieved 
by a vast array of stimulatory, costimulatory and inhibitory receptors (Tables 1.1 and 1.2), signals 
from which are integrated to determine their activation status.  Activating receptors expressed on 
human NK cells include the C-type lectin receptors NKG2D and NKG2C/E, natural cytotoxicity 
receptors (NCR) NKp44, NKp30, NKp46, and CD16 (FC-γ-RIII), the low affinity Fc receptor which 
mediates antibody dependant cytotoxicity (ADCC) (Bauer et al., 1999; Oehler et al., 1978; Pende et 
al., 1999; Sivori et al., 1999; Vitale et al., 1998). 
 
Ligands for these activating receptors are frequently upregulated in viral infections and tumours; 
however, they can also be expressed habitually on healthy cells.  Therefore to prevent alloreactivity 
against normal cells, NK cells receive a dominant inhibitory signal from receptors for major 
histocompatibility complex (MHC) class I molecules which must be overcome before NK cells are 
activated. 
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Table 1.1. Inhibitory NK cell receptors and their ligands 
 
 
HLA, human leucocyte antigen; KIR, killer cell immunoglobulin-like receptor; CTLR, C-type lectin 
receptor; LIR/ILT, leucocyte immunoglobulin-like receptor/immunoglobulin-like transcript 
 
 
 
Table 1.2. Activating NK cell receptors and their ligands 
 
 
 
NCR, natural cytotoxicity receptor 
  
 Receptor Ligand 
KIR family 2DL1 Group 2 HLA-C 
 2DL2/3 Group 1 HLA-C 
 2DL5 Unknown 
 3DL1 Bw4 + HLA-B 
 3DL2 HLA-A3/A11 
CTLR family CD94:NKG2A HLA-E 
 NKR-P1A LLT-1 
LIR/ILT family LILRB1/ILT2/LIR1 HLA-A, -B, -C 
Others LAIR-1 Collagen 
 Siglec-7 Sialic acid 
 KLRG-1/ MAFA Cadherins 
 CEACAM 1 
 
CEACAM 1 
 Receptor Ligand 
NCR family NKp30 BAT-3 
 NKp44 Viral haemagglutinin 
 NKp46 Viral haemagglutinin 
CTLR family CD94:NKG2C HLA-E 
 CD94:NKG2E HLA-E 
 NKG2D MIC-A/B, ULBPs 
KIR family 2DS1 Group 2 HLA-C 
 2DS2 Group 1 HLA-C 
 3DS1 Bw4 + ?HLA-B 
 2DS3 Unknown 
 2DS4 HLA-Cw4 
 2DS5 Unknown 
 2DL4 HLA-G 
Others CD244 (2B4) CD48 
 CD16 IgG 
 CD266 (DNAM-1) CD112, CD155 
 CRACC CRACC 
 NTB-A NTB-A 
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1.2.2. NK cell subsets 
NK cells can be classified into two subsets depending on the level of cell surface CD56, CD56
bright
 and 
CD56
dim
, each with distinct phenotypic properties (Cooper et al., 2001).  CD56
dim
 NK cells express a 
moderate quantity of CD56 and represent the majority (>90%) of the peripheral blood NK cell 
population.  Compared to the CD56
bright
 population, CD56
dim
 NK cells express higher levels of killer 
cell immunoglobulin-like receptors (KIR) and CD16.  They also express a greater quantity of perforin 
and are regarded to have marked cytotoxic capacity.  In contrast CD56
bright
 NK cells express high 
surface density of CD56 and contribute up to 10% of circulating NK cell pool.  They are considered a 
less mature subset with the potential to differentiate into CD56
dim
 NK cells (Chan et al., 2007; 
Romagnani et al., 2007).  CD56
bright 
NK cells express a high level of the inhibitory receptor 
CD94:NKG2A and are generally KIR
-
and CD16
-
. The primary role of the CD56
bright 
NK cell fraction is 
believed to be cytokine production, enabling them to have an immunoregulatory role at sites of 
inflammation where this population may be expanded.  The functional distinction between these two 
subsets is not absolute; CD56
bright
 NK cells can express the degranulation marker CD107a, while 
CD56
dim
 NK cells can produce cytokines.  Indeed the total interferon gamma (IFN-ɣ) production from 
CD56
dim
 NK cells can exceed that of the CD56
bright
 population (Korbel et al., 2009).  Similarly 
CD56
bright
 NK cells are capable of cytotoxicity through the expression of TRAIL (Stegmann et al., 
2010). 
 
1.2.3. Role of cytokines in NK cell regulation 
 
Signals derived from activating and inhibitory receptors are integrated by the NK cell to ultimately 
determine their functional outcome.  However, a variety of cytokines such as IFN-α, IL-2, IL-12, IL-15, 
IL-18, Il-21 and IL-23 also play a role in NK cell development and function.   To enable cytotoxicity of 
a target to occur a number of coordinated processes need to happen. These include cell adhesion, 
synapse formation, granule polarization and granule exocytosis. The relative contributions of these 
signals to activate an NK cell may vary according to the target cell involved, and it is clear that there is 
interplay between cytokine- and receptor-mediated signalling. For instance the adaptor molecule 
DAP10, which transduces activating signals from NKG2D, is associated with the IL-15 receptor b- and 
c-chains and this adaptor molecule can be phosphorylated by the IL-15-receptor-associated Jak-3 
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kinase (Horng et al., 2007). This system therefore provides a proximal molecular link between 
cytokine and receptor-mediated NK cell activation, which may extend to other cell surface activating 
receptors.  IL-15 also plays an important role in NK cell development, promoting the differentiation of 
predominantly cytokine producing CD56
bright
 NK cells into cytotoxic CD56
dim
 NK cells (Huntington et 
al., 2009).  IL-12 increases NK cell IFN-ɣ production while IL-2 enhances NK cell cytotoxicity (Biron et 
al., 1999). 
 
1.2.4 “Missing-self” recognition, pathways to inhibition, and NK cell education 
 
The critical role of inhibition as a means of regulating NK cell function was determined following a 
series of cytotoxicity experiments using MHC class I-deficient targets (Karre et al., 1986). The results 
of these were synthesized in the landmark ‘missing-self’ hypothesis (Ljunggren and Karre, 1990).  In 
humans, MHC class I molecules comprise the classical human leukocyte antigen (HLA) HLA-A, -B, 
and –C (MHC class Ia), and the non-classical HLA-E, -F, and -G (MHC class Ib) molecules.  They are 
key regulators of NK cell activity that are expressed ubiquitously on healthy cells and provide NK cells 
with a means of identifying ‘self’.  Down-regulation or modification of MHC class I expression during 
viral infection, cellular stress or carcinogenesis releases the inhibitory signal to NK cells and permits 
their activation (Figure 1.2).  Several inhibitory receptors for MHC class I have now been identified. 
The KIR family and the lectin-like CD94:NKG2A receptor play the most prominent role in NK 
regulation by MHC class I.   These MHC specific receptors are also important for maturation of NK 
cells to a fully functional state in a process referred to interchangeably as 'licensing' or 'education' 
(Kim et al., 2005).  There are several proposed theories for NK cell licensing, including the ‘arming’ 
and ‘disarming’ models (Raulet and Vance, 2006).  The arming model proposes that, in the context of 
NK cell licensing, self-MHC inhibitory receptors serve similar functions to activating receptors 
providing positive signals that drive NK cell functional maturation (Yokoyama and Kim, 2006).  The 
disarming model proposes that to acquire functional capacity NK cells require balanced activation and 
inhibitory signalling.  In the absence of self-MHC class I recognition, NK cells are rendered anergic by 
dowregulation of unopposed activation receptor signalling pathways.  Therefore whilst these self-MHC 
receptors generate an inhibitory signal in the context of an effector response against targets, they 
emanate different signals to induce NK cell tolerance. 
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Figure 1.2. Receptor mediated regulation of NK cell activity and the “missing self” hypothesis 
(a) In the absence of ligands for inhibitory or activating NK cell receptors, there is no activation of NK 
cells.  Hyporesponsiveness is also seen in NK cells lacking inhibitory receptors for MHC class I which 
are necessary for NK cell education.  (b) Healthy target cells express a normal quantity of MHC class 
I that interacts with inhibitory NK cell receptors conferring protection against NK cell mediated lysis.  
(c) In viral infection or tumour transformation there may be upregulation of activating ligands, with 
downregulation of MHC class I, leading to NK cell activation.  (d) In the presence of activating and 
inhibitory ligands, NK cell activity is determined by signals integrated from activating and inhibitory 
signals.  
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1.3. KIR receptors 
 
Killer cell immunoglobulin-like (KIR) receptors are type I transmembrane glycoproteins expressed on 
NK cells, γδ T cells and a minority of CD8 αβ T cells (Uhrberg et al., 2001).  Encoded on chromosome 
19 (19q13.4), they represent a tremendously polymorphic group of receptors, showing diversity at 
both locus and allelic levels (Middleton et al., 2008; Wilson et al., 2000; Wilson et al., 1997). There are 
15 different KIR genes (13 expressed, KIR2DL1, KIR2DL2/L3, KIR2DL4, KIR2DL5A, KIR2DL5B, 
KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1/S1, KIR3DL2, KIR3DL3 and two 
pseudogenes, KIR2DP1 and KIR3DP1) expressed in a stochastic fashion to generate a repertoire of 
NK cells expressing different combinations of KIR in the same individual (Gardiner, 2008; Khakoo and 
Carrington, 2006; Robinson et al., 2013) (Figure 1.4).  Their ligands, HLA-A, -B, and –C molecules, 
are encoded on chromosome 6 and are equally polymorphic.  The rapid evolution and diversity of 
KIR/HLA genes supports the notion that they are subject to pathogen-mediated selection.  This theory 
is reinforced by the observation that KIR receptor-ligand interactions may influence the outcome of 
viral infections such as HCV and HIV (Alter et al., 2007a; Khakoo et al., 2004; Martin et al., 2007). 
 
1.3.1. KIR structure 
 
KIR can be subcategorized by their number of extracellular immunoglobulin domains, either two or 
three (‘2D’ or‘3D’), and by the length of their cytoplasmic tails, short or long (‘S’ or ‘L’) (D'Andrea et al., 
1995; Wagtmann et al., 1995).  In general, long cytoplasmic tails are associated with immunoreceptor 
tyrosine-based inhibitory motifs (ITIMs).  In contrast KIR members with a short cytoplasmic tail contain 
a charged lysine in their transmembrane domain, allowing association with the adaptor protein DAP-
12, consistent with an activating function.  Receptor nomenclature would therefore imply that KIR2DL 
is composed of two immunoglobulin domains (2D), with a long (L) intracytoplasmic tail and an 
inhibitory function.  The immunoglobulin domains, designated D0, D1 and D2, are the site of ligand 
recognition and can be used to further classify KIR receptors into three groups. Type I KIR2D 
receptors possess two immunoglobulin domains with a D1 and D2 conformation.  The structurally 
divergent Type II KIR2D receptors have two extra-cellular domain proteins with a D0 and D2 
conformation, where KIR3D receptors have three immunoglobulin domains (D0, D1 and D2) (Vilches 
and Parham, 2002).  Crystal structure analysis of KIR2DL2 and KIR2DL3 has revealed variations in 
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the orientation of the D1 and D2 domains (Boyington et al., 2000a; Maenaka et al., 1999b).  This 
difference in orientation may account for the higher avidity of KIR2DL2 compared to KIR2DL3 for HLA-C1 
ligands (Moesta et al., 2008).   Furthermore, the D1 and D2 domains contact the MHC class I molecule 
such that they overlap the C-terminal end of the bound peptide (Boyington et al., 2001).  This may 
explain the peptide sensitivity of inhibitory KIR, particularly at positions 7 or 8 of the peptide (Fadda et 
al., 2010). 
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Figure 1.3. Schematic diagram of how KIR diversity may influence NK cell function 
From (Cheent and Khakoo, 2009).  KIR diversity can impact NK cells at different levels.  Variations in 
gene content and allelic diversity at the KIR locus results in different individuals having variable 
numbers of activating and inhibitory KIR.  KIR are expressed stochastically on NK cells to generate a 
‘KIR’ repertoire, which varies among different individuals. The presence or absence of human 
leucocyte antigen (HLA) class I ligands for these KIR may further impact on this repertoire, and on the 
functionality of these KIR-expressing subpopulations in different individuals.  
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1.3.2. KIR ligands 
 
The various KIR receptors have discrete HLA ligands (Tables 1.1 and 1.2).  For example, KIR2DL1 
recognises HLA-C allotypes with a lysine at position 80 of the heavy chain (group 2 HLA-C, or HLA-
C2), whereas KIR2DL2 and KIR2DL3, which segregate as alleles of the same locus, recognise the 
remaining HLA-C allotypes with asparagine at position 80 (group 1 HLA-C; HLA-C1) (Keaney et al., 
2004; Mandelboim et al., 1996).  Although KIR2DL2 and KIR2DL3 bind the same ligands, there are 
subtle differences.  Disease association studies have shown that KIR2DL3 and HLA-C1, but not 
KIR2DL2, is protective against chronic HCV infection (Khakoo et al., 2004; Romero et al., 2008).  This 
observation may be supported by the finding that KIR2DL3 binds more weakly to its ligands than 
KIR2DL2, therefore permitting a lower threshold for NK cell activation (Fadda et al., 2010; Winter et 
al., 1998).  Whereas all HLA-C alleles encode KIR ligands, this is only the case for 46% of HLA-A 
alleles and 36% of HLA-B alleles (Parham et al., 2012).  KIR3DL1 binds HLA-B allotypes carrying the 
Bw4 motif (Cella et al., 1994; Gumperz et al., 1995), while no KIR have been shown to bind to the 
alternative motif, Bw6.  KIR3DL2 binds to HLA-A3 and HLA-A11 allotypes in a peptide specific 
manner (Dohring et al., 1996; Hansasuta et al., 2004).  KIR2DL4, the only activating KIR receptor with 
a long tail, binds the non-classical MHC class I molecule HLA-G (Ponte et al., 1999). 
 
1.3.3. Evolutionary aspects of KIR/ MHC class I 
 
Simian primates and rodents utilise structurally diverse, distinctly evolved but functionally similar KIR 
and Ly49 as their receptors for polymorphic MHC class I molecules (Parham, 2008).  Although KIR-
like sequences have been found recently in ungulates and other mammals, cattle are the only non-
primate species to have a diversified family of KIR (McQueen et al., 2002).  Phylogenetic analysis 
suggest that KIR genes evolved in mammals from the ancestral KIR3D gene that duplicated to form a 
common ancestor of the 3DL gene and 3DX gene (Guethlein et al., 2007).   In humans KIR3DL 
expanded rapidly, most likely driven by highly diversified MHC class I molecules and pathogen 
selection, whereas KIR3DX became redundant.  Meanwhile, cattle diversified the KIR3DX gene while 
retaining a single copy of the KIR3DL gene.  Few KIR remain orthologous in primates, the exception 
being 2DL4, which is present in humans, apes and monkeys (Sambrook et al., 2006). 
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The MHC class I molecule HLA-C is more recently evolved than its HLA-A and -B counterparts and 
likely diversified from an HLA-B- like ancestor possessing the C1 epitope (Moesta et al., 2009).  
Indeed HLA-C has evolved to be a more specialized ligand for KIR, as evidenced by the observation 
that all HLA-C allotypes can serve as KIR ligands, compared to only a fraction of HLA-A and B 
allotypes (Parham et al., 2012).  
 
 
A unique feature of the human KIR is the segregation into two groups of KIR haplotype, designated 
groups A and B.  Haplotype A is enriched for inhibitory KIRs, whereas B haplotype is more varied and 
is distinguished by the accumulation of genes encoding activating KIR receptors (Uhrberg et al., 
1997).  All human populations possess both A and B haplotypes, suggesting that they have balancing 
functions.  Selection for KIR A haplotypes may be important for the successful outcome of viral 
infections.  For example, KIR2DL3, an A haplotype allele, is protective against chronic HCV infection, 
whereas KIR2DL2, a B haplotype allele, is not (Khakoo et al., 2004).  In addition to their importance 
immune defence, NK cells have a key role in reproductive health.   Haplotype B selection may confer 
reproductive success, as evidenced by mothers who lack this haplotype (AA genotype) having higher 
rates of preeclampsia and miscarriage, particularly if the foetus expresses HLA-C2 (Hiby et al., 2008; 
Hiby et al., 2004).  Such disorders of pregnancy have been linked with insufficient uterine invasion of 
the foetal trophoblast cells, a process that is guided by activated uterine NK cells from the mother. 
Thus activating KIR associated with the KIR B haplotype may be beneficial for promoting better 
placental development, thus maintaining selection of this group of alleles. 
 
 
1.4. CD94 and NKG2 members 
 
CD94 is a type 2 transmembrane glycoprotein belonging to the C-type lectin-like receptor (CTLR) 
family, which includes the inhibitory subunit NKG2A (which has a splice variant NKG2B) and the 
activating subunits NKG2C, NKG2E, and NKG2D.  The genes for this family are encoded in the NK 
cell receptor complex on chromosome 12p13 (Plougastel and Trowsdale, 1998).CD94 exists on the 
cell surface primarily in a heterodimeric form with either NKG2A/C or E.  NKG2D is somewhat distinct 
to the other CTLR molecules, operating as a homodimer.  Whereas CD94/NKG2 bind the non-
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classical MHC molecule HLA-E, human NKG2D recognises stress-induced and tumour ligands such 
as MHC class I-related chain A (MICA), MICB and UL-16 binding proteins (ULBP) 1-5 (Bauer et al., 
1999). 
 
1.4.1. CD94:NKG2A structure 
 
CD94:NKG2A is a heterodimeric inhibitory receptor consisting of two C-type lectin subunits, CD94 (30 
kDa) and NKG2A (43 kDa), linked by disulphide bonds (Lazetic et al., 1996).  Typical C type lectins 
are defined by their binding to carbohydrates in a Ca
2+
 dependent manner.  In contrast CD94:NKG2 
molecules lack these Ca
2+ 
binding residues and therefore do bind carbohydrates (Day, 1994).  CD94 
also lacks one of two alpha helices known to be present in C-type lectins (Boyington et al., 1999).  
Instead of an a2 helix, CD94 possesses a long unstructured loop region that makes extensive 
intramolecular interaction with its counterpart.  Although CD94 can exist as a homodimer, its preferred 
assembly is as a heterodimer with an NKG2A/C or E molecule (Boyington et al., 1999).  This is partly 
explained by the fact that CD94 lacks signalling capacity as it does not possess a cytoplasmic tail, 
unlike NKG2A which has an ITIM containing cytoplasmic domain, and NGK2C/E which harbour the 
ITAM-containing adaptor protein DAP-12 conferring an activating function.   
 
The structure of CD94:NKG2A interacting with HLA-Epeptide has been recently determined (Kaiser et 
al., 2008; Petrie et al., 2008). On binding with HLA-Epeptide, no structural rearrangement of 
CD94:NKG2A is observed, indicating that a lock and key mechanism is used. The CD94 subunit 
forms the majority of the interactions with HLA-E. The peptide contributes 23% of the interface 
between receptor and ligand.  CD94 remains dominant (80%) in the interaction with the peptide, 
making contact with P5, P6, and P8 residues whereas the NKG2A moiety only interacts with the P5 
residue (Petrie et al., 2008).  Thus CD94 may be crucial to interacting with ligand, while NKG2A 
serves to provide signalling capacity to the receptor.  This theme is covered in greater detail in 
Chapter 4. 
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1.4.2. CD94:NKG2A ligand 
 
Compared to KIR, CD94:NKG2A is relatively non-polymorphic as is its ligand, the MHC class Ib 
molecule HLA-E.  HLA-E is expressed on virtually all healthy cells but at lower levels than MHC class 
Ia molecules (Braud et al., 1999).  Its cell surface expression requires specific nonameric peptides 
derived from the leader sequence (amino acids 3–11) of MHC class Ia molecules HLA-A, -B and –C, 
and the MHC class Ib molecule HLA-G (Braud et al., 1998; Llano et al., 1998).  HLA-E is unable to 
bind its own leader peptide; therefore HLA-E expression reflects the presence of the other MHC class 
I molecules, and the capacity of the cell to process and present antigen (Hoare et al., 2008).  Only two 
variants of HLA-E have been described, HLA-E
R
 and HLA-E
G
, differing only at one amino acid 
position with either an arginine or a glycine at position 107, respectively (Strong et al., 2003).  This 
system enables NK cells to observe the presence of a diverse panel of polymorphic MHC-class I 
molecules using a single, highly-conserved receptor-ligand combination.  The affinity and kinetics of 
CD94:NKG2A/ HLA-E interaction are very similar to those seen between certain KIR receptors and 
their MHC class I ligands, characterised by remarkably fast association and dissociation rates and 
relatively weak affinities for MHC class I (Vales-Gomez et al., 1999; Vales-Gomez et al., 1998). 
 
1.4.3. CD94 evolution 
 
CD94:NKG2A has been conserved throughout evolution, with functional equivalents present in mice 
and primates (Shum et al., 2002; Vance et al., 1999).  There are several benefits offered by the 
CD94:NKG2A receptor system.  As the vast majority of NK cells express CD94:NKG2A, the presence 
of this highly conserved receptor:ligand pairing may safeguard against alloreactivity in face of the 
highly polymorphic KIR:HLA system.  Furthermore, CD94:NKG2A provides a constancy of NK cell 
education as determined by response to an MHC deficient target compared to the variability of KIR 
education (Yawata et al., 2008).  CD94 also plays a crucial role in the protection against mousepox, a 
lethal viral infection in mice (Fang et al., 2011).   
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1.5. MHC class I 
 
MHC class I molecules were acknowledged as potential ligands for NK cell receptors following the 
discovery that target cell susceptibility to NK cell mediated lysis was inversely related to the level of 
MHC class I expressed by the target cell (Karre et al., 1986; Storkus et al., 1989).  Subsequent 
studies revealed the existence of multiple NK cell receptors that recognised distinct MHC class I 
ligands.  NK cells expressing “p58” molecules (58kDa proteins later identified as KIR2DL members), 
were shown to specifically interact with HLA-C (Ciccone et al., 1992; Moretta et al., 1993).  
Transfection of HLA-Cw3 into an MHC deficient P815 murine cell line protected these cells against 
p58
+
 NK cell lysis.  However, transfection with other MHC class I alleles (HLA-A molecules) did not 
confer protection.  Moreover, NK cells expressing receptors other than p58 still lysed HLA-Cw3 
transfected targets.  It is now accepted the various KIR receptors bind distinct HLA-A, -B and –C 
molecules, whereas the relatively conserved CD94:NKG2A receptor binds to HLA-E. 
 
All functional MHC class I molecules are heterotrimeric complexes consisting of a polymorphic MHC-
encoded heavy chain, a non-MHC-encoded light chain called β2-microglobulin and a short peptide 
fragment comprising 8-10 residues (Marsh et al., 2000; Schumacher et al., 1990; Townsend et al., 
1989).  In healthy cells, these tightly bound peptides are derived from a variety of intracellular proteins 
that are degraded by cytosolic proteases leading to the generation of an array of self peptides (Figure 
1.4).  MHC class Ia molecules (HLA-A, -B, and –C) bind a highly diverse group of peptides, in contrast 
to HLA-E which predominantly binds a restricted set of peptides derived from the leader sequence of 
MHC class Ia molecules and HLA-G  (Braud et al., 1997; Braud et al., 1998; Lee et al., 1998).  The 
peptides are translocated to the endoplasmic reticulum via ATP-dependent transporter associated 
with antigen processing (TAP) molecules where they associate with assembling MHC-class I to form a 
stable complex which can then be expressed at the cell surface.  Each MHC-class I molecule is 
capable of binding a different peptide, leading to the presentation of a broad range of self peptides at 
the cell surface.  Utilising their α/β T cell receptor (TCR), cytotoxic T lymphocytes (CTL) are able to 
survey a cells cytoplasmic contents via MHC-class I, monitoring for the presence of non-self peptides.  
In viral infections, the peptide repertoire of MHC-Class I may change as viral proteins are degraded in 
the cytosol (Hickman et al., 2003; Meiring et al., 2006).  Presentation of viral peptides by MHC class I 
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may therefore represent an important mechanism by which CTLs identify virus infected cells.  
However, such peptide-MHC complexes can also influence NK cell activity. 
 
Each MHC class I molecule has a strict preference for the peptide sequence it will bind.  There are 
key residue positions that anchor the peptide to MHC class I, therefore alterations to the peptide 
sequence can promote or interfere with binding to the MHC class I molecule.  However, both KIR and 
CD94:NKG2A recognition of MHC class I is also sensitive to the particular peptide bound to the class 
I molecule.  Consequently not all MHC class I bound peptides will be recognised by NK cell receptors. 
 
 
 
 
 
Degradation of cellular contents by cytosolic proteases, such as the multicatalytic proteasome 
complex, leads to the generation of a variety of self peptides.  These peptides are translocated from 
the cytoplasm into lumen of the endoplasmic reticulum (ER) by a transporter associated with antigen 
processing (TAP) dependent mechanism.  Here they bind to a complex of β2-microglobulin and MHC 
class I heavy chain to form a stable complex which then leaves the ER via the secretory pathway to 
reach the cell surface.  Adapted from O’ Callaghan, (2000). 
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Figure 1.4. Peptide loading onto MHC class I 
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1.6. NK cells and viruses 
 
Although NK cells were first described on the basis of their anti-tumour functions, they play a central 
role in defence against pathogens, particularly viruses (Brandstadter and Yang, 2011).  NK cell 
deficiencies have been reported in individuals with human cytomegalovirus (HCMV), Epstein Barr 
virus (EBV), Human immunodeficiency virus (HIV), Hepatitis B virus and Hepatitis C virus; however, it 
is often difficult to establish whether such deficiencies are a cause or consequence of infection 
(Bonavida et al., 1986; Corado et al., 1997; Dunn et al., 2009; Merino et al., 1986).  Mice that are 
depleted or deficient of NK cells have increased susceptibility to herpes simplex virus (HSV), murine 
cytomegalovirus (MCMV), cocksakie virus and influenza (Bukowski et al., 1984; Godeny and Gauntt, 
1987; Habu et al., 1984; Stein-Streilein and Guffee, 1986).  The crucial role of NK cells in viral 
infections is perhaps best illustrated by a small number of individuals in whom NK cells are absent.  
For example, a longitudinal follow-up of a female patient with an isolated deficiency affecting NK cells 
demonstrated recurrent severe herpesvirus infections, including varicella zoster, human 
cytomegalovirus (HCMV) and herpes simplex virus (HSV) (Biron et al., 1989).  Thus, the critical 
function of NK cells in viral infections is unequivocal, and is further supported by the various strategies 
viruses have evolved to subvert NK cell immune surveillance (Figure 1.5). 
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Figure 1.5. Viral mechanisms for evading NK cells 
The strategies by which viruses evade NK cells fall into five categories and are depicted in the 
interaction between a virus infected target cell (left) and an NK cell (right). (a) NK cells can be 
inhibited by a viral MHC class I homologue with structural similarity to endogenous host class I that 
binds to inhibitory class I receptors on NK cells. (b) Viruses can inhibit expression of HLA-A and HLA-
B, resulting in a relative increase in HLA-C and HLA-E on the surface of the target cell; these inhibit 
NK cells through the class I inhibitory receptors CD94:NKG2A and KIR, respectively. Alternatively, 
viral gene expression can result in selectively increased expression of HLA-E, which inhibits NK cells 
through CD94:NKG2A. (c) Virus-encoded proteins can function as cytokine binding proteins that block 
the action of NK cell activating cytokines. In addition, viruses can produce homologues, or increase 
host production of cytokines that inhibit NK cells. (d) NK cell activities can also be avoided by 
decreased expression of NK cell−activating ligands in virus-infected target cells, which prevent signal 
transduction via NK cell−activating receptors. To achieve the same end, viruses can encode 
antagonists of the activating receptor−ligand interaction. (e) Viruses can also directly inhibit NK cells 
by infecting them or using envelope proteins to ligate NK cell inhibitory receptors. Proteins outlined in 
red are virally encoded.  From Orange et al, (2002). 
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1.6.1 NK cells in HIV infection 
 
Emerging evidence from both in vitro and animal studies demonstrate the importance of NK cells in 
limiting viral activity during the early stages of human immunodeficiency virus (HIV)-1 infection (Alter 
and Altfeld, 2009; Alter et al., 2007b).  This role is emphasised by the influence of variegated KIR on 
the outcome of HIV infection.  Martin et al. provided the first demonstration of the role of KIR 
polymorphisms in determining the outcome of a viral infection when they reported that the activating 
receptor KIR3DS1 in combination with HLA-B alleles that have the Bw4 serological epitope with 
isoleucine at position 80 (HLA-Bw4
80I
) were associated with a delayed progression of HIV infection 
(Martin et al., 2002).  More recently, it has been shown that inhibitory KIR/HLA incompatibility 
between sexual partners confers protection against HIV-1 transmission possibly due to alloreactive 
NK cells from the exposed partner killing KIR ligand-mismatched target cells from an HIV-1 infected 
partner (Jennes et al., 2013).  NK cells can suppress HIV replication through direct cytotoxic activity 
against infected cells as well as the production of anti-viral cytokines such as IFN-γ. Consistent with 
this, exposed uninfected individuals exhibit greater in-vitro NK cell cytotoxicity and IFN-γ production 
(Ravet et al., 2007; Scott-Algara et al., 2003).  However, HIV appears to have the ability to escape NK 
cell immune responses (Alter et al., 2005; Fogli et al., 2004; Kottilil et al., 2003; Nattermann et al., 
2005b).  NK-cell cytotoxicity and cytokine secretion are impaired during chronic HIV infection, but 
these deficiencies likely occur earlier in the course of infection (Naranbhai et al., 2013).  Most studies 
assessing immune responses in HIV infection compare infected individuals with an uninfected control 
group of individuals.  Naranbhai et al. (2013) analysed samples from 41 high-risk heterosexual 
women enrolled in a randomised controlled trial of Tenofovir microbicide gel.  Paired samples were 
collected from initially HIV-uninfected individuals prior to HIV acquisition, and during viraemic acute 
HIV-1 infection.  They demonstrate that NK cells are activated during acute HIV-1 infection with IFN-γ 
production correlating with viral load.  Alter et al. report an initial expansion of NK cells during acute 
HIV-1, particularly of the cytotoxic CD56
dim
 subset that may account for the early fall in viraemia.  An 
increase in KIR
+ 
but not NKG2A
+ 
NK cells is observed during acute HIV infection which suppresses 
NK cell cytotoxicity compared to the KIR
-
 population (Mavilio et al., 2003; Naranbhai et al., 2013).   
 
In chronic HIV infection there is an expansion of a functionally defective CD56
-
 CD16
+
 NK cell subset 
with an associated reduction in both the CD56
bright
 and CD56
dim
 NK populations (Alter et al., 2005; 
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Mavilio et al., 2005; Mavilio et al., 2006).  HIV also targets MHC class I expression to escape 
recognition by CTLs while maintain protection against NK cells.  For example the HIV protein Nef 
selectively targets HLA-A and HLA-B, while leaving HLA-C and HLA-E relatively intact (Bonaparte 
and Barker, 2004; Cohen et al., 1999; Williams et al., 2002).  Consequently, NK cells expressing 
KIR3DL1 are more likely to be released from inhibition by HIV-infected targets than are NK cells that 
express other inhibitory receptors, or even NK cells expressing KIR3DL1 in combination with an 
inhibitory receptor for HLA-C.  There is also greater complexity at the HLA-B locus for the Bw4-
positive allotypes and KIR3DL1.  Different KIR3DL1 alleles are expressed on the cell surface in 
varying quantities and individual KIR3DL1 allotypes bind to diverse HLA-B allotypes with different 
avidities.  The clinical correlate of this observation is that in HIV infection KIR3DL1 alleles that are 
expressed at high levels confer the greatest protection (Martin et al., 2007). 
 
Blocking the interaction between HLA-C and -E and their corresponding KIR and CD94:NKG2A 
inhibitory receptors increases NK cell killing of CD4
+
 T cells infected with HIV strains that reduce MHC 
class I expression (Bonaparte and Barker, 2004).  However, HIV may potentially modulate 
CD94:NKG2A mediated NK cell regulation by encoding for a peptide that increases HLA-E 
expression.  Peptide HIVp24 aa14-22 (AISPRTLNA; HIVp2414-22) is a well recognised T cell epitope 
that was identified using a motif based approach at a potential ligand for HLA-E (Nattermann et al., 
2005b).  Nattermann et al. (2005b) showed that HIVp2414-22 increased cell surface HLA-E expression 
leading to a subsequent inhibition of cytotoxicity of an NKL cell line via the CD94:NKG2A receptor.  
Furthermore, this study demonstrated that lymphocytes from HIV infected individuals have a 
significantly greater expression of HLA-E compared to healthy control lymphocytes, and that in-vitro 
infection of PBMCs with HIV-1 leads to an increase in HLA-E expression protecting these cells from 
NK cell mediated lysis despite down-regulation of classical MHC class I molecules.  Thus, increased 
cell surface HLA-E on HIV-infected cells may play a part in the immune escape from NK cell 
surveillance. 
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1.6.2. NK cells in CMV infection 
 
Human Cytomegalovirus (HCMV), a double stranded DNA virus belonging to the β-herpesvirus family, 
is highly prevalent in humans.  Seropositivity detected in up to 80% of UK adults and potentially 
higher prevalence in the developing world (Vyse et al., 2009).  Infection is usually acquired at a young 
age and the majority of immunocompetent hosts are asymptomatic (Jost and Altfeld, 2013).  
However, reactivation of latent CMV infection is a significant cause of morbidity and mortality following 
solid organ and haemopoetic transplantation, immunosuppressive treatment and acquired immune 
deficiency syndrome (AIDS).  Reactivation or acquisition of infection in pregnancy is a major cause of 
congenital CMV which may result in sensorineural deafness and developmental delay.  Most of the 
animal models to assess CMV infection have used murine CMV (MCMV), a closely related virus 
sharing approximately 50% homology to HCMV.  Both MCMV and HCMV have evolved a number of 
mechanisms to escape NK cell recognition of infected cells.  For example, CMV can down-regulate 
ligands for the NK cell activating receptor NKG2D.  In mice, the ligands for NKG2D include the stress 
induced molecules RAE-1, MULT1 and H60 (Diefenbach et al., 2000).  The MCMV proteins m152, 
m145 and m155 down-modulate expression of RAE-1, MULT1 and H60, respectively (Arapovic et al., 
2009; Krmpotic et al., 2005; Lodoen et al., 2004).  The human NKG2D ligands, MICB, ULBP-1 and 
ULBP-2 are down-regulated by the HCMV glycoprotein UL16, whilst UL142 reduces expression of 
MICA (Ashiru et al., 2009; Bacon et al., 2004; Cosman et al., 2001; Wills et al., 2005).  Thus, 
attenuated expression of NKG2D ligands mediated by CMV may impair NK cell activation and 
cytolytic activity against infected cells.  
 
HCMV can also interfere with signalling at the NK cell inhibitory receptors CD94:NKG2A and LILRB1 
(ILT-2). The HCMV UL40 glycoprotein contains a nonameric peptide, VMAPRTLIL, which is an exact 
homologue to an HLA-E binding HLA-C derived leader peptide.   This peptide therefore increases cell 
surface HLA-E expression leading to inhibition of CD94:NKG2A
+
 NK cells (Tomasec et al., 2000; 
Ulbrecht et al., 2000).  HCMV also possesses the glycoprotein UL18, a viral mimic of MHC Class I 
that can bind to β2m (Beck and Barrell, 1988). Cell surface UL18 binds to LILRB1 with greater affinity 
compared to MHC Class I, thus inhibiting activation of NK cells expressing this receptor (Chapman et 
al., 1999; Cosman et al., 1997; Prod'homme et al., 2007). 
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One of the most consistent findings in CMV infection is an expansion and persistence of NKG2C
+
 NK 
cells (Beziat et al., 2012; Foley et al., 2012; Guma et al., 2004; Guma et al., 2006; Lopez-Verges et 
al., 2011).  The activating receptor NKG2C is expressed in under 2% of HCMV seronegative 
individuals, compared to up to 25% in those with positive HCMV serology (Guma et al., 2004; Guma 
et al., 2006).  This NKG2C
+
 subset represent a more differentiated phenotype as evidenced by the 
acquisition of the maturation marker CD57, KIR positivity, and the absence of the inhibitory receptor 
NKG2A (Della Chiesa et al., 2012; Foley et al., 2012; Lopez-Verges et al., 2011).  Foley et al. (2012) 
also demonstrate this specific NK-cell subset persists and expands on HCMV reactivation, while a 
similar memory has also been observed in Ly49 expressing NK cells in MCMV infection (Sun et al., 
2009).  Thus, at least in CMV infection, there is evidence that NK cells develop a memory phenotype 
previously thought to be specific to adaptive immune cells.  NKG2C acquisition is therefore likely 
represents a protective host response to CMV infection.  However, the precise mechanism by which 
NKG2C
+
NK cells recognises HCMV has yet to be elucidated.  NKG2C binds HLA-E with a six-fold 
lower affinity that its inhibitory counterpart NKG2A (Kaiser et al., 2005), and at present an HCMV-
encoded protein that directly binds NKG2C has not been identified.   
 
 
1.7. NK cells in the liver 
 
The liver is enriched in NK cells.  This intrahepatic NK cell population embedded in the endothelial 
lining of the liver sinusoids were originally termed ‘pit cells’ (Wisse et al., 1976).  These are large 
granular lymphocytes that are capable of spontaneous cytotoxicity against an MHC deficient cell line 
without prior sensitisation, a defining NK cell characteristic (Bouwens et al., 1987; Kiessling et al., 
1975).  They contain distinctive granules and, uniquely, rod-core vesicles (Kaneda and Wake, 1983). 
They can be sub-classified based on the density and size of their granules which are either low-
density and small or high-density and large, with NK cells expressing the latter resembling peripheral 
blood NK cells.  It has been shown in rats that peripheral blood high-density large granular cells 
migrate to the liver and differentiate into liver specific low-density small granular NK cells 
(Vanderkerken et al., 1993). 
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Intrahepatic NK cells may behave differently to NK cells in other areas due to the tolerogenic 
environment in the liver.  Murine intrahepatic NK cells are hyporesponsive.  They are less cytotoxic 
and have an altered cytokine profile producing lower levels of IFN-γ and greater levels of 
immunoregulatory cytokines, such as IL-10, compared to peripheral blood and splenic NK cells 
(Lassen et al., 2010). This hyporesponsive state has been described in the early stages of hepatitis B 
virus infection and may contribute to the establishment of chronic infection (Dunn et al., 2009). 
 
In addition to their role in protection against pathogens and tumour transformation, intrahepatic NK 
cells have been demonstrated to have anti-fibrotic functions via inhibition of hepatic stellate cells 
(HSC). They are capable of directly inducing HSC apoptosis, and producing IFN-γ which inhibits HSC 
activation (Baroni et al., 1996; Melhem et al., 2006; Notas et al., 2009).  Moreover, greater levels of 
peripheral blood NK cell cytotoxicity have been associated with less liver fibrosis in patients with 
chronic HCV, consistent with the lysis of activated hepatic stellate cells (Morishima et al., 2006). 
 
1.7.1. NK cells in acute HCV infection 
 
NK cells have been recently been implicated in the acute phase of HCV infection.  Nowadays, these 
patients rarely come to the attention of clinicians as they are frequently asymptomatic and therefore 
do not seek medical assistance.  Amadei et al. reported an increase in CD56
bright
 NK cells (with 
associated reduction in CD56
dim
 subset) in acute HCV patients compared to healthy individuals 
(Amadei et al., 2010).  Individuals who spontaneously cleared the virus show a decline in the 
CD56
bright 
population, with levels comparable to healthy control individuals after 1-3 months, indicating 
a return to baseline which is not observed in those who progressed to chronic infection.  Expression 
of the activating receptor NKG2D is also increased in the acute phase of infection.  Functional 
experiments show augmented IFN-γ production and cytotoxicity in these patients and a trend for more 
NK cell degranulation in individuals expressing HLA-C1 specific KIR receptors, which is maximal in 
those with self-limiting infection.  Thus in the acute phase of HCV infection there is activation of NK 
cells indicating their role in the immune response at this stage (Figure 1.6).  Pelletier et al. have also 
studied individuals in the acute phase of HCV infection (Pelletier et al., 2010).  They also found 
increased activity of NK cells in the acute phase of infection, as determined by a degranulation assay.  
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However, they show that the NK cells from intravenous drug users have generally lower levels of IFN-
γ secretion compared to healthy control NK cells, postulating this may be connected to opioid use. 
They demonstrated that the quantity of the inhibitory receptor NKG2A declined on CD56
bright
 NK cells 
during the follow-up phase only in spontaneously resolvers.  Moreover, they were able to correlate NK 
cell activity with T cell activity, implying a co-ordinated innate and adaptive immune response to HCV 
in the acute phase of infection.  Thus there is activation of NK cells in the acute phase of HCV 
infection which declines in those clearing HCV and persists in those remaining chronically infected. 
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Figure 1.6. NK cells in acute HCV infection 
As a component of the innate immune system, natural killer (NK) cells represent the primary effector 
population in the early stages of acute hepatitis C virus (HCV) infection.  Downregulation of major 
histocompatibility complex (MHC) class I on virus infected hepatocytes reduces the inhibitory signal to 
NK cells, shifting the balance towards NK cell activation.  Dendritic cells (DC) engage with NK cells 
via the NKp30 receptor, and produce cytokines that boost NK cell proliferation towards an “NK1” 
phenotype.  In addition to direct cytotoxicity of target cells, activated NK1 cells produce cytokines 
such as IFN-γ and TNF-α which suppress HCV replication, reciprocally activate DCs, and prime naive 
CD4 T-cells inducing a T-helper (Th)-1 response.  
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1.7.2. NK cells in chronic HCV infection 
 
NK cells are more amenable to study in individuals with chronic HCV infection. Comparison with 
healthy donors reveals perturbations in NK cell frequency, phenotype and function (Figure 1.7).  
Peripheral blood NK cell frequencies, both absolute number and percentage of total lymphocyte 
population, are reduced in chronic HCV compared to healthy individuals (Bonorino et al., 2009; 
Dessouki et al., 2010; Meier et al., 2005; Morishima et al., 2006; Oliviero et al., 2009).  The reduction 
in NK frequency may either be a consequence of HCV infection or a predisposing factor to chronic 
HCV infection, and both hypotheses have some support.   In individuals with chronic HCV infection, 
NK cell frequency increases following successful antiviral therapy while reduction in peripheral blood 
NK cell frequency in individuals with chronic HCV as compared to spontaneous resolvers has also 
been noted.  IL-15, a pivotal cytokine for NK cell development, proliferation and function, may be 
relevant here.  Meier et al. demonstrate a significant reduction in serum IL-15 levels in HCV patients 
as compared to healthy controls and show that exogenous IL-15 rescues HCV NK cells from 
apoptosis, increasing ex-vivo proliferation and function (Meier et al., 2005).  Furthermore, DCs are an 
important source of IL-15 and have been shown to cross talk with NK cells.  In chronic HCV infection, 
Il-15 production by IFN-α-stimulated DCs is deficient (Jinushi et al., 2003).  Thus a downstream 
consequence of DC dysfunction could be a failure of production or proliferation of NK cells. 
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Figure 1.7. NK cells in chronic HCV infection 
In chronic HCV infection, changes occur in NK cell frequency, phenotype and function.  HCV core 
encoded peptides upregulate MHC class I (particularly HLA-E) on virus infected cells, which may 
impair NK cell surveillance.  Upregulation of the inhibitory receptor CD94:NKG2A binding to its ligand 
HLA-E leads to skewing of the NK cell cytokine profile towards the immunoregulatory cytokines IL-10 
and TGF-β.  These NK2 cytokines influence DC and T cell function, leading to further production of 
immunoregulatory cytokines and generation of a T-helper (Th)-2 response. Altered production of 
cytokines crucial for NK cell development leads to a reduction in NK cell frequency.  These changes 
collectively provide an environment permissive for HCV infection.  Additionally, upregulation of NK cell 
tumour necrosis factor related apoptosis inducing ligand (TRAIL) contributes to liver injury while 
increased TGF-β and attenuated IFN-γ production promotes activation of hepatic stellate cells (HSC) 
leading to fibrosis. Regulatory T cells (Treg) may suppress the tumour surveillance function of NK 
cells, increasing the risk of hepatocellular carcinoma.  
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1.7.3. Skewing of subset distribution 
 
A number of studies have documented a relative increase in circulating CD56
bright
 but not CD56
dim
 NK 
cells in individuals with chronic HCV compared to healthy individuals and spontaneous resolvers 
(Bonorino et al., 2009; De Maria et al., 2007; Golden-Mason et al., 2008; Lee et al., 2010; Lin et al., 
2004; Morishima et al., 2006).  This is unlikely to be due to preferential retention of the CD56
dim
 NK 
cells in the liver as Bonorino et al. (2009) demonstrate that the intrahepatic CD56
dim
 population as a 
percentage of total NK cells is also reduced (80.5% intrahepatic compared to 94% in peripheral 
blood), while the CD56
bright
 population is expanded (19.5% intrahepatic compared to 6.0% in 
peripheral blood).  CD56
- 
CD16
+ 
NK cells appear to represent a more terminally differentiated NK cell 
subset and there is an expansion of this population in chronic HCV infection (Gonzalez et al., 2009).  
CD56
- 
CD16
+ 
NK cells have reduced perforin expression compared with CD56
dim
 NK cells and have 
been shown to be hypofunctional, particularly in their interactions with DCs (Mavilio et al., 2006).  In 
HCV, chemokine production by this subset is skewed towards MIP-1β, and there is also a reduction in 
IFN-γ and TNF-α secretion compared to the CD56
+
 NK population.  Thus overall there is a skewing of 
NK cells away from the CD56
dim
 CD16
+
 subset, thought to be the main cytotoxic subset of NK cells.  
This is may be an effect of IFN-α, as there is a strong IFN-α response to HCV infection, while therapy 
with PEGylated IFN-α and ribavirin leads to an increase in CD56
bright
 and a decline in CD56
dim
 NK 
cells (de Oliveira Crispim et al., 2012; Su et al., 2002).   
 
1.7.4. Alterations in Phenotype 
 
Changes in phenotype may reflect changes in subset distribution and also the effect of cytokines on 
specific subsets of NK cells.  The most consistent finding in chronic HCV infection has been an 
increase in NKG2A expression (Jinushi et al., 2004; Nattermann et al., 2006; Nattermann et al., 
2005a). This occurs on both intrahepatic and peripheral blood NK populations (Bonorino et al., 2009), 
and likely represents expansion of CD56
bright
 NK cells that are KIR-negative and NKG2A-positive 
(Dessouki et al., 2010; Jinushi et al., 2004; Oliviero et al., 2009; Su et al., 2002).  Expression of 
activating receptors is also increased.  Such receptors include NKG2C, NKp44, NKp46 and NKp30 
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(Ahlenstiel et al., 2010; De Maria et al., 2007; Harrison et al., 2010).  Initial reports of decreased 
expression of NKp46 have not been subsequently confirmed (Nattermann et al., 2006).  Similarly 
there is conflicting evidence with respect to NKG2D expression which has been reported to be up-
regulated, down-regulated and also unchanged (De Maria et al., 2007; Harrison et al., 2010; Jinushi 
et al., 2004; Takehara and Hayashi, 2005).  Such contrasting data may relate to genuine differences 
in NK cell phenotype and function, difference in the populations studied, or technical issues such as 
sample preparation, cytokine stimulation or freezing.  However, taken together there appears to be an 
activation of NK cells in the acute phase of HCV infection, which persists into the chronic phase. 
 
1.7.5. Altered function 
 
Initial reports suggested diminished natural cytotoxicity in chronic HCV that was restored by 
successful HCV clearance with IFN-α and ribavarin therapy (Bonavita et al., 1993; Corado et al., 
1997; Crotta et al., 2002; Par et al., 2002).   However the number of cytotoxic CD56
dim
 NK cells in the 
peripheral blood is depressed and hence, recent studies which take into account cytotoxicity per NK 
cell have demonstrated normal or increased NK cell cytotoxicity in chronic HCV (Ahlenstiel et al., 
2010; De Maria et al., 2007; Duesberg et al., 2001; Golden-Mason et al., 2008; Morishima et al., 
2006; Oliviero et al., 2009; Yoon et al., 2009).  There is greater expression of activation markers such 
as CD122 (a subunit of IL-2 receptor that is crucial for IL-2 and IL-15 signalling), CD69, and NKp44 
(Ahlenstiel et al., 2010; Oliviero et al., 2009).  Up-regulation of tumour necrosis factor-related 
apoptosis-inducing ligand (TRAIL) on NK cells also may be an important mechanism underlying the 
anti-HCV effect of NK cells.  Liver NK cells expressing TRAIL kill autologous hepatocytes in mice 
(Ochi et al., 2004), and may therefore contribute to liver injury. NK cell TRAIL expression is increased 
in chronic HCV, and these cells have a phenotype consistent with IFN-α stimulation (Ahlenstiel et al., 
2010; Stegmann et al., 2010).   
A change in the cytokine profile of NK cells in chronic HCV may be relevant to the persistence of HCV 
infection.  Failure of NK cell production of IFN-γ in chronic HCV has been reported (Ahlenstiel et al., 
2010; Dessouki et al., 2010; Oliviero et al., 2009).  IFN-γ has potent anti-HCV properties, directly 
blocking HCV replication in a dose-dependent manner (Crotta et al., 2010; Jo et al., 2009; Wang et 
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al., 2008).  IFN-γ also indirectly suppresses HCV activity by polarising T cell differentiation towards a 
virus specific Th1 phenotype.  Additionally, increased HCV-NK cell production of Th2 cytokines such 
as IL-10 and TGF-β, and the chemokine IL-8, may skew the cytokine profile to environment which is 
more permissive for HCV (Crotta et al., 2010; De Maria et al., 2007; Jinushi et al., 2004; Oliviero et 
al., 2009; Polyak et al., 2001). Cytokines may also affect the differentiation and maturation of NK cells 
(Loza and Perussia, 2001).  In particular NK cells can be polarised towards an NK2 phenotype under 
the influence of IL-4 and IL-13 (Peritt et al., 1998).  Thus the cytokine microenvironment regulates 
both NK cell phenotype and function.  In chronic HCV infection the dominant effect on NK cells 
appears to be of IFN-α, but the roles of IL-4, IL-10 and IL-13 warrants further investigation. 
NK cells may also be modulated by direct cellular interactions, especially with DCs.  All mature NK 
cells express the activating receptor NKG2D, the ligand for which are MHC class I chain related (MIC) 
proteins.  In HCV infection there is an impairment of MIC-A/B expression which may impair NK cell 
activation (Jinushi et al., 2003).  NK cell activation of DCs may be reciprocally perturbed.  When co-
cultured with human hepatic cells, healthy control NK cells enhance maturation and activation of DCs 
to promote a Th1-polarised CD4 T-cell response (Jinushi et al., 2004).  HCV-NK cells have a reduced 
capacity to activate DCs due to CD94:NKG2A-mediated NK cell inhibition.  This has a reciprocal 
effect of skewing NK cell cytokine expression towards the immunoregulatory cytokines IL-10 and 
TGF-β, which promote Th2 type differentiation.  Interestingly, inhibition of NKG2A restored the ability 
of HCV-NKs to activate DCs, and also the production of the Th1 cytokines IFN-γ and TNF-α.  This 
may be important as HCV can up-regulate cell surface HLA-E, the ligand for NKG2A, in vivo 
(Nattermann et al., 2005a). 
The activation status of NK cells correlates with liver inflammation.  Increased expression of NKG2A, 
CD69 and CD107a (a marker of NK cell degranulation) on peripheral blood NK cells have all been 
linked with disease-related elevation of ALT levels.  Additionally, Oliveiro et al showed an inverse 
correlation of peripheral NK cell NKG2D expression with ALT (Ahlenstiel et al., 2010; Bonorino et al., 
2009; Oliviero et al., 2009; Stegmann et al., 2010).  NK cells have been localised to necrotic areas in 
liver biopsy specimens in chronic HCV, but not chronic HBV (Bonorino et al., 2009).  These 
intrahepatic NK cells express higher levels of TRAIL and the activating receptor NKp46 (Ahlenstiel et 
al., 2010).  Bonorino et al have shown an inverse correlation between NKG2A-positive NK cells and 
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viral load (Bonorino et al., 2009).  However although correlations with disease and RNA levels have 
significant p values, they have relatively low values for the correlation coefficient “r” indicating that 
much of the variability in inflammation and RNA levels is accounted for by factors other than those 
specifically studied. 
 
1.8. NK cells and the outcome of HCV infection 
 
NK cells were originally implicated in determining the outcome of HCV infection in an immunogenetic 
study of the KIR genes and their HLA-C ligands (Khakoo et al., 2004).  By comparing the presence or 
absence of KIR genes and their HLA ligands in over 1000 individuals exposed to HCV it was shown 
that the specific combination of the inhibitory receptor KIR2DL3 and its group 1 HLA-C ligand (HLA-
C1) was protective against chronic HCV infection (Khakoo et al., 2004). The protective effect of this 
gene combination was limited to individuals infected by intravenous drug use or accidental needle-
stick injury. No protective effect was observed in subjects infected by transfusion of blood products in 
whom the innate immune response was thought to be overwhelmed by the higher infecting inoculum. 
The association of KIR2DL3 and HLA-C1 has subsequently been confirmed in a smaller study of 
intravenous drug users of Puerto-Rican origin, indicating that this protective effect is consistent across 
different populations (Romero et al., 2008).  It has been postulated that this gene combination is 
protective because the KIR2DL3 binds HLA-C1 with a lower avidity than other inhibitory KIR, and thus 
NK cells expressing this specific inhibitory receptor have a lower threshold for activation (Fadda et al., 
2010; Moesta et al., 2008).  Consistent with this, NK cells expressing KIR2DL3 respond more rapidly 
to influenza infected cells in vitro (Ahlenstiel et al., 2008). 
 
The oligomorphic MHC class I molecule HLA-E has also been associated with the outcome of HCV. 
In a genetic study homozygosity for the HLA-E
R 
allele has been shown to be protective against 
chronic infection with HCV genotypes 2 and 3 (Schulte et al., 2009).  This protective effect was 
thought to be due to an effect on HLA-E restricted T cells, although the HLA-E
R 
allele may have a 
lower affinity for peptides and hence be expressed at lower levels.  This could therefore lead to less 
inhibition of NK cells via the CD94:NKG2A receptor (Strong et al., 2003). 
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1.9. Background to this study 
 
1.9.1.Viral peptide mediated up-regulation of MHC class I and immune escape 
 
Up-regulation of cell surface MHC-class I expression in viral infection has been shown to impair NK 
cell cytotoxicity, and may represent a mechanism employed by viruses to subvert the innate immune 
response (Herzer et al., 2003; Nattermann et al., 2005a; Nattermann et al., 2005b; Tomasec et al., 
2000; Ulbrecht et al., 2000).  A peptide derived from HCV core protein, YLLPRRGPRL (HCV core 
amino acids 35-44; HCV core35-44), is a well recognised HLA-A2 epitope that is also capable of 
binding to HLA-E in-vivo (Nattermann et al., 2005a).  The NK cell receptor for HLA-E is CD94:NKG2A, 
which is also up-regulated in chronic HCV infection (Harrison et al., 2010; Jinushi et al., 2004; 
Nattermann et al., 2006; Nattermann et al., 2005a).  Thus, increased expression of HLA-E and 
CD94:NKG2A in chronic HCV may represent an important mechanism by which HCV escapes NK cell 
immune surveillance.  HIV, EBV and CMV also encode for HLA-E binding peptides therefore this 
mechanism may also be relevant to other viruses. 
 
1.9.2. Changes in peptide repertoire and NK cell activation 
 
In addition to binding MHC class I-derived and virus-derived peptides, HLA-E can also bind stress 
related peptides such as the heat shock protein 60 (hsp60) signal peptide.  hsp60 is a mitochondrial 
chaperone protein found in all cells, expression of which is increased when cells are exposed 
stressful stimuli (Michaelsson et al., 2002).  hsp60sp (QMRPVSRVL) shares key anchor residues with 
MHC class I derived signal peptides, favouring binding to HLA-E.  However, P5 valine (compared to 
P5 arginine in MHC Class I derived signal peptides) abrogates recognition by CD94:NKG2A, and may 
represent a mechanism by which NK cells can recognise stressed cells in a peptide dependent 
manner.  A recent publication by our group revealed that HLA-C bound peptides that induce weak KIR 
binding can antagonise the effects of peptides that bind more strongly to KIR (Fadda et al., 2010).   In 
this study, VAPWNSFAL (VAP-FA) and VAPWNSDAL (VAP-DA) were both shown to induce similar 
levels of HLA-Cw*0102 stabilisation on a TAP-deficient cell line.  The subtle differences at P7 and P8 
of these peptides led to differences in their interaction with KIR receptors: VAP-FA strongly inhibited 
degranulation of CD158b
+ 
NK cells, while VAP-DA did not inhibit degranulation, despite promoting 
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clustering at the interface of effector and target cells.  Interestingly, when the two peptides were 
mixed, the VAP-DA peptide appeared to antagonise the inhibitory effect of VAP-FA.  This was a novel 
finding where non-inhibitory KIR binding MHC class I peptides can depress the inhibitory effect of a 
strong KIR binding peptide, thus acting as altered peptide ligands.  Similarly, hsp60sp could potentially 
act as an altered peptide ligand at CD94:NKG2A and antagonise the inhibitory effect of HCV core35-44. 
 
1.9.3.Aims and objectives 
 
In this thesis, we aimed to: 
 
1) Confirm the peptide specificity of HLA-E/ CD94:NKG2A and HLA-Cw0102/ KIR2DL2/3 looking 
particularly at: 
a. HCV core35-44 peptide 
b. Other viral peptides derived from EBV and HIV 
c. MHC class I derived signal peptides 
 
2) Determine whether changes in peptide repertoire at HLA-E lead to antagonism at 
CD94:NKG2A in analogy to KIR antagonism induced by altered peptide ligands of HLA-C. 
 
3) Analyse the differences between the KIR and CD94:NKG2A receptor systems. 
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Chapter 2. Materials and Methods 
 
2.1. Cell lines and culture methods 
 
2.1.1 .721.174 (.174) 
The mutant human B-cell line LBL 721.174 (.174) is capable of synthesising MHC-class I molecules 
but has lost its ability to present intracellular self or viral peptides due to deficiency in transporter 
associated with antigen processing (TAP) (Cerundolo et al., 1990; Spies and DeMars, 1991).  MHC 
class I molecules that reach the cell surface are most likely bound to low affinity peptides and 
therefore dissociate rapidly, leading to five-fold reduction in MHC class I expression at the .174 cell 
surface (Weinzierl et al., 2008).   However, .174 cells can be loaded with exogenous peptide leading 
to stabilisation of MHC-class I at the cell surface when incubated at 26˚C (Correa and Raulet, 1995). 
 
2.1.2. K562 
The K562 cell line is a human erythroleukaemic cell line derived from patient with chronic myeloid 
leukaemia.   K562s represent a sensitive NK cell target as they fail to express MHC-class I due to a 
lack of β2-microglobulin. 
 
2.1.3. NKL 
NKLs represent a CD3
-
 CD56
+
 CD16
+
 cell line first isolated from the peripheral blood of a patient with 
large granular lymphocyte leukaemia (Robertson et al., 1996).  They are KIR
-
 but express 
endogenous CD94 and NKG2A. 
 
2.1.4. Jurkat cells and CD94-transfected Jurkats 
Jurkat cells represent an leukaemic T cell line isolated from the peripheral blood of a 14 year old boy 
with T cell leukemia (Schneider et al., 1977).  Jurkat cells stably transfected with CD94 (CD94 
Jurkats) were obtained from Miguel López-Botet. 
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2.1.4. Cell culture 
.174, K562, Jurkat and CD94 Jurkat cells were cultured and maintained in R10 medium containing 
RPMI 1640 (Biowhittaker, U.K.) supplemented with 10% heat-inactivated fetal calf serum (Lonza), 1% 
penicillin/ streptomycin (Biowhittaker, U.K.) and L-glutamine (Biowhittaker, U.K.) at 37˚C, 5% CO2.  
Cell line cultures were maintained in logarithmic phase at neutral pH by performing a 1:10 dilution 
every 72 hours.  NKL cell lines were cultured in R10 medium supplemented with 1ng/ml recombinant 
human IL-2 (National Cancer Institute Biometric Research Branch; Fisher BioServices) at 37˚C, 5% 
CO2. 
 
2.1.5. Isolation of PBMCs 
Peripheral blood mononuclear cells (PBMCs) were obtained from patients with haemochromatosis 
and healthy control donors at St Mary’s Hospital, London.  Each patient provided informed consent.  
PBMCs were isolated using Ficoll-Hypaque (Amersham Biosciences, U.K.) density centrifugation, 
suspended in 90% FCS/ 10% DMSO, and stored at -80˚C in a Mr Frosty Cryo 1˚C freezing container 
(Nalgene) for 24 hours, before transferring to liquid nitrogen (-140˚C) until use. 
 
2.1.6. NK cell isolation 
Purified untouched NK cells were isolated from PBMCs using a negative selection kit (Dynabeads, 
Invitrogen, U.K). The kit depletes non-NK cells (T cells, B cells, monocytes, platelets, dendritic cells, 
granulocytes and erythrocytes) leaving negatively isolated human NK cells. An antibody mix towards 
the non-NK cells is added to PBMCs and allowed to bind to the cells before adding Dynabeads which 
will bind to the antibody-labelled cells. The bead-bound cells are then separated on a magnet and 
discarded, leaving untouched human NK cells, which were analysed for purity using flow cytometry. 
 
2.2. Peptide Synthesis 
Peptides were purchased from Peptide Protein Research Ltd (Hampshire, UK), with identity confirmed 
by MS (>95% purity).  They were dissolved in DMSO and then added at a final concentration of 0-100 
μM. 
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2.3. Antibodies and staining reagents 
The following monoclonal antibodies were used for flow cytometry.  Anti-human HLA-E 
 phycoerythrin-conjugated (3D12; eBioscience), anti-human HLA-C*0102 (VP6G3; provided by Arend 
Mulder, Leiden, Netherlands), fluorescein isothiocyanate conjugated goat anti-human IgM antibody 
(AbDSerotec), fluorescein isothiocyanate conjugated anti HLA-A2 (BB7.2; Abcam), anti-CD3 eFluor 
450 (OKT3; eBioscience), anti-CD56 Cy7 coupled to phycoerythrin (HCD56, Biolegend), anti-CD159a 
conjugated to phycoerythrin (Z199; Beckman Coulter), fluorescein isothiocyanate conjugated anti-
CD158b (CH-L; BD Pharmingen), Alexa Fluor 647–conjugated antibody to human CD107a (H4A3; 
eBioscience), anti-NKG2C Peridinin-Chlorophyll-Protein-Complex (PerCP) (134591; R& D Systems, 
U.K.).  For blocking experiments and microscopy: anti-human CD94 (DX22; eBioscience), anti-human 
CD85j (HP-F1; eBioscience), anti-CD158b (GL183 Abcam, U.K.) anti-CD159a (Z199; Beckman 
Coulter), Alexa Fluor-488 goat anti-mouse IgG (Invitrogen).   
 
 
2.4. MHC class I stabilisation assay 
 
1 x 10
5
 .174 cells were incubated overnight at 26˚C in R10 medium alone or R10 containing 0-100 
micromolar (μM) of the specified peptide (HPLC tested >95% purity, Peptide Protein Research Ltd., 
U.K.).  The cells were then stained for HLA-E (3D12), or HLA-A2 (BB7.2), or the corresponding 
isotype control, maintained at 4 °C and in the dark for 30 minutes before washing twice with FACS 
wash (PBS with 0.002% NaN3 and 1% BSA) and fixing in 1% paraformaldehyde (PFA).  For HLA-
Cw*0102 detection, VP6G3 antibody was used at room temperature for 30 min.  After washing twice 
to remove unbound antibody, cells were stained with F-ab goat anti-human IgM-FITC for 30 minutes 
at 4 °C and in the dark.  As a negative control, .174 cells were incubated with the secondary antibody 
in the absence of the VP6G3. After two further washes the cells were fixed in 1% PFA and analysed 
by on a BD FACS Canto II analyzer (Becton Dickinson).  Mean fluorescent intensity (MFI) of 10,000 
cells gated by forward and side scatter was recorded. 
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2.5. CD107a/ LAMP-1 Degranulation assay 
 
2.5.1. Effector cell preparation 
Frozen PBMCs were washed in RPMI 1640 and resuspended in R10 at final concentration 1.5x10
6
 
cells/ ml.   Interleukin (IL)-15 (R&D Systems U.K.) was added at 1ng/ml prior to incubating 200 μl 
(3x10
5
 cells/ well overnight in a 96 well plate for 16 hours at 37˚C, 5% CO2. 
 
2.5.2. Target cell preparation 
6x10
4
 .174 cells alone or with varying concentration of peptide (0-100 μM) were incubated in a 96 well 
plate at 26˚C, 5% CO2 for 16 hours.  For peptide mix experiments, target cells were simultaneously 
loaded with two peptides with final concentration as indicated.  MHC class I negative K562 cells were 
used as a positive control. 
 
2.5.3. Degranulation Assay 
The next day, IL-15 containing media was removed from the PBMCs before resuspending in CD107a-
Alexa Fluor 647 (H4A3), or Mouse IgG1-k Alexa Fluor647 isotype control.  The target cells were also 
resuspended in fresh R10 media +/- peptide.  PBMCs were stimulated with target cells at an effector 
to target (E:T) ratio of 5:1 for a total of 4 hours at 26˚C, 5% CO2.  Optimal E:T ratio was determined by 
an E:T titration from 50:1 to 1:1, with additional assays performed to ascertain optimal incubation time 
and temperature.  K562 target cells were used as a positive control.  Spontaneous expression of 
CD107a was determined for PBMCs in the absence of target cells.  After 1 hour of incubation, 7 μl of 
monensin was added to each well (Golgi-Stop, BD Biosciences, U.K.) at a final concentration of 7 
μg/ml before incubating for a further 3 hours at 26˚C, 5% CO2.  Monensin reduces degradation of re-
internalised CD107a by preventing acidification of endocytic vesicles, allowing visualisation of 
CD107a following stimulation.  After the 4 hour incubation, PBMCs were resuspended in blocking-
buffer (10% human serum (Cambrex, U.K.) in FACS wash) at 4˚C for 30 minutes.  PMBCs were then 
stained using CD3 eFluor-450, CD56-PECy7, CD158b-FITC (identifies KIR2DL2/ KIR2DL3 subset) 
and NKG2A-PE (Beckman Coulter, U.K.).  BD Compbeads (B.D. Biosciences, U.K.) were used for 
compensation controls.  Cells were stained at 4˚C for 30 minutes in the dark before washing twice 
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with FACS wash and fixing in 1% PFA.  Flow cytometric analysis was performed using a FACS Canto 
analytical flow cytometer (B.D. Biosciences, U.K.).  I gated on the lymphocyte population, before 
gating on CD3
-
 CD56
+ 
cells to define the NK cell population.  A total of 10,000 NK cell events were 
acquired and analysed using BD FACS Diva software (B.D. Biosciences, U.K.).  CD107a expression 
by the various NK cell subsets was analysed. CD107a expression was defined as a percentage of the 
NK population expressing CD107a, minus spontaneous CD107a expression by PBMCs incubated in 
the absence of target cells. 
 
2.5.4. Blocking experiments 
For the blocking experiments, PBMCs were incubated with 25 μg/mL DX22 (anti-CD94), HP-F1 (anti 
LIRB1), GL183 (anti-CD158b) or IgG1 control antibody for 30 minutes at room temperature, before 
addition of .174 cells.  Remainder of protocol as per NK cell degranulation assay, except 
degranulation gated on either CD3
-
 CD56
+
 or CD3
- 
CD56
+
 CD158b
-
 NK cells as stated. 
 
2.6. Microscopy 
0.5 x 10
6
 .174 cells were incubated overnight at 26 °C alone or with 0-100 μM peptide, then co-
incubated with NKL cells, primary NK cells or CD94-Jurkat transfectants at an E:T ratio of 2:1 at 37 °C 
for 10 min. Cells were fixed in pre-warmed 2% PFA for 30 min at 37 °C before permeabilising with 
0.01% Triton X-100 for 1 min.   Cells were then stained with CD94 (DX22) or NKG2A (Z199), washed, 
stained with Alexa Fluor-488 goat anti-mouse IgG (staining performed at 4 °C in dark) followed by a 
further wash. Cells were imaged using a Leica SP2 upright microscope (Leica Microsystems) with 
transmission images and FITC emission collected in separate channels. Data were processed using 
Leica imaging software (Leica Microsystems) and Image-J. The increase in fluorescence intensity at 
the immune synapse was calculated as a ratio of the average fluorescence intensity along the 
effector-.174 interface compared with the average fluorescence intensity along a non-contact area of 
the effector cell plasma membrane, with both values corrected for background fluorescence as 
measured within an acellular region of the image.  The percentage of conjugates with >1.4 fold 
increased fluorescence at the synapse was also calculated. 
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2.7. Statistical analysis 
 
All statistical analyses were performed using GraphPad Prism, version 5 (GraphPad Software).  A p 
value of less than 0.05 (p <0.05) was deemed to be significant. 
  
56 
 
Chapter 3. MHC-class I binding peptides and NK cell inhibition 
 
3.1. Peptide processing and specificity of MHC class I 
 
MHC class I molecules are expressed by all nucleated cells, presenting peptides derived from nuclear 
and cytosolic proteases at the cell surface.  Such peptides gain access to the endoplasmic reticulum 
(ER) by transporter associated with antigen processing (TAP) molecules.  In the absence of peptide, 
the MHC-encoded heavy chain and a β2-microglobulin light chain (β2m) are partially folded and 
stabilised in the endoplasmic reticulum by various chaperone proteins including tapasin, calreticulin 
and ERp57.  Collectively, these components form the peptide loading complex (PLC). Tapasin 
interacts closely with TAP, coupling peptide delivery into the endoplasmic reticulum with loading onto 
MHC class I (Figure 3.1) (Neefjes et al., 2011).  Within the ER, peptides may be trimmed by 
aminopeptidases producing a sequence of 8-10 amino acids.  Following successful peptide loading 
on to MHC class I, the chaperone proteins are released while the stable MHC class I heterotrimer 
leaves the endoplasmic reticulum for presentation at the cell surface (Marsh et al., 2000; Schumacher 
et al., 1990; Townsend et al., 1989).    MHC class I molecules and peptides that fail to associate in the 
endoplasmic reticulum are returned to the cytosol where they are degraded (Hughes et al., 1997; 
Koopmann et al., 2000). 
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In a healthy cell, degradation of cellular contents by cytosolic proteases, such as the multicatalytic 
proteasome complex, leads to the generation of a variety of 8-12 amino-acid self-peptides.  These 
peptides are translocated from the cytosol into lumen of the endoplasmic reticulum (ER) by ATP-
dependent transporter associated with antigen processing (TAP) molecules.  The peptides are further 
trimmed by aminopeptidases to produce 8-10 amino-acid peptides.  The peptide loading complex 
(PLC)- consisting of TAP, tapasin, calreticulin and ERp57- load peptide onto β2m and α-heavy chain 
to form a stable MHC class I molecule.  The MHC class I heterotrimer is then transported to the golgi 
before exiting via the secretory pathway to reach the cell surface.   
 
 
 
 
  
Figure 3.1. Peptide loading onto MHC class I 
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A variety of self peptides are thus displayed  at the cell surface by MHC class I, providing information 
for CD8
+
 T cells surveying for the presence of non-self peptides using their α/β TCR.  MHC class I 
levels are sensitive to the amount of peptide available, which in turn relates to the rate of protein 
synthesis within the cell.  Various stimuli such as ionizing radiation, IFN-γ and microRNAs can affect 
protein synthesis within a cell.  Viral infection or tumorigenesis can result in alterations to intracellular 
protein production, leading to a change in the MHC class I bound peptide as these proteins are 
degraded in the cytosol (Hickman et al., 2003; Meiring et al., 2006).  Such perturbation of peptide 
presentation by MHC class I enables CD8
+
 T cells to recognise unhealthy cells. Functional studies 
demonstrate that NK cells also demonstrate peptide specificity, in addition to recognising any overall 
reduction in MHC class I expression as a result of impaired protein synthesis or peptide processing 
within the cell.  
 
Although MHC-Class Ia molecules can bind a diverse array of peptides, the various subclasses (HLA-
A, -B and C) display a preference for particular amino-acids at certain positions in the peptide 
sequence.  This is attributable to the high level of polymorphism in the heavy chains, resulting in a 
variety of peptide-binding grooves with distinct anchor positions to which peptides bind (Trowsdale, 
2005).  HLA-C is usually expressed at the cell surface at lower levels than HLA-A and HLA-B, despite 
similar intracellular levels of the heavy chains (Neefjes and Ploegh, 1988).  This is partly explained by 
a more selective peptide repertoire for HLA-C; HLA-Cw*04 and HLA-Cw*02 require a 10 fold increase 
in peptide concentration to dissociate from TAP compared to HLA-A and –B alleles (Neisig et al., 
1998).  Consequently, 30-70% of HLA-C molecules may be retained in the ER bound to TAP awaiting 
an appropriate allele specific peptide (Neefjes et al., 2011).   This may also make HLA-C more 
available for peptides that arise during viral or stress conditions.   
 
Although HLA-C tends to be expressed at lower cell surface levels than HLA-A and HLA-B, it is 
perhaps more important in the regulation of NK cell function than these molecules.  This is 
emphasised by recent immunogenetic studies showing the association of HLA-C polymorphisms and 
the outcome of HIV and HCV infection (Fellay et al., 2007; Khakoo et al., 2004; Romero et al., 2008).  
There is a dearth of data for peptide binding motifs of the various HLA-C alleles, but perhaps best 
characterised is HLA-Cw*0102, a HLA-C1 molecule that functions as a ligand for KIR2D receptors.  
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Barber et al. eluted HLA-Cw*0102 peptides, determining their sequence using Edman degradation 
and tandem mass spectrometry.  A motif for HLA-Cw*0102 binding was proposed comprising a 
leucine or alanine at amino acid position 2 (P2) and a leucine at P9, which are referred to as anchor 
residues (Figure 3.2) (Barber et al., 1996).  
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Figure 3.2. Peptide binding preference of HLA-Cw*0102 
Dominant anchor residues for HLA-Cw*0102 are the C-terminus P9 residue and the P2 residue, 
favouring a leucine and alanine or leucine respectively.  Predicted binding of amino acids at other 
residue positions are shown, decreasing in affinity from top to bottom. Adapted from Barber et al 
(1996). 
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The non classical MHC Class Ib molecule HLA-E is the oligomorphic ligand for the CD94:NKG2A 
receptor.  In contrast to MHC class Ia molecules which bind a diverse range of peptides, HLA-E 
primarily binds a closely related set of nonameric peptides derived from other MHC class I molecules 
(Braud et al., 1997; Braud et al., 1998; Lee et al., 1998).  HLA-A, -B, -C and HLA-G are expressed 
with a leader sequence targeting them to the secretory pathway.  This leader sequence is thought to 
be cleaved from the ER membrane by a signal peptide peptidase. In the cytosol, the peptide is 
trimmed further by the proteasome to liberate a highly conserved nonameric signal peptide, 
corresponding to amino acids residues 3-11 of the leader sequence (Bland et al., 2003).   The signal 
peptide enters the ER by a TAP dependent mechanism and is eventually presented at the cell surface 
by HLA-E (Lemberg et al., 2001).  HLA-E is unable to bind its own signal peptide.  Thus, HLA-E 
expression provides an indirect indicator of the production of the polymorphic MHC class I molecules, 
and the capacity of the cell to process and present antigen (Bland et al., 2003).   
 
The principles governing the restricted peptide binding of HLA-E can be explained by its crystal 
structure (O'Callaghan et al., 1998).  Five anchor positions have been described for HLA-E, compared 
to only two or three for MHC class Ia molecules (Sullivan et al., 2008).  The dominant anchor residues 
are P2 and P9, however, further anchor positions exist at P3, P6 and P7.  Folded HLA-E complexes 
have a strong preference for methionine and leucine at P2 and P9 respectively; with these residues 
present in all MHC Class I derived signal peptides that bind HLA-E.  Leucine is also tolerated at P2; 
however, threonine is not favoured.  This would explain the lower affinity of HLA-E for several of the 
HLA-B derived signal peptides containing threonine at P2 (Table 3.1.) (Brooks et al., 1999).  
Sequences predominating in hydrophobic amino acids could potentially bind strongly to HLA-E, 
therefore permitting binding of peptides that do not conform to predicted motifs (Miller et al., 2003; 
Stevens et al., 2001).  This enables non-MHC class I derived peptides to bind to HLA-E, as has been 
demonstrated for the heat shock protein 60 signal peptide (hsp60sp) QMRPVSRVL, and the HCV 
core35-44 peptide YLLPRRGPRL (Michaelsson et al., 2002; Nattermann et al., 2005a). 
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3.1.1. Peptide preference of NK cell receptors 
 
The MHC class I specificity of the various NK cell receptors is well characterised.  KIR2DL receptors 
recognise HLA-C ligands but they discriminate between allotypes grouped according to the amino 
acid located at positions 77 and 80 on the alpha 1 helix of the HLA-C heavy chain.  KIR2DL2 and 
KIR2DL3 receptors bind to HLA-C alleles with Serine at P77 and Asparagine at P80.  Collectively, 
these molecules are called HLA-C1 allotypes.   In contrast KIR2DL1 receptors recognise HLA-C2 
allotypes with Asparagine at P77 and lysine at P80 (Vitale et al., 1995).  KIR recognition of their 
cognate MHC class I ligands is sensitive to the nature of the bound peptide adding a further level of 
complexity to this system (Maenaka et al., 1999a; Malnati et al., 1995).  KIR2D receptors display 
peptide selectivity for binding to HLA-C molecules and are most sensitive to substitutions at P7 and 
P8 (Rajagopalan and Long, 1997; Zappacosta et al., 1997).  Rajagopalan and Long showed that 
HLA-Cw4 transfected RMA-S cells had a similar affinity for a range of peptides; however, those HLA-
Cw4 bound peptides with a negatively charged P8 residue were not recognised by KIR2DL1 
(Rajagopalan and Long, 1997).  Analysis of the crystal structure of KIR2DL1 bound to HLA-Cw4 
reveals that KIR2DL1 has a negatively charged polar surface around the P8 lysine side chain of the 
peptide that discourages acid residues at that position.  Crystal structure studies of KIR2DL2 bound to 
the group 1 HLA-C molecule HLA-Cw3 reveal that the receptor makes direct contact with residues 7 
and 8 of the peptide (Boyington et al., 2000a).  Additionally, alterations to contact residues P7 and P8 
of peptides bound to HLA-Cw*0102 can promote, abrogate and predict a hierarchy in KIR binding 
(Fadda et al., 2010). 
 
The nature of the bound peptide can also markedly influence the affinity of the interaction between 
HLA-E and CD94:NKG2A.  P5, P6 and P8 have been identified as the major contact residues with 
CD94:NKG2A.  There is an absolute specificity for P5 arginine, as P5 lysine (representing a 
conserved substitution with positive charge) completely abrogates binding to CD94:NKG2A (Miller et 
al., 2003).  The critical role of the P5 residue in HLA-E recognition by CD94:NKG2A is further 
exemplified by the observations of Michaelsson et al., using a peptide derived from the signal 
sequence of heat shock protein 60, a protein induced in response to cellular stress (Michaelsson et 
al., 2002).  hsp60sp (QMRPVSRVL) has the preferred methionine at P2 and leucine at P9, but a valine 
residue at P5 interferes with recognition by CD94:NKG2A.  Although P5 arginine to valine or lysine 
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substitution of HLA-E binding peptides abrogates inhibition at CD94:NKG2A, the reciprocal change in 
hsp60sp (P5 valine to arginine) was insufficient to promote recognition at this receptor.  This would 
suggest that other residue positions are important in CD94:NKG2A recognition, possibly changing the 
conformation of the peptide within the HLA-E binding groove.  Llano et al. suggest P6 is also an 
important contact residue, as substitution of threonine with alanine, as seen naturally in the C7 leader 
peptide VMAPRALLL, results in loss of recognition by CD94:NKG2A (Llano et al., 1998).  The residue 
at P8 may predict a hierarchy in binding to CD94:NKG2 receptors, with phenylalanine the strongest 
binder (Miller et al., 2003).  This would explain the higher affinity of HLA-G signal peptide (sp) 
VMAPRTLFL for CD94:NKG2A compared to the MHC class Ia derived peptides (Table 3.1).  
 
HLA-E can also bind to the activating C-type lectin receptor CD94:NKG2C.  Interestingly, 
CD94:NKG2C has a six-fold lower affinity for HLA-E than both CD94:NKG2A and CD94:NKG2E 
(Kaiser et al., 2005; Vales-Gomez et al., 1999).  Peptides bound to HLA-E can differentially affect 
binding to the inhibitory and activating receptors (Brooks et al., 1999; Llano et al., 1998; Vales-Gomez 
et al., 1999).  The functional significance of this is not clear; however, HLA-E: HLA-Gsp triggers 
NKG2C activation very efficiently (Llano et al., 1998). 
 
In this chapter, MHC class I signal peptide, virus derived peptides and hsp60sp binding to HLA-E and 
HLA-Cw*0102 was compared using a TAP deficient .174 cell line pulsed with these various peptides.   
Recognition of peptide-MHC complexes by NK cell inhibitory receptors was ascertained by multi-
parameter flow cytometry utilising CD107a expression as a marker of NK cell activation using PBMCs 
as effector cells against .174 cell targets.  
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Table 3.1. MHC class I derived signal peptides and their affinities for HLA-E and CD94:NKG2A.  
Adapted from Sullivan et al, (2008). 
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3.2. Results 
 
3.2.1. MHC Class I binding assays 
 
HCV core35-44 (YLLPRRGPRL) and hsp60sp (QMRPVSRVL) have been shown to bind to HLA-E.  To 
confirm this, MHC deficient .174 cells were incubated overnight at with varying concentrations (0-100 
μM) of these peptides, before staining for cell surface HLA-E (3D12) and HLA-Cw*0102 (VP6G3) 
(Figure 3.3).  As a positive control, MHC class I stabilisation was assessed using the host derived 
MHC class I signal peptides HLA-Gsp (VMAPRTLFL), HLA-A*02sp (VMAPRTLVL) and -B*07sp 
(VMAPRTVLL). 
Flow cytometric analysis showed that although HLA-E and HLA-Cw*0102 expression was detectable 
on .174 cells incubated without peptide, cell surface levels increased when loaded with these specific 
peptides.  In agreement with the previous observations, incubation with HCV core35-44 led to enhanced 
HLA-E expression on .174 cells, saturating at ~80 µM (Nattermann et al., 2005a).  HLA-Gsp, HLA-A2sp 
and HLA-B7sp also bound to HLA-E, consistent with previous findings.  HLA-B7sp and HLA-A2sp had a 
higher affinity for HLA-E, achieving a higher mean fluorescent intensity and saturating at ~10 µM and 
~40 µM respectively, compared to HLA-Gsp which reached saturating levels at ~80 µM (Figure 3.3. b 
and f).   
hsp60sp enhanced HLA-E expression, but with a lower affinity than the other peptides (Figure 3.3 g).  
This is consistent with results from Michaelsson et al. who showed that HLA-E expression is maximal 
at 300 µM hsp60sp (Michaelsson et al., 2002).  As a negative control, we used the HLA-A2 restricted 
influenza matrix peptide GILGFVFTL (GILG).   This peptide binds strongly to HLA-A2 (detected using 
BB7.2), however at 300 µM GILG, there was no significant binding to either HLA-E or HLA-Cw*0102 
(Figure 3.3 h & i).  This would indicate that not all peptides can bind to HLA-E and HLA-Cw*0102. 
Unexpectedly HCV core35-44, HLA-A2sp, HLA-B7sp and HLA-Gsp also increased cell surface HLA-
Cw*0102 (Figure 3.3 c & d). 
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Figure 3.3. Specific peptides induce MHC-Class I stabilisation on .174 cells 
.174 cells were incubated for 16 hours at 26˚C either alone or with the specified peptide, before 
staining with an anti-HLA-E antibody (3D12), anti-HLA-Cw*0102 (VP6G3), anti-HLA-A2 (BB7.2) or an 
isotype control, as described in Materials and Methods.  Data represent mean fluorescent intensity of 
10,000 gated events, shown as histograms and plotted against peptide concentration.  HLA-E 
upregulated on the surface of .174 cells by (a & b) HCVcore35-44,(e & f) A2sp and B7sp. HLA-
Cw*0102upregulated by (c & d) HCV core35-44 and HLA-Gsp. hsp60sp also binds to HLA-E (g); 
however the irrelevant HLA-A2 restricted peptide GILGFVFTL (GILG) binds neither HLA-Cw*0102 or 
HLA-E (h).  (i) GILG increases cell surface HLA-A2.  
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3.2.1.1. Effect of incubation temperature on MHC Class I stabilisation 
 
“Empty” MHC class I molecules, consisting of α-heavy chain and β2 microglobulin, can be assembled 
and expressed at the cell surface in the absence of endogenous peptide provided the cells are 
cultured at temperatures below 37 ˚C (Karre et al., 1986; Ljunggren et al., 1990).   TAP deficient .174 
cells can be loaded with exogenous peptide to enhance this cell surface MHC class I but are known to 
be sensitive to incubation temperature (Levy et al., 1991).    To confirm this, peptide induced MHC 
class I stabilisation on .174 cells was compared following overnight incubation at 26 °C and 37 °C 
(Figure 3.4 a & b).  Incubation at 26 °C with 100 µM HLA-Gsp increased cell surface levels of both 
HLA-E and HLA-Cw*0102 compared to .174 cells incubated in the absence of peptide, whereas 
incubation at 37°C did not.  Additionally, in the absence of exogenous peptide, at 26 °C there was a 
higher constitutive level of both of these class I molecules compared to overnight incubation at 37 °C.    
 
To determine the stability of MHC class I complexes a similar assay was performed, incubating .174 
cells alone or loaded with 100 µM HLA-Gsp.   Following overnight incubation at 26°C, peptide loaded 
.174 cells were exposed to a 37 °C water bath for 0-5 hours, before placing on ice and staining for cell 
surface HLA-E and HLA-Cw*0102 (Figure 3.4 c & d).  Peptide loaded .174 cells not exposed to 37 °C 
temperature had increased levels of both HLA-E and HLA-Cw*0102 compared to unpulsed .174 cells, 
consistent with previous experiments.  However, following incubation at 37 °C there was a time 
dependent reduction in mean fluorescent intensity (MFI) of the stained samples indicating dissociation 
of MHC class I complexes.  After 3 hours at 37 °C, MFI for HLA-E and HLA-Cw*0102 staining was 
comparable to that for unpulsed .174 cells.  Therefore although CD107a degranulation is greater at 37 
°C than at 26 °C, there is rapid decay in cell surface stabilised MHC class I at the higher temperature.  
Therefore, 26 °C was selected as the temperature for the .174 cell/ PBMC co-incubation step in 
degranulation assays. 
. 
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Figure 3.4. Effect of temperature on MHC class I stabilisation 
.174 cells unloaded (np) or pulsed with 100 µM HLA-Gsp were incubated overnight either at 26˚C or at 
37˚C before staining for (a) HLA-E (3D12) and (b) HLA-Cw*0102 (VP6G3), or the appropriate isotype 
control (cIg).  (c) & (d) .174 cells incubated overnight at 26˚C either alone (np) or with 100 µM HLA-
Gsp.  Cells were then transferred to 37˚C water bath for indicated time in hours (hr), before staining for 
(c) 3D12, (d) HLA-Cw*0102 or isotype control as previously.   Data represent mean fluorescent 
intensity (MFI) of 10,000 gated events.   
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3.2.3. CD107a degranulation assays assessing recognition of Peptide:MHC class I by NK cell 
inhibitory receptors 
 
Lysosomal associated membrane protein-1 (LAMP-1 or CD107a) is expressed on the membrane of 
cytolytic granules and can be used as a sensitive marker of NK cell activation, correlating with both 
cytokine secretion and target cell lysis (Alter et al., 2004).  To determine the effects of cell surface 
stabilised MHC class I on NK cell activity a CD107a degranulation assay was performed.  IL-15 
treated PBMCs were incubated at 26˚C with 721.174 targets in the presence of monensin and an anti-
CD107a antibody or istotype control antibody.  Five colour flow cytometric analysis enabled 
identification of the lymphocyte population (forward and side scatter), total NK cell population (CD3
-
, 
CD56
+
), KIR2DL2/2DL3 (CD158b
+
) and CD94:NKG2A (NKG2A
+
) subsets (Figure 3.5 a).   The 
percentage of CD107a
+ 
NK cells was determined in PBMCs stimulated with IL-15 alone, or PBMCs 
stimulated with IL-15 and .174 target cells (data from one donor shown in Figure 3.5 b).  NK cell 
CD107a expression increased in the presence of unloaded .174 target cells (36.8%) compared those 
stimulated with IL-15 alone (2.4%). 
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a
 
 
b 
 
 
 
Figure 3.5. NK cell CD107a degranulation assay- data from one representative experiment 
Example of gating strategy used for FACS analysis (a).  Top row (L to R).  The lymphocyte population 
is identified on forward and side scatter.  The NK cell population is identified as CD3
-
 CD56
+
.   CD3
-
 
CD56
+
 NK cells can be subdivided into NKG2A
+
 and NKG2A
-
.  Bottom row (L to R).  CD3
-
 CD56
+
 NK 
cells sub-classified for into CD158b
+
 and CD158b
-
.  CD3
-
 CD56
+
 separated into 4 populations based 
on expression of NKG2A and CD158b: NKG2A
+
 CD158b
-
, NKG2A
-
 CD158b
+
, NKG2A
+
 CD158b
+
 
(double positive) and NKG2A
-
 CD158b
-
 (double negative). (b) histograms illustrating the percentage 
of CD3
-
 CD56
+
 NK cells expressing CD107a following incubation with .174 target cells at E:T ratio 5:1 
in the presence of CD107a antibody or an isotype control. 
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3.2.4. Optimisation of CD107a assay 
 
The optimal incubation time, effector to target cell (E:T) ratio and IL-15 concentration was determined 
for the CD107a assay using a series of experiments. 
 
3.2.4.1. Incubation time 
To determine whether a 4 hour co-incubation time is adequate to observe maximal CD107a 
expression, IL-15 stimulated PBMCs were incubated alone or with unloaded .174 target cells for 
between 1-6 hours at 26˚C.    CD107a was detectable on NK cells after 1 hour of co-incubation with 
.174 cells, reaching saturating levels after 4 hours (Figure 3.6), confirming this was a sufficient 
incubation time. 
 
3.2.4.2. E:T ratio 
To assess the optimal E:T ratio, IL-15 stimulated PBMCs were incubated with .174 cells (unloaded or 
pulsed with 100 µM HLA-Gsp) at E:T ratios ranging from 40:1 to  1:1 for 4 hours (Figure 3.7).  The 
maximal difference in CD107a expression induced by unloaded .174 cells compared to HLA-Gsp 
pulsed .174 was observed at an E:T of 5:1, therefore this ratio was used for all further experiments. 
 
3.2.4.3. IL-15 concentration 
IL-15 stimulation increases NK cell CD107a expression in the presence of MHC deficient target cells.  
PBMCs were incubated overnight at a range of IL-15 concentrations (0-3 ng/ml), before co-incubation 
with .174 target cells (unpulsed or loaded with 100 µM HLA-Gsp) at an E:T ratio of 5:1 for 4 hours at 
26˚C (Figure 3.8).  1 ng /ml IL-15 produced almost saturating levels of CD107a expression when 
stimulated with unloaded .174 cell targets.  Although higher IL-15 concentrations produced a small 
increase in CD107a expression, there was also an increase in CD107a expression in the presence of 
peptide loaded .174 cells.  Thus, the optimal IL-15 concentration required to observe the inhibitory 
effect of MHC class I binding peptides is 1ng/ ml.  
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Figure 3.6. Kinetics of CD107a expression on NK cells following stimulation with .174 cells 
CD107a assay protocol as described in Materials and Methods.  IL-15 treated PBMCs were incubated 
alone or with unloaded .174 cells at an E:T ratio of 5:1 at 26˚C for between 1-6 hours.  NK cell 
CD107a expression was determined using a FACS Canto flow cytometer. 
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Figure 3.7. Optimal E:T ratio for CD107a assay 
CD107a assay performed as described in Material and Methods.  3 x 10
5
 PBMCs co-incubated with 
different concentrations of .174 target cells (unpulsed or loaded with 100 µM HLA-Gsp) to determine 
the optimal E:T ratio for CD107a expression. 
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Figure 3.8. Determining the optimal IL-15 concentration required to stimulate PBMCs for 
CD107a assay 
CD107a assay performed as described in Material and Methods.  PBMCs stimulated overnight with 
different concentrations of IL-15 (0 - 3ng/ ml), before co-incubating with .174 cells (unloaded or pulsed 
with 100 µM HLA-Gsp) at an E:T ratio of 5:1 for 4 hours at 26˚C.   
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3.2.5. Peptide specific NK cell inhibition by HLA-E and HLA-Cw*0102 
 
MHC class I stabilisation assays revealed that HCV core35-44 and HLA-Gsp both increased cell surface 
HLA-E and HLA-Cw*0102 on .174 cells.  To determine the effects of peptide:MHC class I complexes 
on NK cell inhibition a CD107a degranulation assay was performed.   .174 cells were incubated 
overnight at 26˚C either alone, or in the presence of 100 µM HCV core35-44 or HLA-Gsp, before co-
incubating with IL-15 stimulated PBMCs for 4 hours at 26˚C.  Multiparameter flow cytometry was 
performed to determine the frequency of CD107a
+
 cells in each of the defined NK cell populations, 
including NKG2A (receptor for HLA-E) and CD158b (receptor for HLA-Cw102).  
In the absence of peptide, MHC deficient .174 cells stimulated NK cell activation, with increased 
CD107a frequency in the total NK (CD3
-
 CD56
+
), NKG2A
-
 CD158b
+
 and NKG2A
+
 CD158b
-
 
subpopulations (Figure 3.9).  In the presence of 100 µM HCV core35-44, there was a reduction in total 
CD107a expression, from 19.4% to 13.2%.  Looking at the subpopulations, no inhibition was 
observed in the NKG2A
+
 CD158b
-
 subpopulation (27.9% no peptide v 27.4% 100µM HCV core35-44).  
However, HCV core35-44 induced strong inhibition at NKG2A
-
 CD158b
+
, with a 65% reduction in 
CD107a expression (14.6% no peptide v 5% 100 µM HCV core35-44).  
100 µM HLA-Gsp also inhibited CD107a expression on the total NK cell population (19.4% no peptide 
v 8.1% 100 µM HLA-Gsp).  In contrast to HCV core35-44, the inhibitory effect HLA-Gsp was mediated by 
NKG2A
+
 subset (27.9% no peptide v 5.2% 100 µM HLA-Gsp), while no inhibition was seen at NKG2A
-
 
CD158b
+
 subpopulation (14.6% no peptide v 17.7% 100 µM HLA-Gsp).   
As a control, MHC class I negative K562 cells were incubated alone or with peptide.  Addition of 
peptide to K562 cells did not confer protection against PBMC degranulation, implying the effect of 
these peptides is mediated by the surface stabilisation of MHC class I as opposed to a direct effect of 
the peptide at inhibitory NK cell receptors. 
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Figure 3.9. Peptide specific recognition of MHC class I by NK cells 
CD107a (LAMP-1) was used as a marker of NK cell activation and degranulation.  A summary of the 
results from one representative assay are presented here.  Briefly, .174 target cells were incubated 
overnight at 26˚C either alone (no peptide) or with 100 µM of the indicated peptide.   The following 
day the .174 cells were used to stimulate IL-15 treated PBMCs for 4 hours at 26˚C in the presence of 
CD107a antibody.  Histogram plots for CD107a expression by the total NK (CD3
-
 CD56
+
), NKG2A
-
 
CD158b
+ 
and NKG2A
+
 CD158b
- 
subsets are shown. 
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To confirm the differing effects of HCV core35-44 and HLA-Gsp on NK cell degranulation, the experiment 
was repeated including a peptide titration 0-100 µM.  (Figure 3.10).  This confirmed that both HCV 
core35-44 and HLA-Gsp inhibit NK cell degranulation in a dose dependent manner (one way ANOVA 
p<0.0001).  However, they appear to mediate their inhibitory effects by different mechanisms.  HCV 
core35-44 inhibits the KIR2DL2/KIR2DL3
+ 
(CD158b
+
) subset (p<0.0001) but has no effect on the 
CD94:NKG2A
+
 NK cells (p=0.94).  In contrast, HLA-G sp inhibits via CD94:NKG2A
+
 NK cells (p 
<0.0001) and has no effect on KIR2LD2/2DL3
+
 NK cells (p = 0.99).  Thus, although both these 
peptides upregulate HLA-Cw*0102 and HLA-E expression on .174 cells, there appears to be a 
difference in recognition of these peptide complexes when bound to MHC class I.  HLA-E:HLA-Gsp 
complex is recognised by CD94:NKG2A
+
 NK cells, leading to inhibition of degranulation, while HLA-
E:HCV core35-44 complex does not appear to be recognised by this NK cell subset.  In contrast, HLA-
C:HCV core35-44 complex interacts with KIR2DL2/2DL3
+
 NK cells leading to inhibition of this subset, 
while HLA-C:HLA-Gsp complex is not recognised by this receptor.   
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Figure 3.10. CD107a degranulation assay including peptide titration 
CD107a assay was repeated on single donor to include varying concentrations 0-100 µM of indicated 
peptide.  (a) HCV core35-44 (n=9), (b) HLA-Gsp (n=4) CD107a expression presented for CD3
-
 CD56
+
 
(total NK), NKG2A
-
 CD158b
+ 
and NKG2A
+
 CD158b
-
 subsets. CD107a measured as percentage of 
specified population expressing CD107a.  The means and SEM are shown.  p values calculated using 
one-way ANOVA. 
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To confirm the differential effects of HCV core35-44 and HLA-Gsp pulsed .174 cells on NK cell 
degranulation, the CD107a assay was performed using blocking antibodies (Figure 3.11).  Antibodies 
to KIR2DL2/ KIR2DL3 (GL183), CD94 subunit of CD94:NKG2A (DX22) or an isotype control IgG1 
antibody, were added to PBMCs 30 minutes before the addition of target cells.  In the presence of a 
IgG1 control antibody, degranulation of the total NK population fell from a mean of 14.9% in the 
absence of peptide, to 8.6% in the presence of 100 µM HCV core35-44.  However, incubation of 
PMBCs with GL183 for 30 minutes prior to adding target cells completely abrogated the inhibitory 
effect of HCV core35-44 on NK cell degranulation (14.9%), whilst DX22 had no effect on inhibition 
(8.5%).  100 µM HLA-Gsp produced a reduction (4.8%) in CD107a expression after pre-incubation with 
the IgG1 control antibody compared to no peptide (14.9%).  DX22 negated the inhibitory effect of 
HLA-Gsp (16.2%) while GL183 did not interfere with inhibition (4.3%).   
The results of the blocking assay support the observation that HLA-E:CD94:NKG2A interaction is not 
responsible for the inhibitory effect of HCV core35-44.  Instead HCV core35-44 directly inhibits NK cell 
degranulation via enhanced expression of HLA-Cw*0102 interacting with KIR2DL2/2DL3 NK cell 
receptors.  In contrast, HLA-Gsp inhibits NK cell degranulation via CD94:NKG2A
+ 
and not 
KIR2DL2/2DL3
+ 
NK cells. 
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Figure 3.11. Effect of blocking antibodies on NK cell degranulation 
PBMCs were pre-incubated with blocking antibodies to KIR2DL2/2DL3 (GL183), CD94:NKG2A 
(DX22) or an isotype matched IgG1 control antibody. After 30 minutes, .174 target cells were added, 
either unpulsed (np) or loaded with 100 µM (a) HCV core35-44 or (b) HLA-Gsp.  Degranulation of CD3
-
 
CD56
+ 
NK cells was assessed using the previously described protocol.  Mean +/- SEM of 2 
experiments is shown. 
  
81 
 
3.2.6. Peptide mix experiments 
 
It has recently been demonstrated that HLA-C bound peptides that induce weak KIR binding can 
depress the inhibitory effect of a strong KIR binding peptide, thus acting as antagonistic peptide 
ligands (Fadda et al., 2010).  Having observed that HCV core35-44:HLA-E complex does not appear to 
be recognised by CD94:NKG2A, a peptide mix experiment was performed to determine whether HCV 
core35-44 could interfere with the inhibitory effects of HLA-Gsp at CD94:NKG2A (Figure 3.12).  1 µM of 
HLA-Gsp was sufficient to inhibit degranulation of approximately 35% of the .174 reactive NKG2A
+
 NK 
cells (23.2% no peptide v 15.1% 1 µM of HLA-Gsp), whereas 100 µM of HCV core35-44 had no effect 
(22.9%).  However, when 100 µM of HCV core35-44 was mixed with 1 µM of HLA-Gsp, rather than 
interfering with the inhibitory effect of HLA-Gsp there was a two fold increase in NK cell inhibition 
(6.4%). 
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Figure 3.12. HCV core35-44 and HLA-Gsp peptide mix assay 
CD107a assay of NKG2A
+ 
NK cells in response to 0-100 µM HCV core35-44 or HLA-Gsp alone or in 
combination.  Dot plots are gated on CD3
- 
CD56
+
 CD158b
-
 lymphocytes.  Percentage indicates 
frequency of CD107a positive events.   
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Figure 3.13. NK cell degranulation in response to increasing concentrations of HCV core35-44 in 
the presence or absence of 1 µM HLA-Gsp 
CD3
- 
CD56
+ 
NKG2A
+ 
CD158b
-
 NK cells are shown in the panel (a) and CD3
- 
CD56
+ 
NKG2A
- 
CD158b
+
 
in panel (b).  The mean +/- SEM of 3 independent experiments using one donor are shown.  Slope 
difference p values were calculated using linear regression comparing difference between the two 
lines.  All other p values calculated using one-way ANOVA. 
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Further assays were performed using different concentrations (0-100 µM) of HCV core35-44 alone or in 
addition to 1µM HLA-Gsp (Figure 3.13a).  HCV core35-44 in isolation did not inhibit degranulation of 
CD94:NKG2A
+
 NK cells (p= 0.49), as demonstrated in previous experiments.  However, in the 
presence of 1 µM HLA-Gsp, the addition of HCV core35-44 had a synergistic inhibitory effect at 
CD94:NKG2A (one way ANOVA p <0.0001).  This synergy was specific to the NKG2A
+
subset, and 
was not observed for CD158b+ cells (p=0.51) (Figure 3.13b).   
 
3.2.6.1. Effect of HLA-Gsp concentration on HCV core35-44synergy 
 
HLA-Gsp mediated inhibition at CD94:NKG2A saturates at approximately 50 µM (Figure 3.10 b).   The 
synergistic effect of HCV core35-44 at NKG2A was determined at saturating levels of inhibition of HLA-
Gsp (Figure 3.14. a) to determine whether any additional inhibition occurs.  At 100 µM HLA-Gsp, the 
presence of HCV core35-44 produced no additional inhibitory effect at NKG2A compared with 100 µM 
HLA-Gsp alone.  A titration of HLA-Gsp was performed to observe what effect changes in sub-
saturating levels of HLA-Gsp would have on HCV core35-44 mediated synergy.  In the absence of HCV 
core-35-44, increasing HLA-Gsp from 1-4 µM produced an increase in NK cell inhibition.  However, there 
was no significant increase in the maximum HCV core35-44 mediated synergistic inhibition at 
CD94:NKG2A (Figure 3.14 b).  Thus the synergistic effect of HCV core35-44 does not exceed the 
inhibitory effect of saturating levels of HLA-Gsp.   
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Figure 3.14. The effect of saturating levels of HLA-Gsp inhibition at NKG2A on HCVcore35-44 
mediated synergy 
(a) CD107a assay performed using .174 target cells incubated alone (no peptide), with 100 µM HCV 
core35-44 (HCV), 100 µM HLA-Gsp (Gsp), or 100µM of both peptides (Gsp + HCV). Mean and SEM 
CD107a
+
 NKG2A
+
 CD158b
-
 NK cell events are shown from 3 experiments using one donor.  Statistics 
calculated using one way ANOVA; ns = p> 0.05, *** = p<0.0001. (b) Titration of HLA-Gsp and HCV 
core35-44 synergy.  Percentage of CD107a
+
 NGK2A
+
 CD158b
-
 NK cells are shown at varying 
concentrations of HCV core35-44 and HLA-Gsp.  Mean and SEM of 3 experiments using one donor. 
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3.2.6.2. HCV core35-44 synergy in the presence of other MHC class I leader peptides 
 
As HLA-G is primarily expressed in the foetal trophoblast, HCV core35-44 mix experiments were 
repeated using leader peptides derived from more widely expressed classical MHC class I molecules 
HLA-A2 (HLA-A2sp- VMAPRTLVL) and HLA-B7 (HLA-B7sp- VMAPRTVLL).  As was observed with 
HLA-Gsp, the presence of HCV core35-44 peptide significantly enhanced NKG2A-mediated inhibition of 
NK cells by HLA-A2sp or HLA-B7sp (both p <0.0001), (Figure 3.15).  The synergy of HCV core35-44 with 
HLA-A2sp was confirmed in PBMCs from three additional healthy donors (Figure 3.16). 
HCV core35-44 induced a lower percentage synergistic effect in the presence of 1 µM HLA-B7sp. This 
may be because HLA-B7sp was a more potent inhibitor via CD94:NKG2A, thus inhibition was already 
approaching the maximal level induced by this peptide. 
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Figure 3.15. NK cell degranulation to .174 cells with HCV core35-44 in the presence or absence 
of HLA-A2sp and HLA-B7sp 
Data are normalised to CD107a expression by CD3
-
 CD56
+
 NGK2A
+
 CD158b
- 
NK cells incubated with 
unloaded .174 cells (HCV core35-44 alone), or to the level of inhibition at 1 µM HLA-A2sp or 1 µM HLA-
B7sp.  Mean + SEM of 6 independent experiments are shown.  P values calculated using one way 
ANOVA. 
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Figure 3.16. Synergy at NKG2A observed for three other donors 
Degranulation of CD3
+
 CD56
-
 NKG2A
+
 CD158b
-
 NK cells in response to .174 cells incubated with 0-
100 HCV core35-44 alone (closed symbols) or in the presence of 1 µM HLA-A2sp (open symbols).  Data 
from three independent experiments showing mean and SEM; p values calculated using one-way 
ANOVA.   
  
89 
 
3.2.6.3. Other viral and host derived peptides inducing synergy at NGK2A 
 
Peptides derived from a variety of viruses, including EBV, HIV and CMV, are known to bind HLA-E 
(Nattermann et al., 2005b; Tomasec et al., 2000; Ulbrecht et al., 1998).  The HIV p24 peptide 
residues 14-22 (HIVp2414-22; AISPRTLNA) was identified by a motif-based approach (Nattermann et 
al., 2005b). In chronic HIV infection there is up-regulation of HLA-E on CD4
+
 T cells resulting in 
increased inhibition of NKG2A
+
 NK cells (Martini et al., 2005; Nattermann et al., 2005b).  The peptide  
SQAPLPCVL  from EBV BZLF-1 protein residues 39-47 (EBVbzlf39-47) has also been shown to bind to 
HLA-E (Ulbrecht et al., 1998).  Our data showed that although both these viral peptides stabilize cell 
surface HLA-E on the .174 cell line (Figure 3.17), in isolation they do not inhibit NKG2A
+
 NK cells.  
However in the presence of 1µM HLA-A2sp, these peptides had a dose dependent synergistic 
inhibitory effect (Figure 3.18).   Similarly hsp60sp, the host derived stress induced peptide that is 
known to bind to HLA-E but does not inhibit at CD94:NKG2A, had a synergistic effect on NKG2A
+
 cell 
inhibition mediated by HLA-A2sp.  Thus, synergistic inhibition at CD94:NKG2A can be induced by both 
host and viral peptides. 
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Figure 3.17. HLA-E stabilisation by other viral and host derived peptides 
HLA-E upregulated on the surface of .174 cells by (a) EBV bzlf39-47, (b) HIV p2414-22 and (c) hsp60sp.  
.174 cells were incubated for 16 hours at 26˚C either alone or with the specified peptide, before 
staining with an anti-HLA-E antibody, as described in Materials and Methods.  Data represent mean 
fluorescent intensity of 10,000 gated events shown as histograms.   
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Figure 3.18. Synergy at NKG2A is a shared mechanism for other viral and host derived 
peptides 
CD3
-
 CD56
+
 NKG2A
+
 CD158b
- 
NK cell degranulation in response to increasing concentrations of 
indicated peptide in the presence or absence of 1µM HLA-A2sp.  Data are normalised to NK cell 
degranulation in response to unpulsed .174 cells (in the absence of HLA-A2sp) or to 1 µM  HLA-A2sp.   
(a) EBV BZLF peptide (residues 39-47).  (b) HIVp24 peptide (residues 14-22). (c) hsp60 signal 
peptide.  Mean +/- SEM of 3 independent experiments using one donor are shown, p values 
calculated using one-way ANOVA. 
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3.2.6.4. Peptide synergy is specific to NKG2A 
 
The effect of synergistic peptides at NKG2A and KIR2DL2/2DL3 (CD158b) was further characterised 
by comparing CD107a expression by different NK cell subsets: NKG2A
+
 CD158b
-
, NKG2A
-
 CD158b
+
, 
NKG2A
+
 CD158b
+
 and NKG2A
-
 CD158b
-
.  At CD158b, HCV core35-44 and HLA-A2sp independently 
produce direct inhibition; however, no synergistic inhibitory effect was observed at this receptor when 
these peptides were mixed (Figure 3.19).  Synergy was specific to the NKG2A
+
 CD158b
-
 population, 
and was not observed in the NKG2A
-
 CD158b
-
 population. 
In contrast to HCV core35-44, EBV bzlf39-47 alone did not inhibit NKG2A
-
CD158b
+
 NK cells (Figure 
3.20).  Additionally, in the presence of HLA-A2sp, EBV bzlf39-47 did not synergise to inhibit NKG2A
-
CD158b
+
, or the NKG2A
-
 CD158b
- 
subset.  A synergistic effect was observed for NKG2A
+
 CD158b
-
 
NK cells, with a similar level of inhibition seen for the NKG2A
+
 CD158b
+
 subset.   
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Figure 3.19. HCV core35-44 and HLA-A2sp peptide mix experiment comparing different NK cell 
populations 
CD3
-
 CD56
+ 
NK cell degranulation in response to increasing concentrations of HCV core35-44 alone 
(black symbols/ line) or mixed with 1µM HLA-A2sp (blue symbols/ line).  Top left panel gated on 
NKG2A
-
 CD158b
-
, top right panel NKG2A
+
 CD158b
-
, bottom left panel NKG2A
+
 CD158b
+
, bottom right 
panel NKG2A
-
 CD158b
+
 subset.  Mean +/- SEM of 3 independent experiments using one donor are 
shown. Slope difference p values were calculated using linear regression comparing difference 
between the two lines.   
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Figure 3.20. EBV bzlf39-47 and HLA-A2sp peptide mix experiment 
CD3
-
 CD56
+ 
NK cell degranulation in response to increasing concentrations of EBV bzlf39-47alone 
(black symbols/ line) or mixed with 1µM HLA-A2sp (blue symbols/ line).  Top left panel gated on 
NKG2A
-
 CD158b
-
, top right panel NKG2A
+
 CD158b
-
, bottom left panel NKG2A
+
 CD158b
+
, bottom right 
panel NKG2A
-
 CD158b
+
 subset.  Mean +/- SEM of 3 independent experiments using one donor are 
shown. Slope difference p values were calculated using linear regression comparing difference 
between the two lines.   
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3.2.6.5. Variant of HCV core35-44 peptide 
 
HCV sequence screening from a cohort of individuals infected with a single source exposure to HCV 
demonstrated only one variant of the HCV core35-44 peptide, that has a lysine for arginine substitution 
at position 9 (HCV coreR9K- YLLPRRGPKL).   This epitope has previously been shown to be a CTL 
escape variant at HLA-A2, but in general is well conserved (Nattermann et al., 2005a).   HCV coreR9K 
stabilised HLA-Cw*0102 and HLA-E to similar levels as HCVcore35-44 (Figure 3.21).  In degranulation 
assays, HCV coreR9K did not inhibit CD158b
+
 NK cells but had a similar synergistic inhibitory effect to 
the wild-type peptide on NKG2A
+
 NK cells (Figure 3.22).  Thus although this mutation retains the 
ability of the wild type epitope to inhibit NK cells through NKG2A, it loses the ability to inhibit through 
engagement of KIR. 
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Figure 3.21. HCV coreR9K induces stabilisation of HLA-E and HLA-Cw*0102 
.174 cells were incubated for 16 hours at 26˚C either alone or with the specified peptide, before 
staining with (a) anti-HLA-E antibody (3D12) or (b) anti-HLA-Cw*0102 (VP6G3), or an isotype control 
as described in Materials and Methods.  Data represent mean fluorescent intensity of 10,000 gated 
events shown as histograms.   
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Figure 3.22. NK cell degranulation (CD107a expression) in response to target cells incubated 
with 0-100 µM HCVcoreR9K 
Gated on (a) Total NK (CD3
-
 CD56
+
), (b) NKG2A
-
 CD158b
+
, (c & d) NKG2A
+
 CD158b
-
, comparing 
effect in the presence or absence of 1 µM HLA-A2sp.  Mean +/- SEM of 3 independent experiments 
using one donor are shown, p values calculated using one-way ANOVA. 
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3.3. Discussion 
 
The non-classical MHC class Ib molecule HLA-E is known to bind a closely related set of highly 
conserved nonameric peptides derived from the leader sequences of other MHC class I molecules 
(Miller et al., 2003).  However, it is also capable of binding viral peptides and peptides composed of 
hydrophobic residues, which may not conform to predicted binding motifs (Brooks et al., 1999; 
Michaelsson et al., 2002; Nattermann et al., 2005a; Nattermann et al., 2005b).  Flow cytometry 
assays confirmed that the classical MHC class I signal peptides HLA-A2sp, HLA-B7sp and HLA-Gsp all 
enhanced cell surface HLA-E on an MHC deficient .174 cell line.  HLA-E binding was also 
demonstrated for virus derived peptides HCVcore35-44, EBVbzlf39-47, HIVp2414-22 and the leader 
sequence of the heat shock protein 60 peptide, hsp60sp, consistent with published observations.    
CD107a degranulation assays were used to investigate the effects of host and virus derived peptides 
on NK cell activity.  HLA-E bound HLA-A2sp, HLA-B7sp and HLA-Gsp all inhibited degranulation of the 
NKG2A
+
 NK cell subset, whereas HCV core35-44, EBV bzlf39-47, HIV p2414-22 and hsp60sp did not.   
 
It has recently been demonstrated that HLA-C bound peptides that induce weak KIR binding can 
interfere with the inhibitory effect of a strong KIR binding peptide (Fadda et al., 2010).  This study 
used two peptides, VAP-FA (VAPWNSFAL) and VAP-DA (VAPWNSDAL), that had similar affinity for 
HLA-Cw*0102.  VAP-FA:HLA-C was recognised by CD158b
+
 NK cells producing inhibition of this NK 
cell subset, whereas VAP-DA:HLA-C was not.  However, when these two peptides were mixed, VAP-
DA interfered with the inhibitory effect of the VAP-FA peptide, a phenomenon termed peptide 
antagonism.  To determine whether comparable antagonism occurred at CD94:NKG2A, peptide mix 
experiments were performed using HLA-Gsp and HCV core35-44.  In the absence of MHC class I leader 
peptides, HCV core35-44 pulsed .174 cells did not inhibit degranulation of NKG2A
+
 NK cells.  However, 
.174 cells pulsed with HCV core35-44 and 1 µM HLA-Gsp led to twice as much inhibition of the NKG2A
+
 
subset compared to 1 µM HLA-Gsp alone.  This enhanced inhibition in the presence of HCV core35-44, 
termed peptide synergy, was also observed in the presence of 1 µM HLA-A2sp and 1 µM HLA-B7sp 
and was confirmed in three independent PBMC donors.   
99 
 
HCV core35-44, EBV bzlf39-47, HIV p2414-22 and hsp60sp all induce dose related synergistic inhibition at 
CD94:NKG2A when mixed with 1 µM MHC class I leader peptide, without any direct inhibitory effect 
at this receptor in single peptide experiments.  This would suggest that synergy at CD94:NKG2A is a 
shared mechanism for viral and certain host peptides that bind to HLA-E.  Additionally, the 
observation of peptide synergy at CD94:NKG2A contrasts peptide antagonism seen at KIR.  
 
hsp60sp (QMRPVSRVL) and EBV bzlf39-47 (SQAPLPCVL) have previously been shown to bind to HLA-
E but not CD94:NKG2A (Brooks et al., 1999; Michaelsson et al., 2002).  hsp60sp contains P2 
methionine and P9 leucine, consistent with HLA-E binding MHC class I derived leader peptides, but 
the presence of P5 valine is thought to interfere with  recognition by CD94:NKG2A.  EBV bzlf39-47 has 
glutamine at P2, which is reported to be second only to methionine in predicted affinity for HLA-E, 
while P9 leucine would favour binding to HLA-E (Miller et al., 2003).  However, P5 leucine does not 
permit recognition by CD94:NKG2A. HCV core35-44 (YLLPRRGPRL) and HIVp2414-22 (AISPRTLNA) 
also bound to HLA-E, consistent with previous studies (Nattermann et al., 2005a; Nattermann et al., 
2005b).  HCV core35-44 does not conform to the predicted binding motif of HLA-E, but has an 
abundance of hydrophobic residues which favour binding.  HIVp2414-22 has P2 isoleucine, has been 
predicted to permit HLA-E binding, while the residues at lesser anchor positions of P4, P6 and P7 are 
shared with host MHC class I signal peptides that bind to HLA-E (Miller et al., 2003).  Both HCV 
core35-44 and HIV p2414-22 contain P5 arginine, which is known to be dominant contact residue for 
binding to CD94:NKG2A; however, in our single peptide experiments neither of these peptides were 
capable of inhibiting NKG2A
+
 cells.  It is possible that with HCV core35-44 being a 10 amino-acid 
peptide, there is an alteration in the conformation of this peptide within the binding groove of HLA-E.  
In 9mer peptides, the P5 and P6 side chains align toward the α2 and α1 helices, respectively, but for 
the 10mer the orientation changes so that P5 points toward the α1 helix and P6 toward the α2 helix 
(Madden et al., 1993; O'Callaghan et al., 1998).  In the case of HIV p2414-22 residues P8 (asparagine) 
and P9 (alanine) may be relevant, as a standard conformation of P8 and P9 residues is imposed by 
conserved network of hydrogen bonds.  Alterations at P8 and P9 can affect side chain positions at the 
centre (P5, P6, or P7) of the peptide (Madden et al., 1993).  Thus, although both HCV core35-44 and 
HIV p2414-22 contain P5 arginine, our experiments suggest this is not sufficient to enable inhibition at 
CD94:NKG2A.  This may be explained by crystal structure analyses showing that binding affinities of 
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peptides to HLA-E are complex and amino acid residues interact within the peptide to produce 
conformational structures that may conflict with current binding prediction motifs.  
 
Peptide stabilisation assays showed that HLA-A2sp, HLA-B7sp, HLA-Gsp, hsp60sp, HCV core35-44 and 
EBV bzlf39-47 also increased cell surface HLA-Cw*0102, the ligand for KIR2DL2/2DL3 (CD158b) 
receptor.  This dual affinity of peptides for HLA-C and HLA-E may be consistent with published data.  
It has been reported that HLA-C and HLA-A2 bind similar peptides, as do HLA-E and HLA-A2 
(Andersen et al., 1999; Lampen et al., 2013).  Therefore, it could be predicted that HLA-C and HLA-E 
may have similar peptide binding affinities.  These peptides also conform to predicted HLA-Cw*0102 
binding motifs.  MHC class I derived signal peptides, hsp60sp and EBV bzlf39-47 are all nonameric 
peptides possessing P9 leucine, which is a key anchor residue for HLA-Cw*0102.  The decamer HCV 
core35-44 has P2 and P3 leucine, which would predict binding, while P10 leucine may also be relevant 
in the conformational structure of the peptide. 
 
.174 target cells pulsed with HCV core35-44  induce direct inhibition of the CD158b
+
 subset, whereas 
EBV bzlf39-47 had no inhibitory effect.  Residues P7 and P8 of HLA-Cw*0102 bound nonameric 
peptides can predict recognition by KIR2DL2/2DL3
+
 NK cells, as demonstrated by Fadda et al, 2010.  
Using this predicted binding tool, EBV bzlf39-47 (SQAPLPCVL) would be predicted to have low affinity 
for HLA-Cw*0102, consistent with our findings.  As HCV core35-44 (YLLPRRGPRL) is a decamer, the 
predicted binding tools could be less accurate as the exact conformation of the peptide may vary 
compared to nonamer sequences.  Glycine, proline and arginine are favourable residues at P7 or P8, 
once again consistent our findings.  In peptide mix experiments using MHC class I signal peptides 
and either HCV core35-44 or EBV bzlf39-47, analysis of NK cell subsets showed no synergistic effect 
observed for either peptide at CD158b, suggesting that peptide synergy is specific to the NKG2A
+
 
cells.       
 
HCV sequence screening from a cohort of individuals infected with a single source exposure to HCV 
demonstrated just one variant of HCV core35-44 with a P9 lysine for arginine substitution (HCV 
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coreR9K).  In peptide stabilization assays, HCV coreR9K enhanced cell surface HLA-Cw*0102 and HLA-
E to similar levels as HCVcore35-44.  CD107a assays revealed HCV coreR9K did not inhibit CD158b
+
 
NK cells but induced synergy similar to HCVcore35-44 on NKG2A
+
 NK cells.  Thus although this 
mutation retains the ability of the wild type peptide to inhibit NK cells by engaging NKG2A, it has lost 
the ability to inhibit through KIR. 
The next chapter will address possible mechanisms for peptide synergy observed at CD94:NGK2A. 
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Chapter 4. CD94 homodimers and peptide synergy 
 
4.1. Introduction 
 
CD94:NKG2A is a heterodimeric inhibitory receptor belonging to the C-type lectin-like receptor family.  
This family of transmembrane glycoproteins additionally includes the activating molecules NKG2C, 
NKG2E and NKG2D.  NKG2C and NKG2E also dimerise with CD94, displaying over 90% sequence 
homology to NKG2A in their ectodomains (Lazetic et al., 1996).  In contrast, NKG2D appears a 
somewhat different receptor sharing only 21% homology with other NKG2 molecules (Ho et al., 1998).  
NKG2D does not pair with CD94, instead operating as a homodimer (McFarland and Strong, 2003).   
 
CD94:NKG2 receptors are expressed in both man and mouse.  In humans, all CD94:NKG2 members 
share HLA-E as their ligand with the CD94 moiety dominating (80%) interaction with this MHC class 
Ib molecule (Braud et al., 1998).  The main cell types expressing CD94:NKG2 receptors are NK cells 
and CD8
+
 T cells.  Following successful ligation of CD94:NKG2A, an inhibitory signal is mediated 
through two ITIM sequences attached to the cytoplasmic tail of the NKG2A moiety.  Though the 
activating molecules NKG2C and NKG2E do not possess a cytoplasmic signalling domain, they have 
a positively charged residue within their transmembrane region which forms an ionic bond to the 
ITAM-containing adaptor protein DAP-12 (Lanier et al., 1998).  In contrast, CD94 does not possess its 
own signalling motif and therefore cannot transduce a signal in the absence of its NKG2 partners.   
 
Crystal structure analysis of CD94:NKG2A bound to HLA-E demonstrates CD94 and NKG2A 
interacting mostly with the α1 and α2 domains of HLA-E respectively (Li et al., 2001; Petrie et al., 
2008; Sullivan et al., 2007).  The CD94 footprint on HLA-E is broad, with residues within loops 2, 3, 
and 5, and β strands 6 and 7 from CD94 interacting with a region spanning residues 65-89 of the α1 
helix of HLA-E (Petrie et al., 2008).  The interaction matches a hydrophobic region on HLA-E (Ile73, 
Val76) and a similar region on CD94 (Phe114, Leu162) (Wada et al., 2004).   This hydrophobic region 
is associated with a cluster of complementary charged residues: a basic cluster in HLA-E (Arg75, 
Arg79) and an acidic cluster in CD94 (Asp163, Glu164 and Asp168).   The footprint of NKG2A on 
HLA-E is much smaller compared to CD94, with loop 3 and β strands 2, 5, and 6 interacting with 
residues 151–162 of the α2 helix of HLA-E.  Wada et al. used individual alanine-substitutions to 
103 
 
demonstrate that mutation of Arg75 and Arg79 impairs HLA-E binding to CD94:NKG2 molecules.   A 
distinction between NKG2A and NKG2C recognition of HLA-E was also shown in this study.  D69A 
and H155A mutations on HLA-E selectively impair HLA-E binding to CD94:NKG2A, but generally do 
not affect HLA-E binding to CD94:NKG2C. Asp69 and His155 are situated at the centre of the α1 and 
α2 helices, respectively, which accommodate the HLA-E-bound peptide.  This raises the possibility 
that HLA-E loaded with certain peptides may preferentially bind CD94:NKG2C but not CD94:NKG2A.  
Furthermore, it has been shown that there is a 6-fold greater affinity in the interaction between CD94-
NKG2A/ HLA-E compared to CD94-NKG2C/ HLA-E (Kaiser et al., 2005). 
 
Petrie et al. have shown that the CD94 subunit has a much more dominant role than NKG2A in 
interacting with the peptide bound by HLA-E, forming 80% of the contact mainly over the C terminus 
of the peptide (Petrie et al., 2008).  In agreement with this, it has been observed that substitutions at 
the C-terminus of the HLA-E bound peptide affect the interaction with of all CD94:NKG2 receptors in a 
similar manner (Kaiser et al., 2005).  CD94 interacts with P5 arginine, P6 threonine and P8 
phenylalanine.  In contrast, NKG2A interaction with the peptide is less prominent, with the subunit 
lying adjacent to the P5 arginine, forming van-der-Waals interaction using residue Pro171 (Petrie et 
al., 2008). 
 
In the previous chapter we observed that P5 arginine to lysine impaired recognition by CD94:NKG2A 
but had no effect on HLA-E binding.  The P5 arginine protrudes into a cavity between NKG2A and 
CD94 subunits, with its aliphatic side chain flanked in an anti-parallel manner with Gln112 of CD94 
(O'Callaghan et al., 1998).  The P5 arginine is not well complemented by any charged interactions 
with CD94:NKG2A, which may be attributable to it salt bridging to Glu152 on the top surface of the α2 
helix of HLA-E (Figure 4.1).   Petrie et al. also assessed the effect of P5 arginine to lysine 
substitution.  This abrogates recognition by CD94:NGK2A, suggesting either that the P5 lysine to 
Glu152 salt bridge is lost, thereby introducing a buried positive charge at the interface, or highlighting 
the importance of the P5 residue interacting with Ser110 of CD94 (Petrie et al., 2008).  
In this chapter we assess in greater detail the phenomenon of peptide synergy observed at 
CD94:NKG2A.   We determine whether synergy is specific to HLA-E binding peptides or whether 
peptides binding to other MHC class I molecules behave similarly.  Peptide specificity is also 
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assessed by lysine substitution at certain positions in the peptide sequence.  Finally, using confocal 
microscopy and blocking antibody CD107a assays we determine the respective significance of the 
CD94 and NKG2A subunits in peptide synergy. 
 
 
Figure 4.1. The CD94:NKG2A-HLA-E-HLA-Gsp complex 
NKG2A and CD94 represented as blue and pale green ribbon structures respectively.  The HLA-E 
heavy chain and β2m are shown as violet and cyan ribbons respectively, with HLA-Gsp in orange 
sticks.  (A) side view of CD94:NKG2A docking onto HLA-E:HLA-Gsp.  (B) Top view of CD94:NKG2A 
docking onto the surface of HLA-E:HLA-Gsp.  Figure from Petrie et al. (2008). 
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4.2. Results 
 
4.2.1. Is synergistic inhibition at CD94:NKG2A induced by generalised upregulation of MHC 
class I? 
 
In the previous chapter, we showed that certain virus and host derived peptides (HCV core35-44, HCV 
coreR9K EBV bzlf39-47, HIV p2414-22 and hsp60sp) alone do not inhibit at CD94:NKG2A but promoted 
synergistic inhibition at this receptor when mixed with 1 µM MHC class I leader peptide.  These 
synergistic peptides all bind to HLA-E in MHC class I binding assays.  To determine whether this 
effect is specific to HLA-E, peptide mix experiments were performed using the HLA-A2 specific 
influenza matrix-derived peptide GILGFVFTL (GILG) (Shimojo et al., 1989).  MHC class I stabilization 
assays using the HLA-A2 specific BB7.2 antibody showed increased cell surface HLA-A2 on .174 
cells pulsed with the GILG peptide, with no HLA-E upregulation detected using the HLA-E specific 
3D12 antibody (Figure 4.2 a & b).  Consistent with the absence of HLA-E binding, CD107a 
degranulation assays revealed no inhibitory effect of GILG at CD94:NKG2A.  However, in contrast to 
the HLA-E binding peptides, GILG did not induce synergy at NKG2A when mixed with 1 µM HLA-A2sp 
(Figure 4.3). 
VAPWNSDAL (VAP-DA) is a model peptide that has been shown to bind HLA-Cw*0102 but it does 
not inhibit via KIR2DL2/2DL3 (Fadda et al., 2010).  It was defined following screening of a library of 
variants of the tissue inhibitor of metalloproteinase (TIMP)-1 peptide VAPWNSLSL.  VAP-DA binding 
to HLA-Cw*0102 on .174 cells was confirmed using the VP6G3 antibody, in the absence of HLA-E 
binding.  Once again CD107a assays revealed no inhibition of either KIR2DL2/2DL3
+
 (CD158b
+
) or 
NKG2A
+
 NK cells.  Additionally, peptide mix experiments with 1 µM HLA-A2sp did not promote synergy 
at either NKG2A or CD158b (Figure 4.4).    
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Figure 4.2. MHC class I stabilisation assay for GILG and VAP-DA peptides 
.174 cells were incubated for 16 hours at 26˚C either alone or with the specified peptide, before 
staining with (a & c) anti-HLA-E antibody (3D12), (b) anti HLA-A2 (BB7.2) or (d) anti-HLA-Cw*0102 
(VP6G3), as described in Materials and Methods.  Data represent mean fluorescent intensity of 
10,000 gated events shown as histograms.   
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Figure 4.3. NK cell degranulation in response to increasing concentrations of GILG peptide in 
the presence or absence of 1 µM HLA-A2sp 
The percentage of CD3
- 
CD56
+ 
NKG2A
+ 
CD158b
-
 NK cells expressing CD107a is shown.  Mean +/- 
SEM of 3 independent experiments using one donor are shown.  Slope difference p values were 
calculated using linear regression comparing difference between the two lines.  All other p values 
calculated using one-way ANOVA. 
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Figure 4.4. NK cell degranulation in response to increasing concentrations of VAP-DA peptide 
in the presence or absence of 1 µM HLA-A2sp 
Showing percentage of CD107a
+
 NK cells gated on (a) NKG2A
+ 
CD158b
- 
and (b) NKG2A
- 
CD158b
+
 
subsets. Mean +/- SEM of 3 independent experiments using one donor are shown.  Slope difference p 
values were calculated using linear regression comparing difference between the two lines.  All other 
p values calculated using one-way ANOVA. 
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4.2.2. Is synergistic inhibition at CD94:NKG2A dependent on the presence of a host MHC class 
I derived leader peptide? 
 
We have shown that synergy at CD94:NKG2A occurs in the presence of 1 μM of HLA-Gsp, HLA-A2sp 
or HLA-B7sp.  These host MHC class I derived leader peptides all bind to HLA-E producing inhibition 
at CD94:NKG2A.  To determine if a synergistic peptide requires the presence of a cognate ligand for 
HLA-E/ CD94:NKG2A we repeated HCV core35-44 peptide mix CD107a degranulation assays in the 
presence or absence of either 1 μM VAP-DA or 1 μM GILG peptide (Figure 4.5).  HCV core35-44 failed 
to produce synergistic inhibition at CD94:NGK2A in the presence of either the HLA-Cw*0102 specific 
VAP-DA peptide or the HLA-A2 specific GILG peptide.  Thus, to exert their inhibitory effect, 
synergistic peptides require the presence of a HLA-E/ CD94:NKG2A binding peptide. 
  
110 
 
 
 
 
 
 
 
Figure 4.5.  NK cell degranulation in response to increasing concentrations of HCV core35-44 
peptide in the presence or absence of (a) 1 µM VAP-DA and (b) 1 µM GILG peptide 
Percentage of CD107a
+
 events are shown gated on CD3
-
 CD56
+ 
NKG2A
+ 
CD158b
-
.  Mean +/- SEM of 
3 independent experiments using one donor are shown.  Slope difference p values were calculated 
using linear regression comparing difference between the two lines.  All other p values calculated 
using one-way ANOVA. 
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4.2.3. Do all HLA-E binding peptides induce synergy? Effect of Position 5 Lysine substitution 
 
The P5 residue of HLA-E bound peptide is in direct contact with CD94 and NKG2A (Petrie et al., 
2008).  P5 arginine to lysine (R5K) substitution of HLA-Gsp reduces the affinity of the peptide/HLA-E 
complex for CD94-NKG2A by more than ten-fold (Kaiser et al., 2008).  Host and viral peptides that 
mediate synergy share the common feature of HLA-E binding in the absence of direct inhibition at the 
CD94:NKG2A receptor.  To determine whether interaction with CD94:NKG2A was essential for a 
synergistic peptide, or if HLA-E binding alone was sufficient, peptide mix experiments were performed 
using HLA-GR5K (VMAPKTLFL).  
 
HLA-GR5K stabilized HLA-E to a similar extent as the wild-type peptide, but did not induce inhibition of 
NKG2A
+
 NK cells (Figure 4.6).   Furthermore, the addition of HLA-GR5K to HLA-A2sp did not result in 
synergy.  Instead, as the concentration of HLA-GR5K was increased, there was a dose related reversal 
of NK cell inhibition mediated by HLA-A2sp.  This is most likely due HLA-E becoming progressively 
more occupied with HLA-GR5K rather than the CD94:NKG2A agonist HLA-A2sp. 
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Figure 4.6. HLA-GR5K binding to HLA-E and effect on NK cell degranulation 
(a & b) .174 cells were incubated for 16 hours at 26˚C either alone or with the specified peptide, 
before staining with an anti-HLA-E antibody (3D12), as described in Materials and Methods.  Data 
represent mean fluorescent intensity of 10,000 gated events shown as (a) histograms, (b) plotted 
against peptide concentration.(c) NK cell degranulation in response to .174 cells loaded with 
increasing concentrations of HLA-GR5K or HLAGsp peptide. (d) NK cell degranulation in response to 
.174 cells loaded with HLA-GR5K in the presence or absence of 1 µM HLA-A2sp.(mean +/- SEM of 3 
independent experiments).  p values calculated using one-way ANOVA.  For (c) & (d) Percentage of 
CD107a
+ 
NKG2A
+ 
CD158b
- 
cells shown.   
 
 
 
  
113 
 
The observation that HLA-GR5K binds to HLA-E but does not synergise with MHC class I derived 
peptides to inhibit NK cells led us to investigate the effect of lysine substitution on the synergistic 
effect of HCV core35-44 and EBV bzlf39-47.  As HCV core35-44 is a 10mer, substitutions were performed at 
either position 5 (HCV coreR5K) or position 6 (HCV coreR6K), in both cases replacing an arginine 
residue with lysine.   A position 5 substitution was also performed for the EBV bzlf39-47, in this instance 
replacing leucine for lysine (EBV bzlfL5K).   
The effect of this lysine substitution on HLA-E affinity was determined in an HLA-E stabilization assay, 
in each case comparing the lysine substituted peptide with the wild type peptide (Figure 4.7).     EBV 
bzlfL5K, HCV coreR5K and HCV coreR6K all had similar affinity for HLA-E as their respective wild type 
peptides.  This is consistent with previous observation showing that P5 lysine substitution has a 
relatively small effect on affinity for HLA-E (Miller et al., 2003). 
The effect of lysine substitution on the synergistic inhibition of NK cell degranulation was investigated.  
In the presence of 1 µM HLA-A2sp, HCV core35-44 and EBV bzlf39-44 inhibit CD107a expression of 
NKG2A
+
 in a dose dependent manner, but do not induce inhibition in the absence HLA-A2sp 
consistent with our observations presented in the previous chapter.  In contrast, EBV bzlfL5K, HCV 
coreR5K and HCV coreR6K failed to induce any inhibitory effect on NKG2A
+
 NK cell activity, regardless 
of the presence of HLA-A2sp (Figure 4.8). 
Thus lysine substitution at position 5 of EBV blzf39-47 and position 5 or position 6 of HCV core35-44 
annuls the synergistic inhibitory effect of these peptides on NKG2A
+
 NK cells, without affecting their 
binding to HLA-E.  This would support the model that not all HLA-E binding peptides promote 
synergistic inhibition at CD94:NKG2A. 
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Figure 4.7. Effect of lysine substitution on peptide mediated HLA-E stabilisation 
.174 cells were incubated for 16 hours at 26˚C either alone or with 100 µM of the specified peptide, 
before staining with an anti-HLA-E antibody (3D12), as described in Materials and Methods.  Data 
represent mean fluorescent intensity of 10,000 gated events shown as histograms.   
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Figure 4.8. Effect of lysine substitution on peptide synergy at CD94:NKG2A 
NK cell degranulation (CD107a expression) in response to increasing concentrations of the specified 
peptide, in the presence or absence of 1 µM HLA-A2sp.  (a) left panel HCV core35-44, right panel HCV 
coreR5K, (b)  left panel HCV core35-44, right panel HCV coreR6K, (c) left panel EBV bzlf39-47, right panel 
EBV bzlfL5K.  Percentage of CD107a
+ 
NKG2A
+ 
CD158b
- 
NK cells shown for one donor (mean +/- SEM 
of 3 independent experiments).  Slope difference p values were calculated using linear regression 
comparing difference between the two lines.  All other p values calculated using one-way ANOVA. 
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4.2.4. Peptides that stabilise HLA-E but do not inhibit NK cells induce clustering of CD94 but 
not NKG2A at the Immune Synapse 
 
The signalling component of the CD94:NKG2A heterodimer is NKG2A which possesses two ITIMs 
within its cytoplasmic tail, whereas CD94 contains no signaling motifs.  Confocal microscopy was 
used to examine the effect of peptides presented by HLA-E on CD94 and NKG2A clustering at the 
contact surface formed between effector and target cell membranes, termed the immune synapse.  
NKL cells were co-incubated with .174 cells that were loaded with peptide (HLA-Gsp, HLA-A2sp, 
HCVcore35-44, HLA-A2sp + HCV core35-44, or HLA-GR5K).   The target and effector cell complexes were 
stained for CD94 (mAb DX22) or NKG2A (mAb Z199). Quantification of staining intensity at the 
immune synapse showed that the MHC class I inhibitory peptides HLA-Gsp and HLA-A2sp promoted 
aggregation of both CD94 and NKG2A (Figure 4.9).  However, HCV core35-44 induced clustering of 
CD94 (one way ANOVA p<0.0001), but not NKG2A at the immune synapse (p>0.05).  The 
combination of HCV core35-44 and HLA-A2sp resulted in greater CD94 aggregation (both fold increase 
intensity and as percentage of total aggregates, p<0.05) compared to HLA-A2sp alone, implying 
recruitment of additional CD94-associated complexes.   In contrast, HLA-GR5K did not promote 
aggregation of either CD94 or NKG2A.   
 
Clustering of CD94 but not NKG2A was also demonstrated for target cells loaded with other HLA-E 
binding synergistic peptides, EBV bzlf39-47, HIVp2414-22 and hsp60sp (Figure 4.10).    Therefore 
synergistic peptides appear to induce aggregation of the non-signalling molecule CD94 in the 
absence of the signalling moiety NKG2A.  
 
Imaging of the immune synapse was also performed using untouched primary NK effector cells 
isolated from PBMCs by negative selection.   In contrast to the NKL cell line where CD94:NKG2A is 
expressed on almost all cells (>90% NKL cells are NKG2A
+
 on flow cytometry analysis), NKG2A 
expression on primary NK cell varies from 30-60%.  In the selected donor 45% of NK cells were 
NKG2A
+
 on flow cytometry analysis.   Confocal microscopy revealed a lower fluorescent intensity of 
both CD94 and NKG2A staining compared to NKL imaging, with a proportion of NK cells staining 
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negative for both receptor subunits, consistent with the flow cytometry data for this donor.    HLA-A2sp 
promoted aggregation of both CD94 and NKG2A, while HCV core35-44 induced clustering of CD94 but 
not NKG2A, consistent with experiments performed using the NKL cell line (Figure 4.11).  Similar to 
the HLA-GR5K peptide, imaging showed that HCV coreR5K did not promote clustering of either CD94 or 
NKG2A. Therefore the loss of synergy observed following lysine substitution of HLA-E binding 
peptides is accompanied by an abrogation of CD94 clustering. 
 
Double staining of immune synapses with both CD94 and NKG2A to assess localisation of these 
subunits at the same synapses was attempted but was unsuccessful.  None of the antibody 
combinations suitable for double staining produced sufficient fluorescent intensity on confocal 
microscopy to enable an assessment of clustering.  This may have been due to steric hindrance since 
flow cytometry experiments demonstrated NKG2A (Z199) binding was markedly impaired in the 
presence of anti-CD94 (DX22 clone), despite strong single staining (Figure 4.12).  An alternative 
CD94 clone (3D9) pre-labelled FITC antibody was tried but was only weakly fluorescent on confocal 
microscopy and also seemed to reduce NKG2A (Z199) binding.  An antibody labelling kit was used to 
attach a fluorophore label to unconjugated Z199.  The resulting antibody worked correctly for FACS 
experiments but did not fluoresce adequately on confocal microscopy.  In future, the development of 
new clones and fluorochromes may enable double staining.      
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Figure 4.9. HCV core35-44 induces aggregation of CD94 but not NKG2A at the interface between 
NK and target cells 
(a) Comparison of CD94 (left panel) and NKG2A (right panel) clustering at the interface between NKL 
effector and .174 target cells, loaded with the indicated peptides.  Pseudocolour scales indicates the 
fluorescent intensity from low (black/ violet) to high (white/ orange). (b) Fold increase of fluorescence 
intensity at the interface between NKL and .174 target compared with a non-contact area of the NKL 
plasma membrane, CD94 (left panel) and NKG2A (right panel).  Data from three independent 
experiments including the mean +/- SEM are shown.  (c)The percentage of conjugates with >1.4 fold 
increased fluorescence at the immune synapse was also calculated (mean +/- SEM from three 
independent experiments are shown).  For (b) and (c) statistics were performed using ANOVA with 
Dunnetts post test to compare individual pairs of conditions; * = p <0.05, *** = p < 0.001, ns = non-
significant. 
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Figure 4.10.Selective aggregation of CD94, but not NKG2A, at the immune synapse is a generic 
feature of the known HLA-E binding synergistic peptides 
(a) Fold increase of fluorescence intensity at the interface between NKL and .174 target compared 
with a non-contact area of the NKL plasma membrane, CD94 (left panel) and NKG2A (right panel).  
Data from three independent experiments including the mean + SEM are shown.  (b) The percentage 
of conjugates with >1.4 fold increased fluorescence at the immune synapse was also calculated 
(mean +/- SEM from three independent experiments are shown). p values calculated using ANOVA 
with Dunnetts post test to compare individual pairs of conditions; *** = p < 0.001, ns = non-significant. 
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Figure 4.11. Primary NK cell imaging: effect of P5K substitution on HCV core35-44 mediated 
CD94 clustering 
(a) Comparison of CD94 (left panel) and NKG2A (right panel) clustering at the interface (immune 
synapse) between primary NK cells and .174 target cells, loaded with the indicated peptides.  
Pseudocolour scales indicates the fluorescent intensity from low (black/ violet) to high (white/ orange) 
(b) Fold increase of fluorescence intensity at the immune synapse compared with a non-contact area 
of the NK cell plasma membrane, CD94 (left panel) and NKG2A (right panel).  Data from three 
independent experiments including the mean +/- SEM are shown.  (c) The percentage of conjugates 
with >1.4 fold increased fluorescence at the immune synapse was also calculated (means +/- SEM 
from three independent experiments are shown).  p values calculated using ANOVA with Dunnetts 
post test to compare individual pairs of conditions; * = p 0.05 - 0.01, *** = p < 0.001, ** = p 0.001- 
0.01,  ns = non-significant. 
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Figure 4.12. Impaired NKG2A staining in the presence of anti-CD94 
NKG2A (Z199)-PE staining was assessed in the absence (left panel) or presence (middle panel) of 
anti-CD94 (DX22).  Number, percentage and mean fluorescent intensity of NKG2A events are shown.  
Right panel- Overlay of NKG2A-PE staining in the presence or absence of anti-CD94 (DX22).  Dot 
plots gated on CD3
-
 CD56
+
 NK cells.  
123 
 
4.2.5. Clustering of CD94 in the absence of NKG2A is not due to recruitment of NKG2C 
 
 
Having demonstrated that certain HLA-E binding peptides that do not inhibit NK cells can promote 
clustering of CD94 but not NKG2A at the immune synapse, we wanted to exclude an effect mediated 
by NKG2C.  Firstly, we screened our donors in whom peptide synergy at CD94:NKG2A had been 
demonstrated for NKG2C expression.  NKG2C expression varied between donors, with the majority of 
donors tested expressing a relatively small percentage of NKG2C positive cells (Table 4.1).  This was 
not due to the fluorochrome as we tested both PerCP and PE conjugated NKG2C clones.  One donor, 
Donor 5, had a higher percentage (11.1%) of NKG2C
+
 NK cells.  We repeated the CD107a 
degranulation assay using PBMCs from Donor 5, adding an additional channel for NKG2C-PerCP. 
 
 
 
 
 
 
 
 
 
Table 4.1. NKG2C expression on CD3
-
 CD56
+
 NK cells, comparison between different donors 
Donors in whom peptide synergy was observed at CD94:NKG2A were screened for NK cell NKG2C 
expression.  The percentage of NKG2C
+
 NK cells for each donor is shown.  
 
Six colour flow cytometry revealed that the overwhelming majority of NKG2A
+
 cells were NKG2C
-
 
(Figure 4.13 a).  Gating on NKG2A
+
 NKG2C
-
 CD158b
- 
population showed that NKG2C is not 
necessary for synergy between HCV core35-44 and HLA-A2sp.  NKG2C does not appear to contribute 
to synergy as NKG2A
+
 NKG2C
+
 NK cells had very similar degranulation results to NKG2A
+
 NKG2C
-
 
NK cells (Figure 4.13 b).   Furthermore, neither HCV core35-44 or HLA-A2sp increased CD107a 
expression by NKG2A
-
 NKG2C
+
 cells, suggesting that these peptide:HLA-E complexes do not activate 
the NKG2C
+
 population. 
Donor NKG2C
+
 cells 
(as a % of CD3
-
 CD56
+
 events) 
1 0.5% 
2 0.1% 
3 0.9% 
4 1.2% 
5 11.1% 
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Figure 4.13. Effect of NKG2C on synergy at CD94:NKG2A 
Six colour flow cytometry was performed to include anti-NKG2C staining.  (a) Four quadrant plot of 
NKG2A expression versus NKG2C gated on CD3
-
 CD56
+
 NK cells, showing the percentage of 
NKG2A
+
 NKG2C
-
 and NKG2A
-
 NKG2C
+
 events.  NKG2A
+
 NKG2C
-
 CD158b
-
 NK cell degranulation 
(CD107a expression) in response to .174 cells either unloaded (no peptide) or loaded with the 
specified peptide(s), shown as histograms from one representative experiment.  (b) Data comparing 
CD3
-
 CD56
+
 CD158b
-
 NK cell CD107a expression in the presence or absence of 100 µM HCV core35-
44 and 1 µM HLA-A2sp, gated on NGK2A
+
 NKG2C
-
 (top left), NKG2A
-
 NGK2C
-
 (top right), NGK2A
+
 
NKG2C
+
 (bottom left) and NKG2A
-
 NKG2C
+
 (bottom right).  Means and SEMs from three independent 
experiments are shown. 
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NKL cells were stained for cell expression of CD94, NKG2A, NKG2C and CD158b (Figure 4.14).  
NKL cells express both CD94 and NKG2A, but are negative for NKG2C and CD158b consistent with 
previous observations (Fadda et al., 2010; Michaelsson et al., 2002).  Thus any clustering of CD94 in 
the absence of NKG2A on the surface of NKLs is not due to recruitment of NKG2C. 
 
Finally, we investigated the effect of synergistic peptides on CD94 aggregation on a cell line that does 
not express NKG2A.  The Jurkat cell line is a leukaemic T cell line first isolated from the peripheral 
blood of a patient with T cell leukaemia (Schneider et al., 1977).  Wild type Jurkat T cells do not 
express the CD94:NKG2A receptor.  Perez-Villar et al. successfully managed to stably transfect 
Jurkat cells with non-fluorescent labeled CD94 and kindly donated us this cell line (Perez-Villar et al., 
1996).  We stained the CD94-Jurkats for cell surface CD94, NKG2A and NKG2C expression, 
confirming expression of CD94 but not the NKG2 molecules.(Figure 4.15)  As a control, we also 
stained non-transfected Jurkats, which failed to express CD94, NKG2A or NGK2C. 
 
Confocal imaging was performed on CD94 Jurkat cells incubated with .174 cells in the absence or 
presence of peptide (Figure 4.16).     Microscopy revealed contacts between CD94 Jurkat cells and 
.174 cell targets.  HLA-A2sp and HCV core35-44 loaded .174 cells induced aggregation of CD94, 
whereas HCV coreR5K and HLA-GR5K did not.  These findings suggest that cells expressing CD94 have 
the ability to interact with HLA-E in the absence of NKG2 partners. However, HLA-E/ CD94 interaction 
can be abrogated with R5K lysine substitution of the HLA-E bound peptide.  These observations are 
consistent with our flow cytometry data presented in the previous chapter, showing that peptide 
synergy is abrogated by lysine substitution at position 5 of the synergistic peptide. 
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Figure 4.14. NKL staining for CD94, NKG2A, NKG2C and CD158b 
NKL cells were stained for cell surface (a) CD94 (clone DX22), (b) NKG2A (clone Z199) or (c) 
NKG2C (clone 134591), (d) CD158b (clone CH-L) or the corresponding isotype control antibody, as 
described in Materials and Methods.  Data represent mean fluorescent intensity of 10,000 gated 
events shown as histograms. 
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Figure 4.15. Comparison between cell surface expression of CD94, NKG2A and NKG2C on 
CD94 transfected Jurkat cells (CD94-Jurkat) compared with wild-type Jurkat cells 
CD94-Jurkat cells (left panels), were stained for cell surface (a) CD94 (clone DX22), (b) NKG2A 
(clone Z199) or (c) NKG2C (clone 134591), or the corresponding isotype control antibody, as 
described in Materials and Methods.  Comparison was made with wild-type Jurkat cells (right panels).  
Data represent mean fluorescent intensity of 10,000 gated events shown as histograms. 
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Figure 4.16. CD94 aggregation at the immune synapse between CD94-Jurkat cells and .174 cell 
targets 
(a) CD94 clustering at the interface between CD94 transfected Jurkat cells and .174 target cells, 
loaded with the indicated peptides. Pseudocolour scales indicates the fluorescent intensity from low 
(black/ violet) to high (white/ orange). (b) Fold increase of CD94 fluorescence intensity at the interface 
(immune synapse) between CD94 Jurkat cell and .174 target compared with a non-contact area of the 
NK cell plasma membrane.  Data from three independent experiments including the mean +/- SEM 
are shown.  (c)  The percentage of conjugates with >1.4 fold increased fluorescence at the immune 
synapse was also calculated (means +/- SEM from three independent experiments are shown). p 
values calculated using ANOVA with Dunnetts post test to compare individual pairs of conditions; *** 
= p < 0.001, ** = p 0.001- 0.01,  ns = non-significant. 
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4.2.6. Blocking assays showing that CD94 but not LILRB1 is essential for synergy 
 
It has been shown using a human NK cell line that ITIM deficient KIR can mediate an inhibitory signal 
through interaction with LILRB1 receptors (Kirwan and Burshtyn, 2005).  In their model, Kirwan and 
Burshtyn showed that LILRB1 expression alone was insufficient to respond to HLA-C expressed on 
target cells.  However, LILRB1 was able to signal in a KIR-dependent manner, revealing a co-
operation between these two receptor families.  Mutant KIR signalling could be abrogated by 
antibodies which block the interaction between KIR and HLA-C, or between LILRB1 and the α3-
domain of MHC class I molecules.  LILRB1 binds a broad range of MHC class I ligands, including 
HLA-A, -B, C and HLA-G (Chapman et al., 1999; Cosman et al., 1997; Fanger et al., 1998; Shiroishi 
et al., 2003).  HCV core35-44 is an HLA-A2 binding epitope that also binds to HLA-Cw*0102, therefore 
could potentially interact with LILRB1.  Therefore, to address whether CD94 or LILRB1 was required 
for CD94:NKG2A synergy, we performed CD107a degranulation assays using blocking antibodies.  
Pre-incubation of PBMCs with anti-CD94 completely reversed the synergistic inhibitory effect of HCV 
core35-44 in the presence of 1 µM HLA-A2sp, but there was no effect observed in the presence of anti- 
LILRB1 specific blocking Ab HP-F1 (Figure 4.17).  Thus, overall, the synergistic effect of HLA-E 
binding peptides is critically dependent on CD94. 
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Figure 4.17. CD107a degranulation assay using blocking antibodies 
Degranulation assay of CD3
-
 CD56
+
 CD158b
-
 NK cells incubated with .174 cells in the presence or 
absence of the indicated peptides and blocking antibodies to CD94 (DX22), LILRB-1 (HP-F1) or an 
isotype control antibody (cIg).  A2sp = 1 µM HLA-A2sp; HCV35-44 = 100 µM HCV core35-44.  The mean 
+/- SEM of 2 experiments is shown.  
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4.3.Discussion 
 
The sensitivity of NK cell inhibitory receptors to the peptide bound to MHC class I is well recognised 
(Brooks et al., 1999; Fadda et al., 2010; Llano et al., 1998; Miller et al., 2003; Sullivan et al., 2008).  
We have demonstrated that certain peptides that bind HLA-E but alone do not inhibit at CD94:NKG2A 
are able to synergistically inhibit at this receptor in the presence of a host MHC class I derived leader 
peptide.  We sought to determine whether peptides that bind to MHC class I molecules other than 
HLA-E also result in synergy.  Peptide stabilisation assays showed that the HLA-A2 specific influenza 
matrix peptide GILGFVFTL (GILG) and the HLA-Cw*0102 binding TIMP1-derived peptide 
VAPWNSDAL (VAP-DA) did not bind to HLA-E.  CD107a assays showed that the neither of these 
peptides induced synergistic inhibition at CD94:NKG2A in the presence of HLA-A2sp.  Thus, it would 
appear that the ability to bind to HLA-E is a pre-requisite for a synergistic peptide.  VAP-DA:HLA-
Cw*0102 complexes do not inhibit at KIR2DL2/2DL3, antagonising the inhibitory effect of recognised 
peptides at this receptor (Fadda et al., 2010).  We have shown that HLA-A2sp is a weak agonist at 
KIR2DL2/2DL3; however, peptide mix experiments did not demonstrate any synergistic inhibition at 
KIR2DL2/2DL3 when VAP-DA was added to HLA-A2sp.    This would imply that peptide synergy is a 
specific feature of HLA-E binding peptides and CD94:NKG2A. 
With the knowledge that synergistic peptides bind to HLA-E without inhibiting at CD94:NKG2A, we 
wanted to determine whether interaction with the CD94:NKG2A was essential for synergy.  Position 5 
of HLA-E bound nonameric peptides is known to be a key contact residue with CD94:NKG2A 
receptor, with a lysine residue poorly tolerated at this position (Michaelsson et al., 2002; Miller et al., 
2003; Petrie et al., 2008; Sullivan et al., 2008).  Using the HLA-Gsp sequence, we mutated position 5 
substituting the P5 arginine for a lysine residue (HLA-GR5K).  This mutation did not affect the key 
anchor residue positions P2, 6, 7 or 9, as demonstrated by a similar affinity for HLA-E compared to 
the wild type peptide.  Consistent with expectations, HLA-E:HLA-GR5K had no inhibitory effect at 
CD94:NKG2A, in contrast to HLA-E:HLA-Gsp which is a potent inhibitor at this receptor.  Thus HLA-
GR5K shares some characteristics with the synergistic peptides HCV core35-44, HIVp14-22, EBV bzlf39-47 
and hsp60sp by binding to HLA-E in the absence of inhibition at CD94:NKG2A.  However, in peptide 
mix CD107a assays HLA-GR5K failed to synergise with HLA-A2sp.  Mutation of P5 of EBV bzlf39-47 
(EBV bzlfL5K) and P5 or P6 of the 10mer peptide HCV core35-44 (HCV coreR5K and HCV coreR6K, 
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respectively) annulled the synergistic inhibitory effect of these peptides without affecting their binding 
to HLA-E.  Thus, lysine substitution at position 5 or 6 of synergistic peptides abrogates their 
synergistic effect, suggesting that interaction with CD94:NKG2A is a pre-requisite for this group of 
peptides.  
Confocal microscopy was used to assess peptide promoted clustering of CD94 and NKG2A subunits 
at the immune synapse formed between effector cells and .174 targets.   Target cells pulsed with a 
synergistic peptide induce aggregation of the non-signalling molecule CD94 in the absence of the 
signalling moiety NKG2A, in contrast to the MHC class I derived host peptides HLA-A2sp and HLA-Gsp 
which promote clustering of both subunits.  This is not due to recruitment of NKG2C to the immune 
synapse, as this disparity in CD94 and NKG2A recruitment by synergistic peptide was observed using 
the NKG2C
-
 NKL cell line (Michaelsson et al., 2002).  Furthermore, CD107a assays incorporating 
NKG2C staining showed that NKG2C neither contributed nor was necessary for peptide synergy.  
Imaging of the NKG2A
-
 NKG2C
-
 CD94 tranfected Jurkat T cell line confirmed that .174 cells loaded 
with a synergistic peptide induces accumulation of CD94 at the interface between effector and target 
cell.  Thus, synergistic peptides induce the recruitment of CD94 to the immune synapse but not 
NKG2A and NGK2C signalling partners.  CD94 aggregation in the absence of NKG2 molecules could 
represent the presence of monomeric CD94 or CD94 homodimers.  CD94 monomers are unable to 
bind to HLA-E (Braud et al., 1998).  CD94 homodimers have been observed although the functional 
significance of their binding to HLA-E is unclear due to the absence of an intracellular signalling 
domain (Boyington et al., 2000b; Carretero et al., 1997).   
The formation of homodimers is not usual for C-type lectin molecules.   Several C-type lectin 
molecules are encoded by the NKC complex in rodents and humans, including CD94, NKG2D, CD69 
and Ly49.   CD69, Ly49 family members and NKG2D exist as homodimeric receptors, whereas the 
other NKG2 molecules form heterodimers with CD94 at the cell surface (Brooks et al., 1997; Lazetic 
et al., 1996; Li et al., 2001; Natarajan et al., 2000; Tormo et al., 1999).  Heterodimer formation is 
driven by the attraction of the CD94 and NKG2 C-type lectin domains as evidenced by the extensive 
hydrophobic interface between these domains, the formation of an intermolecular disulphide bond and 
also by asymmetric interactions due the a2 helix of NKG2A interacting with the corresponding 
extended loop region of CD94 (Sullivan et al., 2007). 
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In transfected cell lines lacking NKG2 signalling partners, homodimeric CD94 has been demonstrated 
(Carretero et al., 1997).  Orr et al. used CD94 transgenic mice to demonstrate CD94 expression in the 
absence of NKG2 molecules (Orr et al., 2010).  Following transfection of the CD94 gene into CD94 
deficient mice they observed low level CD94 expression in all cells, including non-immune cells that 
would not express NKG2 molecules, supporting the formation of CD94 homodimers.   Boyington et al. 
assessed the crystal structure of CD94, showing that the extracellular portion of CD94 forms non-
covalent dimers (Figure 4.18) (Boyington et al., 1999).  The interface of the dimer contains a central 
hydrophobic region surrounded by hydrophilic residues.  Hydrogen bonds formed between the first β-
strand of each monomer creates an extended six stranded anti-parallel β sheet.  Residues in the stem 
region of CD94 are critical for the dimerisation of this subunit, with the stemless CD94 construct 
existing in a monomeric form (Boyington et al., 2000b).   
 
Derre et al. assessed CD94 and NKG2A expression on CD8+ T cells following anti-CD3 mAb 
stimulation in the presence of IL-12 (Derre et al., 2002).  A proportion of cultured peripheral blood 
lymphocytes were CD94
+
 but NKG2A
-
.  To distinguish whether this was due to CD94 homodimers or 
CD94 pairing with other NKG2C or NKG2E a functional assay was performed.   Cross-linking of CD94 
by a specific mAb had no effect on redirected lysis, suggesting that these cells do not express a CD94 
linked inhibitory or activating NKG2 moiety. The authors conclude that IL-12 stimulation induces the 
expression of non-functional CD94 homodimers on these CD3-stimulated peripheral blood 
lymphocytes. 
 
Jabri et al. assessed peripheral blood CD8
+
 T Cell expression of CD94 and NKG2A in relation to TCR 
clonotypic specificity (Jabri et al., 2002).  While the majority (90%) of CD94
+
 NKG2A
-
 CD8
+
 T cell 
clones expressed NKG2C or NKG2E, there existed a CD94+ population that lacked transcripts for 
NKG2 signalling partners.  This CD94
+
 NKG2A/C/E
-
 population, thought to express CD94 
homodimers, was shown to be inert following CD94 cross linking, in contrast to NKG2 expressing 
CD94
+
 subsets.  Furthermore, this study reveals that CD8 T cells demonstrate a clonal commitment to 
NKG2A expression.  NKG2A-, NKG2A committed cells express CD94 homodimers, but following TCR 
stimulation in vitro, these cells express CD94:NKG2A.  IL-15 stimulation has also been shown to 
induce increased expression of CD94 but not NKG2A (Jabri et al., 2000). 
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Our findings suggest that target cells loaded with a synergistic peptide induce the formation of CD94 
homodimers on the surface of effector cells at the immune synapse.  By engaging CD94 homodimers, 
such peptides would not trigger any activating or inhibitory effect due to the lack of a signalling 
domain.  However, in the presence of a MHC class I signal peptide:HLA-E complex that is inhibits at 
CD94:NGK2A, the presence of a synergistic peptide amplifies this effect.  The precise mechanism for 
this has not been fully elucidated.  One possibility would be that the formation of CD94 homodimers 
stimulated by synergistic peptides stabilises the immune synapse between effector and target cell, 
thereby potentiating signalling through HLA-E:MHC-class I signal peptide complex at CD94:NKG2A.  
However, this effect appears specific to HLA-E binding peptides and the CD94:NGK2A receptor, as 
the HLA-Cw*0102:VAP-DA peptide complex interacting with KIR2DL2/2DL3 also forms an immune 
synapse, but does not induce synergy at CD94:NKG2A in the presence of host MHC class I leader 
peptides.  Additionally, HLA-E binding synergistic peptides do not synergise with MHC class I leader 
peptides to inhibit at KIR2DL2/2DL3.    
There may be various explanations as to why synergistic peptides recruit CD94 homodimers in 
preference to NGK2 molecules.  Binding of CD94:NKG2A to HLA-E is peptide dependent, with a very 
fast association/ dissociation rate constant for the interaction (Vales-Gomez et al., 1999).  CD94 
forms 80% of the interface with the HLA-E bound peptide (Petrie et al., 2008).  Kaiser et al. showed 
that minor changes in peptide sequences have equivalent effects on the affinities of NKG2A, NKG2C, 
and NKG2E (Kaiser et al., 2005).  They reason that CD94 provides the majority, if not all, of the 
contacts to the C-terminal half of the presented peptide. This would mean that peptide substitutions 
most likely have the same effect on the different NKG2 molecules since the CD94 interface is 
equivalent across the family.  Certain peptide sequences such as those of the synergistic peptides 
may permit binding of CD94 molecules but not NKG2A.   However, interaction with CD94 is abrogated 
by position 5 lysine substitution, whereas other residues such as arginine, leucine and valine are 
tolerated.   
 
CD94 has no inter-chain salt bridges but there are two regions of charge complementarity across the 
modelled CD94:NKG2 interface: one between Asp106 of CD94 and Lys 135 of NKG2A, and the other 
between Arg69 of CD94 and Glu122 of NKG2A.  Lys 135 and Glu122 are conserved sequences 
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across NKG2A, C and E, but are replaced by Ser and Lys respectively in CD94, creating an 
unfavourable Arg69-Lys64 interaction across the CD94/ CD94 interface.  This may partly explain why 
CD94 preferentially forms heterodimers with NKG2 molecules, compared to CD94 homodimers.   
 
It is possible that synergistic peptide induced CD94 clustering defined in microscopy represents a low 
affinity interaction which may not be measurable by surface plasmon resonance assays.  This is true 
for VAP-DA interaction with KIR.   
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Figure 4.18. Ribbon models showing two views of the CD94 dimer 
Each monomer is coloured a different shade of green.  The regions that have low sequence identity 
with NKG2 molecules are shown in purple.  The top view is rotated 90
o
 from the bottom view along 
the horizontal axis.  In the bottom view, residues in the hydrophobic core of the dimer interface (V66, 
Y68, I75, F107 and M108) are represented by ball-and-stick models.  These residues are coloured 
red in one monomer and yellow in the other.  Figure taken from Boyington et al. 1999. 
  
137 
 
Chapter 5. A functional comparison of CD94:NKG2A and KIR 
 
5.1. Introduction 
 
NK cells are kept in check by inhibitory receptors for MHC class I.  The majority of these receptors 
belong to the KIR family, but also include the C-type lectin receptor CD94:NGK2A.  Successful 
ligation of these inhibitory receptors triggers recruitment of the tyrosine phosphatase SHP-1 to ITIM 
motifs within their cytoplasmic domain, leading to abrogation of NK cell activation signals.  NK cells 
sequentially express these receptors during development (Beziat et al., 2010).  A reduction in CD56 
expression is a feature of increasing NK cell maturation, as evidenced by shorter telomere length in 
CD56
dim
 NK cells compared to their CD56
bright
 precursors (Ouyang et al., 2007; Romagnani et al., 
2007),  Furthermore, CD56
bright
 cells represent the majority of NK cells that initially appear following 
haemopoetic stem cell transplantation (Nguyen et al., 2005; Vago et al., 2008).  CD94:NKG2A 
receptors are expressed by virtually all CD56
bright
 NK cells, while the variegated KIR are expressed in 
a stochastic fashion with increasing NK cell maturation to CD56
dim
 NK cells (Figure 5.1).  Beziat et al. 
(2010) elegantly showed that CD56
bright
 NK cells give rise to CD56
dim 
NKG2A
+
 KIR
-
 population, which 
in turn mature into CD56
dim 
NKG2A
+ 
KIR
+
 phenotype followed by terminal differentiation into CD56
dim 
NKG2A
- 
KIR
+
 cells.  Furthermore, they demonstrated that CD56
dim
 NKG2A
- 
NK cells can reacquire 
NKG2A expression following IL-12 and IL-18 stimulation, leading to an increase in IFN-γ production 
by this CD56
dim
 population.  
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Figure 5.1. Sequential expression of CD94 then KIR during NK cell maturation 
CD56
bright
 NK cells represent an immature subset that can differentiate into CD56
dim
 NK cells.  
CD56
bright
 NK cells are KIR
-
 but express high levels of CD94.  With increasing NK cell maturation, 
CD94 expression is lost while KIR receptors are acquired in a sporadic manner. 
 
 
The monomorphic CD94:NKG2A receptor binds HLA-E, a non-classical MHC class Ib that has limited 
polymorphism and a broad tissue distribution.  Moreover, this receptor system has an ancient origin in 
evolution, present in both rodents and primates, albeit with some species-specific variation (Shum et 
al., 2002).  In contrast to the highly conserved CD94:NKG2A/ HLA-E system, the KIR receptors and 
their classical MHC class I ligands, HLA-A, -B and –C, show extensive diversity at both locus and 
allelic levels, and are only expressed in simian primates (Figure 5.2).   As a result, individual KIR are 
expressed in a stochastic fashion, resulting in a diverse NK cell repertoire with NK cell subsets 
expressing different combinations of receptors.  Recognition of MHC class I by CD94:NKG2A and KIR 
and consequent NK cell inhibition is peptide specific.  The cognate peptides for HLA-E constitute a 
restricted set of nonamers derived from the signal peptide of other MHC class I (HLA-A, -B and –C 
and HLA-G) molecules.  Thus NKG2A
+
 cells can recognise down-regulation of several MHC class I 
alleles, if they are no longer synthesized, or translated, but not if the down-regulation is post-
translational.  In contrast, KIR
+
 NK cells only recognize specific MHC class I alleles, therefore any 
effect of MHC down-modulation would be limited to the subset of NK cells expressing a particular 
repertoire of receptors.   
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Figure 5.2. Comparison between CD94:NKG2A and KIR receptor systems 
The C-type lectin receptor CD94:NKG2A is encoded by the natural killer complex (NKC) on 
Chromosome (Ch) 12 whereas the genes for immunoglobulin-like KIR are located in the leukocyte 
receptor complex (LRC) on Ch 19.  The corresponding HLA-ligands are encoded by the HLA complex 
on Ch 6.  The blue text boxes demonstrate the contrasting diversity of the two receptor systems.  
Figure adapted from Parham et al. (2012). 
 
Genetic studies implicating KIR/ HLA polymorphisms in infectious diseases suggest that rapidly 
evolving pathogens may be driving the co-evolution of this receptor ligand system (Alter et al., 2007a; 
Khakoo et al., 2004; Wauquier et al., 2010). Given that KIR/ HLA genes segregate independently on 
different chromosomes it is possible that an individual fails to express the cognate HLA class I ligands 
for any given KIR receptor (Gumperz et al., 1996).   The evolutionary persistence of CD94:NKG2A/ 
HLA-E may therefore pertain to the ability of this system to recognize highly diversified MHC class I 
molecules, a subset of which encode remarkably similar signal peptides.  Collectively, this may exert 
a strong selection pressure thereby guarding against auto-reactivity of NK cells.  In the absence of 
KIR/ HLA pairings, this system may also ensure NK cells are licensed to recognise and be responsive 
to MHC class I down-modulation. 
 
Our data, and that from other groups, demonstrates that certain viral and host derived peptides can 
also bind to HLA-E but, in isolation, these peptide:HLA-E complexes are insufficient to inhibit NKG2A
+
 
NK cells (Brooks et al., 1999; Michaelsson et al., 2002).  However, when these host- and virus-
derived non-inhibitory peptide:HLA-E complexes are combined with cognate leader peptide:HLA-E 
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complexes on target cells they augment the inhibition of the NKG2A
+
 NK cell population. We have 
termed his observation “peptide synergy”.  Synergistic peptides recruit the non-signalling CD94 
moiety but not ITIM-containing NKG2A to the immune synapse, in contrast to MHC-class I leader 
peptides which recruit both CD94 and NKG2A.   
 
This observation of CD94:NKG2A/ HLA-E peptide synergy induced by peptides that are otherwise 
non-inhibitory, contrasts that seen at KIR
+
 NK cells.  Peptides that stabilize HLA-C but do not 
themselves inhibit through KIR, perturb rather than augment the inhibition of NK cells (Fadda et al., 
2010).  The exact mechanism for peptide antagonism at KIR is yet to be elucidated.  Despite not 
inducing inhibition of KIR
+
 NK cells in degranulation assays, such antagonistic peptides still promote 
KIR clustering at the immune synapse.  However, there is a lack of microtubule-organizing centre 
(MTOC) polarization to the synapse and a failure of dephosphorylation of the SHP-1 substrate Vav1.  
It is possible that antagonistic peptide:HLA-C interfere with the KIR clustering induced by inhibitory 
peptide:HLA-C.  The overall significance of this observation is that KIR
+
 NK cells may be activated by 
changes in the peptide repertoire within a cell as can occur during viral infections. 
 
In this chapter we explore some of the differences between CD94:NKG2A and the KIR inhibitory 
receptors.  We assess the effect of HLA-Gsp on HCV core35-44 mediated inhibition of KIR2DL2/ 2DL3
+ 
NK cells. Immunogenetic analyses have revealed that KIR and HLA-C polymorphisms influence the 
outcome of HCV infection.  Homozygosity for KIR2DL3 in combination with its HLA-C1 group of 
ligands has a protective effect against chronic HCV infection (Khakoo et al., 2004; Romero et al., 
2008).  We screen our immunogenetic data set to determine whether individuals who possess a lower 
number of HLA-E/ CD94:NKG2A binding MHC class I leader peptides might be protected from HCV 
as their NK cells may be less inhibited.  We also investigate the stoichiometry of KIR/ HLA-C and 
CD94:NKG2A/ HLA-E interaction.   
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5.2. Results 
5.2.1. HLA-Gsp antagonises the inhibitory effect of HCV core35-44 at CD158b 
 
In chapter 3 we demonstrated that HCV core35-44 peptide and HLA-Gsp bind both HLA-E and HLA-
Cw*0102, with similar affinity for the latter.  However, each peptide:MHC class I complex induces 
contrasting recognition by KIR and CD94:NKG2A.  In CD107a degranulation assays, HCV core35-
44:HLA-Cw*0102 has a direct inhibitory effect at KIR2DL2/2DL3 (CD158b), whereas HLA-Gsp:HLA-
Cw*0102 has no effect.   We measured the effect of these peptides on the CD158b
+ 
NK cell 
subpopulation, to determine whether the non-KIR-binding HLA-Gsp could relieve HCV core35-44:HLA-
Cw*0102 mediated inhibition at KIR2DL2/ 2DL3. In our preliminary experiments we pulsed .174 cells 
overnight with 100 μM HLA-Gsp, 100 μM HCV core35-44, 100 μM of both HLA-Gsp and HCV core35-44 or 
no peptide (Figure 5.3).   Un-pulsed .174 cells stimulated 19.2% of the NKG2A
-
 CD158b
+
 NK cells to 
express CD107a.  .174 cells pulsed with HLA-Gsp did not induce inhibition at NKG2A
-
 CD158b
+
 NK 
cells (20.3%) in contrast to strong inhibition induced by HCV core35-44 (4.5%).  However, when both 
peptides were mixed, HLA-Gsp perturbed HCV core35-44 mediated inhibition at CD158b (14.4%).   The 
effect of HLA-Gsp on HCV core35-44 inhibition at CD94:NKG2A was confirmed at a range of peptide 
concentrations using 1:1 ratio of peptides (Figure 5.4).  There was a greater frequency of activated 
NKG2A
-
 CD158b
+
 NK cells in repsonse to .174 cells loaded with HCV core35-44 in the presence of 
HLA-Gsp compared with in the absence of HLA-Gsp.    
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Figure 5.3. HCV core35-44 and HLA-Gsp peptide mix CD107a assay gated on CD158b
+
 NK cells 
CD107a assay performed using .174 target cells incubated alone (no peptide), with 100 µM HCV 
core35-44, 100 µM HLA-Gsp, or 100 µM of both peptides. Histograms gated on CD3
-
 CD56
+
 NKG2A
-
 
CD158b
+
 NK cells. Percentage indicates frequency of CD107a positive events 
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Figure 5.4. CD107a expression in response to increasing concentrations of HCV core35-44 alone 
or with 1:1 ratio HLA-Gsp 
.174 target cells incubated alone (black bar), or with HCV core35-44 alone (blue bars) or HCV core35-44 
+ HLA-Gsp (pink bars) at the indicated peptide concentrations.  CD107a assay performed as described 
in Material and Methods.  Percentage indicates frequency of CD107a positive events gated on CD3
-
 
CD56
+
 NKG2A
-
 CD158b
+
 NK cells. 
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Following these preliminary experiments, peptide mix assays were repeated using a constant level of 
HLA-Cw*0102 occupancy.  The HCV core35-44:HLA-Gsp ratio was titrated using 20:80, 40:60, 60:40 
and 80:20 mixes, while maintaining a final overall concentration of 100 μM peptide.  Stabilisation 
assays confirmed that HCV core35-44 and HLA-Gsp share a similar affinity for HLA-Cw*0102.  Peptide 
mix revealed a stable level of cell surface HLA-Cw*0102 as the ratio of HCV core35-44:HLA-Gsp was 
increased (Figure 5.5 a).  In CD107a degranulation assays, HCV core35-44 stimulated a dose 
dependent inhibition of CD158b
+
 NK cells (p <0.0001), while HLA-Gsp had no effect (p= 0.93), 
consistent with findings presented in Chapter 3.  The peptide mix titration showed that HLA-Gsp 
reduced the inhibitory effect of HCV core35-44 (p = 0.0007) (Figure 5.5 b). HCV core35-44 peptide 
concentration required to reach 50% inhibition was ~35 μM in the absence of HLA-Gsp but increased 
to ~75 μM in the presence of HLA-Gsp (Figure 5.5 c). 
The above peptide mix experiments were carried out at a concentration of peptide where all available 
HLA-Cw*0102 molecules were presenting peptide, i.e. at saturating levels of peptide.  To determine 
whether the activation of CD158b
+
 NK cells observed in the presence of HCV core35-44 and HLA-Gsp 
was due to displacement of HCVcore35-44 by HLA-Gsp, peptide mix assays were repeated at sub-
saturating final concentrations of peptide (40 μM) (Figure 5.6).  At this peptide concentration, free 
HLA-Cw*0102 molecules are available for unbound HCV  core35-44 and HLA-Gsp to bind.  The 
presence of HLA-Gsp perturbed inhibition of CD158b
+
 NK cells by HCV core35-44 (two way ANOVA p= 
0.003).  The confirmation of this effect at sub-saturating levels of peptide, while maintaining a 
constant level of HLA-Cw*0102 occupation indicate that the observed effect of HLA-Gsp is not due to 
displacement of HCV core35-44. 
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Figure 5.5. HLA-Gsp/ HCV core35-44 peptide mix experiments including stabiilsation assay 
 (a) HLA-Cw*0102 stabilisation was detected using the HLA-Cw*0102 specific antibody VP6G3 for 
.174 cells loaded with HLA-Gsp and HCV core35-44 alone or together.  In peptide mix wells (shown in 
red), the concentration of HCV core35-44 is indicated on the x-axis, with the final concentration of 
peptide made to 100 μM using HLA-Gsp (20:80, 40:60, 60:40, 80:20).  Data shown are mean +/- SEM 
of three consecutive experiments.  (b) CD107a
+
 NK cells in response to .174 cells loaded with the 
indicated peptides, gated on CD3
-
 CD56
+
 NKG2A
-
 CD158b
+
 NK cells.  Data shown are mean +/- SEM 
of triplicates performed using PBMCs from one donor.  (c) Data from (b) was normalised to the 
frequency of CD107a
+
 NK cells following co-incubation with unloaded .174 cells (no peptide).  Broken 
black line indicates a 50% reduction in CD107a expression. 
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Figure 5.6. HLA-Gsp/ HCV core35-44 peptide mix experiments performed at sub-saturating levels 
of HLA-C*0102 occupation 
 (a)  HLA-Cw*0102 stabilisation was detected using the HLA-Cw*0102 specific antibody VP6G3 for 
.174 cells loaded with HLA-Gsp and HCV core35-44 alone or together (0-40 μM).  In peptide mix wells 
(shown in red), the concentration of HCV core35-44 is indicated on the x-axis, with the final 
concentration of peptide made to 40 μM using HLA-Gsp (5:35, 10:30, 20:20, 30:10).  Data shown 
represent mean +/- SEM of three consecutive experiments.  (b) CD107a
+
 NK cells in response to .174 
cells loaded with the indicated peptides, gated on CD3
-
 CD56
+
 NKG2A
-
 CD158b
+
 NK cells.  Data 
normalised to the frequency of CD107a
+
 NK cells following co-incubation with unloaded .174 cells (no 
peptide).  Data shown represent mean +/- SEM of triplicates performed using PBMCs from one donor.  
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The antagonistic effect of HLA-Gsp at CD158b
+
 NK cells was compared with that of VAPWNSDAL 
(VAP-DA) peptide.  VAP-DA has a higher affinity for HLA-C*0102 compared to HCV core35-44 and 
HLA-Gsp, and was therefore used at a 10-fold lower concentration (2, 4, 6, 8, and 10 μM) in both 
stabilisation and degranulation assays (Figure 5.7a and b).  In degranulation assays, .174 cells 
loaded with VAP-DA had no effect on CD158b
+
 NK cell degranulation.  Peptide mix wells showed that 
.174 cells loaded with HCV core35-44 and HLA-Gsp induced a more degranulation of CD158b
+
 NK cells 
compared with those pulsed with HCV core35-44 alone.  Compared with HLA-Gsp, VAP-DA produced 
greater perturbation of HCV core35-44 mediated inhibition at CD158b.  It is possible that this 
observation is due to the high affinity VAP-DA peptide displacing HCV core35-44 from HLA-Cw*0102, 
even at the lower concentrations of VAP-DA used.  However, the shape of the curve appears similar 
to HLA-Gsp mediated relief of HCVcore35-44 antagonism. 
The results from these HLA-Gsp/ HCV core35-44 peptide mix experiments demonstrate that a pair of 
peptides that synergise to inhibit at HLA-E/CD94:NKG2A, have contrasting effects at HLA-C/ KIR, 
where we observe antagonism.  However, the in-vivo relevance of this phenomenon is unclear due to 
high concentration of peptides used and will need to be tested. 
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Figure 5.7. HCV core35-44/ HLA-Gsp peptide mix assay compared to HLA-Gsp/ VAP-DA 
 (a)  HLA-Cw*0102 stabilisation was detected using the HLA-Cw*0102 specific antibody VP6G3 for 
.174 cells loaded with HLA-Gsp, VAP-DA, HCV core35-44, HCV core35-44/ HLA-Gsp mix or HCV core35-44/ 
VAP-DA mix.  In HCV core35-44/ HLA-Gsp and HCV core35-44/ VAP-DA peptide mix wells the 
concentration of HCV core35-44 is indicated on the x-axis.  For HLA-Gsp mix, the final concentration of 
peptide made to 100 μM using (20:80, 40:60, 60:40, 80:20 ratios of HCV core35-44: HLA-Gsp). For 
VAP-DA mix, the following HCV core35-44:VAP-DA ratios were used, 20:8, 40:6, 60:4, 80:2. Data 
shown represent mean +/- SEM of three consecutive experiments.  (b) CD107a+ NK cells in response 
to .174 cells loaded with the indicated peptides, gated on CD3
-
 CD56
+
 NKG2A
-
 CD158b
+
 NK cells.  
Data shown represent mean +/- SEM of triplicates performed using PBMCs from one donor.  
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5.2.2. Differences in the stoichiometry between KIR and CD94:NKG2A receptor systems 
 
Having observed fundamental differences between how KIR
+
 and NKG2A
+
 NK cells respond to 
changes in the peptide content of MHC class I, we determined whether there was also a difference in 
their response to MHC class I down-regulation.  We therefore studied two potent inhibitory peptides; 
HLA-Gsp for NKG2A mediated inhibition and the peptide VAPWNSFAL (VAP-FA) which in a peptide 
screen had the highest affinity for KIR2DL2 and KIR2DL3 (Fadda et al., 2010; Llano et al., 1998).  
Using the MHC deficient .174 cell line, HLA-Gsp and VAP-FA mediated stabilization of HLA-E and 
HLA-Cw*0102 was measured at a range of peptide concentrations (0-100 μM).  Degranulation assays 
were also performed at the same range of peptide concentrations, before normalizing the data and 
plotting MHC class I stabilisation against NK cell inhibition.  Degranulation assays using peptide 
titrations showed that inhibition of NK cells by MHC class I exhibited saturation kinetics for NKG2A
+
 
NK cells (r
2
=0.98) but was linear for KIR
+
 NK cells (r
2
=0.96) (Figure 5.8).  Thus more NKG2A
+
 NK 
cells respond to alterations in MHC class I at low HLA-E levels than at high levels.  However the level 
of HLA-C does not appear to influence the fraction of KIR
+
 NK cells that respond to a given change in 
HLA-C expression.  Hence NKG2A
+
 NK cells are tuned to respond to changes in MHC class I at low 
levels of MHC expression, but this is not the case for KIR
+
 NK cells. 
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Figure 5.8. NKG2A
+
, but not KIR
+
, NK cells are tuned to low cell surface levels of MHC class I 
(a) .174 cells were pulsed with increasing concentrations of HLA-Gsp before measuring HLA-E 
stabilization and performing deganulation assays gating on NKG2A
+
 CD158b
-
 (NKG2A
+
) NK cells.  
Data for MHC class I expression are normalised to “no peptide” and “saturating (100 μM) peptide” 
concentrations (% maximal stabilisation).  Degranulation data are normalised to CD107a expression 
to unloaded .174 cells and loading with saturating (100 μM) peptide (% maximal inhibition).  
Correlations were then made between the levels of cell surface MHC class I and the fraction of 
degranulating NK cells.  (b) Similar experiments were performed with VAPWNSFAL (VAP-FA) loaded 
.174 cells, except staining with HLA-Cw*0102 for stabilisation assays, and gating on the NKG2A
-
 
CD158b
+
 (CD158b
+
) NK cells fraction in degranulation assays. The results of three independent 
experiments are shown 
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5.2.3. Immunogenetic analyses: Predicted peptide binding repertoires of HLA-E and HLA-C and 
the outcome of HCV infection 
 
To test the potential clinical importance of our findings, we performed a series of immunogenetic 
analyses.   
 
5.2.3.1 Effect of the number of CD94:NKG2A cognate MHC class I leader peptides 
 
The cognate peptides for HLA-E are derived from polymorphic MHC class I (HLA-A, -B, -C and HLA-
G) signal peptides.  Not all MHC class I derived signal peptides bind to HLA-E, and of those that do, 
not all of these peptide:HLA-E molecules are recognised by CD94:NKG2A.  We hypothesised that 
individuals who possess a greater number of MHC class I signal peptides that do not permit both 
HLA-E and CD94:NKG2A binding might be protected from chronic HCV infection as their NK cells 
may be less inhibited compared to those individuals whose leader peptides are predicted to bind. 
The data from of 361 individuals with chronic HCV infection (cHCV) and 112 spontaneous resolvers 
(SR) typed for MHC class I were analysed (Figure 5.9) (Khakoo et al., 2004).  Leader peptides 
sequences for HLA-A, -B and –C alleles were derived from the EMBL Bank database and assigned 
as to whether or not they would bind HLA-E and productively engage CD94:NKG2A (Goujon et al., 
2010). No significant difference was noted between the average number of cognate leader peptides 
predicted to bind HLA-E/ CD94:NGK2A between resolvers and chronically infected individuals (cHCV 
3.981, SR 3.982; p=0.82; Mann Whitney test). 
 
5.2.3.2 Influence of the number of HLA-Gsp-binding HLA-C alleles and the outcome of HCV 
infection. 
 
Earlier in this chapter we have shown that HLA-Cw*0102 binds HLA-Gsp and that the resulting 
complexes activate KIR2DL2/2DL3
+ 
NK cells by interfering with inhibitory peptide:HLA-Cw*0102 
complexes.  HLA-G has been shown to be upregulated in chronic HCV and where it may offer a 
protective effect (de Oliveira Crispim et al., 2012). Not all HLA-C alleles bind HLA-Gsp (Appendix 
Figure 9.1.).  We hypothesised that individuals who possess HLA-C alleles that bind HLA-Gsp might 
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be protected from chronic HCV infection as their CD158b
+
NK cells may be activated by HLA-G 
upregulation.  Using software to predict peptide binding to MHC class I molecules, we assessed 
binding of HLA-Gsp (VMAPRTLFL) to individual HLA-C alleles comparing chronic HCV to spontaneous 
resolvers (Hoof et al., 2009).  The data from of 382 individuals with chronic HCV infection (cHCV) and 
122 spontaneous resolvers (SR) typed for MHC class I were analysed (Figure 5.10).  There was no 
significant difference in the number of HLA-C alleles predicted to bind HLA-Gsp (CHC 0.24, SR 0.26; 
p= 0.6; Mann Whitney test). 
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Figure 5.9. Absence of genetic association between the number of NKG2A cognate MHC class 
I leader peptides and the outcome of HCV infection 
(a) Leader peptides from classical HLA-A, -B, -C were assigned either a positive or negative binding 
potential for HLA-E or NKG2A according to the work of Llano et al (Llano et al., 1998).  (b) The data 
from of 361 individuals with chronic HCV infection (CHC) and 112 spontaneous resolvers (SR) typed 
for MHC class I were analyzed.  The number of MHC class I leader peptides in each individual was 
then assessed in individuals that spontaneously resolved HCV infection or remained chronically 
infected.  (c) Mean number of NKG2A cognate peptides and results of the comparison by the Mann 
Whitney test are shown. 
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Figure 5.10. Number of HLA-C alleles predicted to bind HLA-Gsp and the outcome of HCV 
infection 
(a) Data from 382 individuals with chronic HCV infection (CHC) and 122 spontaneous resolvers (SR) 
typed for HLA-C were analysed.  HLA-C alleles were assigned either a positive or negative binding 
potential for HLA-Gsp according to the NetMHCpan prediction tool (Hoof et al., 2009). The number of 
HLA-C alleles predicted to bind HLA-Gsp (VMAPRTLFL) in each individual (between 0-2) was then 
assessed comparing spontaneous resolvers and those who remained chronically infected. (b) Mean 
number +/- SEM of HLA-Gsp binding HLA-C alleles and results of the comparison by the Mann 
Whitney test are shown. 
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5.2.3.3 Influence of the number of HLA-A, –B and -C signal peptides binding HLA-C alleles and 
the outcome of HCV infection. 
 
In chapter 3, we showed that leader peptides derived from HLA-A2 (HLA-A2sp; VMAPRTLVL) and 
HLA-B7 (HLA-B7sp; VMAPRTVLL) bind to HLA-Cw*0102, promoting inhibition of KIR2DL2/2DL3 
(CD158b
+
) NK cells.    NetMHCpan software analysis shows that HLA-Cw*0102 is predicted to bind to 
all classical MHC class I signal peptides shown in Figure 5.9 a, but this is not true for other HLA-C 
alleles (Hoof et al., 2009).  We therefore hypothesised individuals who possess a greater number of 
HLA-A, –B and –C leader peptides predicted to bind to their HLA-C alleles would be more susceptible 
to chronic HCV as their NK cells would be more inhibited.  Data from of 363 individuals with chronic 
HCV infection (cHCV) and 112 spontaneous resolvers (SR) typed for MHC class I were analyzed 
(Figure 5.11 a& b).  Leader peptides sequences for HLA-A, -B and -C alleles were derived from the 
EMBL Bank database (Goujon et al., 2010), followed by NetMHCpan software analysis to assess 
binding of these leader peptides to individual HLA-C alleles (Appendix Figure 9.2.).  Contrary to our 
hypothesis, individuals possessing a greater number of HLA-A, –B and –C leaders binding their HLA-
C alleles were significantly over-represented in the spontaneous resolver group (CHC 2.00, SR 2.50; 
p=0.034; Mann Whitney test).   
The HLA-C1 group of alleles are predicted to bind inhibitory KIR2DL2, KIR2DL3 and activating 
KIR2DS2, whereas HLA-C2 group of alleles bind inhibitory KIR2DL1 and activating KIR2DS1.  We 
therefore categorized the data into those individuals possessing a corresponding inhibitory KIR 
receptor (Figure 5.11 c) or activating KIR receptor (Figure 5.11 d) to their particular HLA-C alleles.  
For individuals with an inhibitory KIR receptor for their HLA-C group of ligands, those with a greater 
number HLA-A, –B and –C leader peptides binding their HLA-C alleles were over-represented in the 
spontaneous resolver group (mean number of binders CHC 2.04, SR 2.50; p=0.04; Mann Whitney 
test).  However, for individuals possessing an appropriate activating KIR receptor for their HLA-C 
group of ligands, this significance was lost (mean number of binders CHC 2.02, SR 2.34; p=0.35; 
Mann Whitney test).  
HLA-C1 homozygosity is observed at higher frequency in individuals who resolve HCV infection 
compared with those with chronic infection (Khakoo et al., 2004; Romero et al., 2008), although the 
effect is limited to individuals also homozygous for the gene encoding the KIR2DL3 receptor.  We 
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speculated that the peptide content of HLA-C1 could influence the outcome of infection, therefore we 
analysed our data comparing individuals homozygous for the C1 group of alleles (C1C1), 
heterozygous (C1C2), or homozygous for the HLA-C2 group (C2C2) (Figure 5.11 e).  Individuals with 
a higher number of HLA-A, -B and -C leader peptides binding their HLA-C alleles were over-
represented in the spontaneous resolver group in C1C1 individuals (mean number of binders CHC 
2.74, SR 3.78; p=0.011; Mann Whitney test), but not C1C2 individuals (mean number of binders CHC 
1.99, SR 1.74; p=0.43; Mann Whitney test) or C2C2 individuals (mean number of binders CHC 0.8, 
SR 0.3; p=0.58; Mann Whitney test).  Furthermore, this protective effect of leader peptide binding at 
C1C1 was present in individuals possessing either a KIR2DL3 allele (mean number of binders CHC 
2.65, SR 3.74; p=0.008; Mann Whitney test) or a KIR2DL2 allele (mean number of binders CHC 2.66, 
SR 3.96; p=0.03; Mann Whitney test) (Figure 5.12).  No significant difference in outcome of the C1C1 
group was seen between individuals homozygous for KIR2DL3 or those homozygous for KIR2DL2. 
 
Further analysis showed that in our cohort, HLA-C1 group of alleles are more likely to bind HLA-A, –B 
and –C leader peptides than HLA-C2 group of alleles (mean number of binders C1C1 3.07, C2C2 
0.72; p<0.0001; Mann Whitney test), see also Appendix Figure 9.3.) 
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Figure 5.11. Number HLA-A, –B and -C leader peptides predicted to bind HLA-C alleles and the 
outcome of HCV infection 
Data from 363 individuals with chronic HCV infection (CHC) and 112 spontaneous resolvers (SR) 
typed for MHC class I were analysed.  HLA-A, -B and –C leader peptides were assigned either a 
positive or negative binding potential for binding to each individual HLA-C allele according to the 
NetMHCpan prediction tool (Hoof et al., 2009). (a) The number of predicted binders (2 HLA-C alleles 
per individual, therefore the potential number of binders varied between 0-12) was then assessed 
comparing spontaneous resolvers and those who remained chronically infected. Mean number +/- 
SEM of HLA-A, –B and -C alleles binding HLA-C alleles and results of the comparison by the Mann 
Whitney test are shown for (b) all data (CHC 363 patients, SR 112 patients); (c) individuals matched 
for an appropriate inhibitory KIR receptor (CHC 337 patients, SR 111 patients); (d) individuals 
matched for an appropriate activating KIR receptor (CHC 199 patients, SR 64 patients); (e) subset 
analysis for individuals possessing C1C1 alleles (CHC 104 patients, SR 49 patients), C1C2 alleles 
(CHC 178 patients, SR 53 patients) and C2C2 alleles (CHC 55 patients, SR 10 patients).  p values 
calculated using Mann Whitney test. 
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Figure 5.12. Number HLA-A, –B and -C leader peptides predicted to bind HLA-C alleles and the 
outcome of HCV infection: C1C1 subset analysis 
Individuals homozygous for C1 alleles were subcategorised based on their 2DL2 and 2DL3 alleles.  
(a) individuals possessing a KIR2DL3 allele (CHC 91 patients, SR 46 patients) or a KIR2DL2 allele 
(CHC 59 patients, SR 23 patients); (b) homozygous for KIR2DL3 (CHC 45 patients, SR 26 patients) 
or KIR2DL2 (CHC 36 patients, SR 7 patients). p values calculated using Mann Whitney test.  
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5.3. Discussion 
 
Our original peptide mix experiments sought to determine whether HCV core35-44 could perturb the 
inhibitory effect of HLA-Gsp at CD94:NKG2A, analagous to peptide antognism observed at KIR where 
HLA-C*0102 bound peptides that induce weak KIR binding depress the inhibitory effect of a strong 
KIR binding peptide (Fadda et al., 2010).  Rather than interfering with CD94:NKG2A binding inhibitory 
peptides, HCV core35-44 augments the inhibitory effect of host MHC-class I derived HLA-Gsp, HLA-A2sp 
and HLA-B7sp, a phenomenon we have termed peptide synergy.  However, HLA-Gsp and HCV core35-
44 have an opposite effect at HLA-Cw*0102, consistent with the peptide antagonism model described 
at KIR.  HLA-Gsp and HCV core35-44 both bind to HLA-Cw*0102.  Whereas HCV core35-44:HLA-
Cw*0102 inhibits NK cell degranulation via CD158b, HLA-Gsp:HLA-Cw*0102 has no effect.  This 
observation was confirmed  using blocking antibodies, as shown in Chapter 3.  In peptide mix 
experiments, HLA-Gsp relieved HCV core35-44 mediated inhibition at KIR2DL2/2DL3.  Thus there are 
fundamental differences in the way in which the KIR and the NKG2A systems respond to changes in 
the peptide content of MHC class I.  Alterations in the peptide repertoire of HLA-E can favour 
inhibition of NKG2A
+
 NK cells, whereas peptide repertoire changes at HLA-C favour activation of KIR
+
 
NK cells.     
The original data demonstrating peptide antagonism at KIR used model peptides based on a variant 
of a TIMP-1 peptide (Fadda et al., 2010).  Our findings presented here may represent a biologically 
plausible mechanism for KIR
+ 
NK cell activation.  HLA-Gsp is derived from processing of the MHC 
class Ib molecule HLA-G, which in health has a tissue distribution limited to the placenta.  HLA-G has 
long been regarded as a tolerogenic molecule, contributing to materno-fetal tolerance through 
enagement of LILRB-1 and KIR receptors on NK cells, DCs and T cells.  However, recently HLA-G 
has been shown to be upregulated in the serum and liver of patients with chronic HBV and HCV, but 
not healthy controls (de Oliveira Crispim et al., 2012; Souto et al., 2010; Weng et al., 2011).  De 
Oliviera et al. (2012) observed HLA-G expression in 51% of liver specimens from patients with chronic 
HCV, but no control liver samples. In view of the known immunosuppressive effect of HLA-G they 
suggest that expression of this molecule could contribute to viral persistence.  Paradoxical to this 
model, HLA-G expression was more frequent in milder necroinflammatory stages of chronic hepatitis 
compared to moderate/ severe, implying a protective effect of HLA-G. 
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Furthermore, Cordero et al. have shown that polymorphisms affecting HLA-G influence the 
susceptibility of HCV infection in patients with sickle cell disease (Cordero et al., 2009).  They looked 
at two polymorphisms in a highly polymorphic promoter region thought to influence microRNA binding, 
thus regulating RNA turnover and miRNA-mediated repression of translation of HLA-G.  The 
expression of polymorphisms associated with higher levels of HLA-G had a dose dependent 
protective effect.  A protective effect of HLA-G was also seen against influenza virus.  At first glance, 
this idea seems counter-intuitive since HLA-G mediated immune tolerance may be expected to 
predispose to viral persistence. However, we speculate that it is the expression of HLA-Gsp not HLA-G 
that leads to the protective effect. Alterations in the peptide repertoire of infected cells leading to an 
increase in HLA-Gsp could theoretically lead to NK cell activation by increasing MHC class I 
occupancy by antagonist peptide. HLA-Gsp mediated NK cell activation would be limited to the subset 
of NK cells that express KIR2DL2/2DL3, possibly in the absence of other receptors that bind HLA-G 
e.g. LILRB-1.  However, given that each individual NK cell expresses a random subset of inhibitory 
KIRs with distinct MHC-I specificity, antagonism of any one of those KIRs may be sufficient to mount 
an antiviral response.  Therefore increased expression of HLA-Gsp may represent an attempted 
protective host response in viral infection.  
 
Immunogenetic analyses have revealed that polymorphism in KIR genes and their HLA-C ligands 
may offer protection against chronic HCV infection (Khakoo et al., 2004; Romero et al., 2008).  
Individuals homozygous for KIR2DL3 and its HLA-C1 group of ligands are less likely to develop 
chronic infection following exposure to HCV. The protective effect of this gene combination may be 
due to KIR2DL3 binding HLA-C1 ligands with a lower avidity than other inhibitory KIR, thereby 
reducing the threshold for activation for NK cells that express this specific inhibitory receptor (Fadda 
et al., 2010; Moesta et al., 2008). Screening of our immunogenetic dataset of individuals exposed to 
HCV demonstrates no effect of the classical MHC class I leader sequences predicted to bind HLA-
E/CD94:NKG2A and the primary outcome of HCV infection.  This contrasts to KIR in which KIR2DL3 
in combination with its HLA-C ligand is protective (Knapp et al., 2010).  Thus at least for HCV, 
consistent with our in vitro data there is in vivo evidence for HCV being better adapted to 
CD94:NKG2A than to KIR. 
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We further analysed our data set HLA-C alleles for their predicted binding to HLA-Gsp.  We 
hypothesised that individuals with a greater number of HLA-Gsp binding alleles would be protected 
from chronic HCV infection as HLA-G upregulation in these individuals may result in HLA-Gsp 
functioning as an antagonistic peptide at HLA-C.  Although HLA-Cw*0102 binds strongly to HLA-Gsp, 
this is not true for the majority of HLA-C alleles which are predicted to be weak binders.  This may 
explain why no significant difference was observed between chronic HCV and spontaneous resolvers 
in the number of HLA-C alleles predicted to bind HLA-Gsp.  HLA-Cw*0102 is predicted to bind all 
classical MHC class I leader peptides. However, other HLA-C alleles vary in their ability to bind these 
leader peptides.  We speculated that individuals who possess a greater number of MHC class I leader 
sequences that bind to their HLA-C alleles may be more susceptible to chronic HCV infection as their 
NK cells would be more inhibited compared to those with fewer binders.  Paradoxical to our model, 
individuals with greater numbers of HLA-A, -B and -C leader peptides predicted to bind to their HLA-C 
molecules are over-represented in the spontaneous resolver group compared to those with chronic 
HCV infection.  Furthermore, this protective effect is restricted to individuals encoding an appropriate 
inhibitory KIR receptor for their HLA-C group of ligands, and also to those individuals homozygous for 
HLA-C1 alleles.  There are various possible explanations for this observation.  The HLA-C1 group of 
alleles are more likely to bind HLA–A,-B and -C leader peptides than the HLA-C2 group (Appendix 
Figure 9.3.), therefore there may be a greater expression of HLA-C1 than HLA-C2 during NK cell 
development.  NK cells necessitate interaction of inhibitory receptors with HLA-class I molecules 
during development to achieve functional status, otherwise known as “licensing” (Kim et al., 2005).  It 
is possible that the quantity of cell surface HLA-C influences NK cell licensing, and therefore 
influences HCV outcome through factors pertaining to NK cell education.  An alternative explanation 
is that HLA-A, -B and -C alleles function as altered peptide ligands at CD158b.  In our experiments 
presented in Chapter 3, although HLA-A2sp and B7sp bind HLA-Cw*0102, the resulting complexes 
have lower affinity for CD158b
+
 NK cells than VAP-FA peptide and could therefore behave as weak 
inhibitors.  
 
Differences in the stoichiometry of CD94:NKG2A and KIR mediated inhibition of NK cells was also 
assessed.  Our assessment of CD94:NKG2A inhibition relative to MHC class I expression implies that 
NKG2A
+
 NK cells are more easily modulated at low levels of HLA-E expression. Accordingly subtle 
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alterations in HLA-E expression result in a greater change in the fraction of responding NK cells when 
cell surface levels of HLA-E are low, than when they are high.  This is different to inhibition by KIR in 
which the stoichiometry is linear across the tested range, which in our experiments reflect 
endogenous MHC levels.  We therefore propose that NK cells expressing the NKG2A receptor 
respond efficiently to changes in the quantity of cell surface MHC class I expression, but not peptide, 
and those expressing KIR respond more efficiently to alterations in peptide repertoire.   
Thus there are fundamental differences in the way in which the KIR and the NKG2A systems respond 
to changes in the peptide content of MHC class I.  Modification of the peptide repertoire of HLA-E can 
favour inhibition of NKG2A
+
 NK cells through a mechanism of synergy, but peptide repertoire changes 
at HLA-C favour activation of KIR
+
 NK cells.  This difference is related to the ability of CD94 to bind to 
HLA-E:peptide complexes in the absence of the inhibitory signalling moiety NKG2A. Viruses can 
therefore exploit the tolerance of the HLA-E:CD94:NKG2A system, by generating HLA-E binding 
peptides to enhance inhibition of NKG2A
+
 NK cells. The evolution of additional receptor families, 
either KIR or Ly49, provides the host with a second inhibitory receptor family for MHC class I.  Peptide 
antagonism is a mechanism by which KIR
+
 NK cell can respond efficiently to changes in peptide 
repertoire and consequently provide the host with selective advantage over the NKG2A system 
(Fadda et al., 2010).  Indeed NKG2A
+
, but not KIR2DL2/3
+
 (CD158b
+
) NK cells are inhibited by the 
naturally occurring HCV variant YLLPRRGPKL, and so for this specific peptide there is evidence for 
host benefit of the KIR over the CD94:NKG2A system. 
Most species tested to date have two distinct inhibitory receptor systems for MHC class I, one of 
which is CD94:NKG2A.   In primates there has been an expansion of the KIR locus which is under 
strong positive selection. The fundamental differences in response to changes in MHC class I level or 
bound peptide between these two receptor:ligand systems provides a rationale for their maintenance 
in extant species. 
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Chapter 6.Final Discussion 
 
NK cells are a pivotal component of the innate immune response, monitoring and defending cells from 
viruses and tumorigenesis.  Their protective role in viral infection is highlighted by reported cases of 
NK cell deficiency, where viruses that normally cause mild disease instead result in severe and life-
threatening illness (Biron et al., 1999).  NK cell functions include cytotoxicity and the production of 
cytokines, which can regulate downstream innate and acquired immune responses in addition to 
having a direct effect on target cells. 
 
NK cell activity is regulated by the integration of signals derived from a repertoire of activating and 
inhibitory cell receptors.  As activating ligands are frequently expressed on healthy cells, to prevent 
autoreactivity NK cells receive a dominant inhibitory signal from receptors for MHC class I.  These 
MHC class I specific receptors include the KIR family and CD94:NKG2A.  Inhibitory KIRs bind 
polymorphic HLA-A, -B and –C molecules, with both receptor and ligands showing huge diversity.  
The consequences of KIR/ HLA diversity are still being unravelled, but we now understand that 
certain polymorphisms may influence the outcome of HIV and HCV infection, autoimmune disease 
and neoplasia (Carrington et al., 2005; Khakoo et al., 2004; Martin et al., 2002; Martin et al., 2007; 
Nelson et al., 2004).   
 
KIR receptors are a rapidly evolving, with a diversified family of receptors present in simian primates.  
Human KIR genes can be divided into two haplotypes which are present in all human populations, 
suggesting they are maintained by balancing selection (Parham and Moffett, 2013).   Hapotype A 
contains almost exclusively inhibitory KIR, compared to haplotype B which has several activating KIR 
receptors.  Activating KIR may be essential in the successful outcome of pregnancy, but KIR2DL3, 
belonging to haplotype A, has been shown to be protective against chronic viral infection (Khakoo et 
al., 2004).  
 
In contrast to KIR/ HLA-A, B and –C, CD94:NKG2A and its ligand HLA-E have been highly conserved 
throughout evolution.  The fact that CD94:NKG2A has persisted following the generation of a new 
family of MHC class I specific NK cell receptors suggests that this system offers complementary 
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functions to KIR.  As KIR and their MHC class I ligands are highly polymorphic and segregate on 
different chromosomes it is possible that an individual may lack an inhibitory receptor-ligand 
interaction, which could impact on NK cell education subsequent function.  HLA-E is found 
constitutively on the surface of healthy cells but this expression requires the presence of a peptide 
derived from proteosomal processing of the highly conserved leader sequence of certain MHC-A, -B 
and –C molecules, and HLA-G (Braud et al., 1998).  NK cells can therefore utilise CD94:NKG2A/ 
HLA-E interaction to observe the presence of polymorphic MHC class I molecules and, as a surrogate 
marker, the cell capacity to process and present these peptides.   
 
The crucial role of NK cells in protecting against viruses is further illustrated by the numerous 
mechanisms employed by viruses to evade NK cells (Orange et al., 2002).  Human CMV (HCMV) 
encodes for the UL18 protein, a homolog of MHC class I which is capable of binding to β2m and 
inhibiting NK cells through the LILRB1 receptor (Chapman et al., 1999; Cosman et al., 1997; 
Prod'homme et al., 2007).  Viruses can escape CTL detection by encoding for proteins that inhibit 
target cell expression of HLA-A and HLA-B, but by selectively preserving expression of HLA-C and 
HLA-E they can also suppress the activity of the majority of NK cells through engagement of 
CD94:NKG2A and KIR, respectively (Bonaparte and Barker, 2004; Cohen et al., 1999; Williams et al., 
2002).  Several viruses have been shown to encode for peptides that increase expression of HLA-E 
(Nattermann et al., 2005a; Nattermann et al., 2005b; Tomasec et al., 2000; Ulbrecht et al., 2000; 
Ulbrecht et al., 1998).   This led us to investigate the effect of HLA-E binding viral and host peptides 
on NK cell activity, and whether these peptides also interacted with HLA-C/ KIR. 
 
Consistent with published observations, we confirmed that peptide sequences encoded by HCV (HCV 
core35-44 and its variant HCV coreR9K), HIV (HIV p2414-22), EBV (EBV bzlf38-47), and the host encoded 
stress protein hsp60 derived peptide (hsp60sp) all bound to HLA-E, enhancing its cell surface 
expression on an MHC class I deficient cell line.  However, all of these peptides, along with the MHC 
class I derived signal peptides HLA-Gsp, HLA-A2sp and HLA-B7sp also bound to HLA-Cw*0102. 
 
In single peptide degranulation (CD107a) assays we observed that HCV core35-44, a HLA-A2 restricted 
T cell epitope, protected target cells from NK cell degranulation.  Blocking antibodies showed that this 
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effect was mediated by interaction between KIR2DL2/2DL3 (CD158b) receptors and HLA-C/ HCV 
core 35-44.  None of our other HLA-Cw*0102 binding viral peptides inhibited the CD158b
+ 
population, 
including, HCV coreR9K, the only known variant of HCV core 35-44, containing a lysine for arginine 
substitution at P9 (Nattermann et al., 2005a).  KIR mediated recognition of HLA-C is influenced by 
residues 7 and 8 of nonameric peptides (Fadda et al., 2010; Rajagopalan and Long, 1997).  Being a 
decamer, HCV core35-44 may have a slightly different conformation in the peptide binding groove such 
that lysine substitution at position 9 is not tolerated by CD158b
+
 NK cells. 
 
Binding of CD94:NKG2A to HLA-E is also sensitive to the nature of the bound peptide (Michaelsson 
et al., 2002).  CD94:NKG2A usually recognises HLA-E containing MHC class I derived signal peptides 
(MHC-Isp) leading to NK cell inhibition, which we confirmed in our degranulation assays using HLA-
A2sp, HLA-B7sp and HLA-Gsp.  Despite binding to HLA-E, none of our viral peptides or hsp60sp induced 
inhibition of the NKG2A
+
 NK cell population in single peptide experiments.  However, when target 
cells were loaded with both MHC-Isp and either viral peptide or hsp60sp, we observed an increase in 
NKG2A
+
 cell inhibition compared to inhibition produced with MHC-Isp alone.  We have termed this 
observation peptide synergy.  Confocal microscopy suggests that HLA-E bound synergistic peptides 
(HCV core35-44, HIV p2414-22, EBV bzlf38-47 and hsp60sp) stimulate the recruitment of CD94 to the 
immune synapse, in the absence of NKG2A.  This is in contrast to HLA-E bound to MHC-Isp that 
induce aggregation of both subunits.  In the next part of this chapter we speculate on how CD94 
recruitment, likely to be in the form of homodimers, may enhance inhibition at NKG2A.   
 
 
Ligation of CD94:NKG2A by HLA-E containing MHC-Isp triggers the phosphorylation of tyrosine 
residues within each of the two ITIM motifs attached to the cytoplasmic tail of NKG2A.  This permits 
the recruitment of src homology 2 domain bearing tyrosine phosphatases (SHP)-1 and/or SHP-2 
(Borrego et al., 2006; Kabat et al., 2002).  Following activation, these phosphatases dephosphorylate 
the Vav guanine nucleotide exchange factor and ERM (erzin/ radixin/ moesin) family proteins leading 
to actin cytoskeletal rearrangements which in turn disrupts activation signalling (Borrego et al., 2005; 
Masilamani et al., 2006).  In contrast to NKG2D and many other receptors which are down-regulated 
upon ligand binding, CD94:NKG2A is continuously renewed at the cell surface (Groh et al., 2002; 
Maxfield and McGraw, 2004).  Given that HLA-E is expressed constitutively on healthy cells this 
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constant recycling of CD94:NKG2A may serve to guarding against autoreactivity by maintaining a 
dominant inhibitory signal. To achieve continuous expression at the cell surface despite binding to 
HLA-E, it has been demonstrated that CD94:NKG2A utilises an uncommon means of endocytosis, 
termed pinocytosis, which is associated with rapid recycling to the cell surface (Masilamani et al., 
2008).  CD94:NKG2A receptor trafficking has been shown to be independent of ligand ligation 
(Borrego et al., 2002). 
 
In the absence of HLA-E, CD94:NKG2A receptors are evenly distributed and free to diffuse along the 
plasma membrane.  On interaction with a target cell bearing HLA-E bound to a MHC class I derived 
signal peptide, CD94 and NKG2A accumulate at the contact site between NK cell and target cell, 
termed the immune synapse, as supported by our microscopy findings.  This localisation of receptors 
to the immune synapse is similar to that observed for inhibitory KIR
+
 NK cells incubated with HLA-C 
bearing target cells (Davis et al., 1999; Fadda et al., 2010).  Using a fluorescent imaging method, 
Sanni et al. demonstrate that the mobility of GFP tagged CD94:NKG2A away from the immune 
synapse is markedly reduced following receptor binding to HLA-E (Sanni et al., 2004).   
 
The reduced mobility of inhibitory NK cell receptors at the immune synapse may be a more complex 
process than passive binding of MHC class I, as suggested by studies looking at KIR2DL2/ HLA-Cw3 
interaction.  It has been shown that KIR/ HLA clustering is in the formation of a doughnut surrounding 
a central cluster of adhesion molecules such as LFA-1 and ICAM-1 (Davis et al., 1999).  The crystal 
structure of KIR/ HLA interaction demonstrates a 1:1 stoichiometry (Boyington et al., 2000a).  
Boyington and Sun proposed models for how this doughnut is formed at the immune synapse, 
centred on KIR/ HLA receptor oligomerisation (Boyington and Sun, 2002).  The first model proposes 
that D1 domain of one receptor interacts with D2 domain of the neighbouring receptor, as observed in 
the crystal structure analysis of KIR2DL2/ HLA-Cw3 complex, leading to receptor oligormisation and 
aggregation (Snyder et al., 1999).  The second oligomerisation form was also observed in the crystal 
structure of the KIR2DL2/HLA-Cw3 complex (Boyington et al., 2000a). Apart from the functional 
interface with HLA-C, each KIR molecule within the crystal lattice makes a Van der Waals interaction, 
with a symmetry related HLA-C molecule in a peptide independent manner.  The resulting oligmer 
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maintains a 1:1 receptor ligand stoichiometry while maintaining the same orientation for all the KIR/ 
HLA complexes. 
 
Thus, in addition to accumulating at the immune synapse, inhibitory NK cell receptors may need to be 
tightly clustered to achieve an inhibitory signal.  This model could be used to explain augmented 
inhibition at NKG2A induced by certain synergistic peptides (Figure 6.1).  At low concentrations (1 
μM) of MHC-class Isp there may be insufficient HLA-E expression to achieve sufficient CD94:NKG2A 
immobilisation at the immune synapse, leading to a relatively weak inhibitory signal.   Synergistic 
peptides induce upregulation of HLA-E; however, they may permit recruitment and immobilisation of 
CD94 (in the form of homodimers) but not NKG2A.  As CD94 does not possess a signalling motif, 
these homodimers alone would be of no functional significance.  Though when synergistic peptides 
are mixed with low concentration MHC-class Isp the recruitment of additional CD94 complexes may 
lead to multimerisation with CD94:NKG2A aggregates.  The resulting immobilisation of CD94:NKG2A/ 
HLA-E/ MHC class Isp enhances the inhibitory signal generated through NKG2A subunits.  
Furthermore, this effect would be dose related as increased concentrations HLA-E-bound synergistic 
peptide would promote the recruitment of further CD94 homodimers leading to stabilisation of the 
NKG2A-containing oligomeric complex.  At high concentrations of MHC class Isp there is already 
sufficient cross linking of CD94:NKG2A due to an abundance of HLA-E, therefore additional CD94 
complexes in the form of synergistic peptide induced CD94 homodimers may not further augment the 
inhibitory signal.   
 
In our model, two potential aggregate interfaces for CD94 are possible, either between adjacent HLA-
E molecules, or between adjacent CD94/NKG2A moieties.  An aggregation interface independent of 
HLA-E could theoretically limit lateral movement of receptor subunits within the plasma membrane of 
resting NK cells, thereby impairing polarisation of CD94:NKG2A during formation of the immune 
synapse.  Therefore the alternative theory that the ligand HLA-E plays a part in oligomerisation may 
be more attractive, as has been postulated for KIR.  
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Figure 6.1. A model for how CD94 homodimers may augment inhibition at NKG2A 
The three cartoons depict the interface between NK and target cell.  (a) In the presence of a target 
cell bearing HLA-E containing a permissive MHC-I signal peptide (MHC-Isp), there is accumulation of 
CD94:NKG2A heterodimers at the immune synapse.  This functional interface triggers ITIMs in the tail 
of NKG2A mediating NK cell inhibition.  An oligomeric aggregate of CD94:NKG2A is formed with 
CD94 interacting with either neighbouring HLA-E in a peptide independent manner (aggregate 
interface 1), or the adjacent receptor (aggregation interface 2).  (b) HLA-E bound synergistic peptides 
permit recruitment of CD94 but not NKG2A, leading to aggregation of non-inhibitory CD94 
homodimers. (c) In the presence of both MHC-Isp and synergistic peptide there is accumulation of 
functional CD94:NKG2A.  The additional CD94 homodimer/ HLA-E interaction may facilitate 
multimerisation of receptor complexes at the synapse through either aggregation interface 1 or 2.  
This would ultimately lead to immobilisation of CD94:NKG2A and augmented inhibition.  
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The oligomerisation model may also explain why synergy mediated by HLA-E binding peptides is 
specific to NKG2A
+
 cells, and not observed at KIR.  HLA-A2sp and HLA-B7sp also bind to HLA-
Cw*0102, inducing inhibition at KIR2DL2/2DL3.  Synergistic peptides (other than HCV core35-44 and 
hsp60sp which bind HLA-Cw*0102 inducing inhibition at KIR2DL2/2DL3) do not augment inhibition at 
KIR2DL2/2DL3.  In this instance, the additional CD94 complexes recruited by the synergistic peptide 
may be unable to interact with KIR therefore immobilisation is not enhanced and no synergistic 
inhibition is observed at this receptor group.  Alternatively, it is possible the failure of synergy at KIR 
may have been due to the low concentration of MHC class I signal peptide used.  MHC-Isp have a low 
affinity for HLA-Cw*0102, with 1 µM peptide insufficient to inhibit at KIR2DL2/2DL3.  To exclude an 
effect at KIR, further assays looking at CD158b
+
 NK cell-inhibiting concentrations of MHC-Isp in the 
presence or absence of synergistic peptides could be performed. 
 
This is not the first description of non-signalling NK cell receptors augmenting inhibition at other co-
expressed NK receptors.   Kirwan and Burshtyn demonstrated that ITIM-deficient KIR can inhibit at 
ILT-2 (LILRB-1) receptors in a mechanism that is dependent on KIR/ HLA-C interaction (Kirwan and 
Burshtyn, 2005).   Using blocking antibodies, they show that the inhibitory effect mediated by ITIM 
deficient KIR requires the interaction between the relatively conserved α3 domain of MHC-class I and 
LILRB-1.  Synergistic inhibition observed at CD94:NKG2A is independent of LILRB-1, as shown in our 
experiments using blocking antibodies.  The discrepancy may be related to the fact that LILRB-1 does 
not bind HLA-E, whereas is shares ligands with KIR, binding a broad range of MHC class I ligands, 
including HLA-A, -B, C and HLA-G (Chapman et al., 1999; Cosman et al., 1997; Fanger et al., 1998; 
Shiroishi et al., 2003).  Therefore ITIM-deficient KIR may induce aggregation of MHC-class I enabling 
engagement with LILRB-1 contributing to receptor oligomerisation.   
 
. 
Antagonism at KIR offers a discrepancy with our model, suggesting there may be a difference 
between how these two receptor systems operate.  It has been shown that two variants of the TIMP-1 
peptide, VAP-FA (VAPWNSFAL) and VAP-DA (VAPWNSDAL) both upregulate HLA-Cw*0102 
expression on MHC deficient target cells.  However, whereas HLA-Cw*0102VAP-FA inhibits at CD158b, 
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HLA-Cw*0102VAP-DA does not.  Although HLA-Cw*0102VAP-DA does not induce inhibition of KIR
+
 NK 
cells, imaging studies show that it still promotes KIR clustering at the immune synapse comparable to 
HLA-Cw*0102VAP-FA.  However, when VAP-DA is mixed VAP-FA, it interferes with VAP-FA mediated 
inhibition at CD158b, termed peptide antagonism.  Therefore, in the case of these particular peptides, 
the additional KIR/HLA-C complexes induced by VAP-DA do not augment the inhibitory effect at KIR.  
This would suggest that the receptor oligomerisation model for inhibition does not apply to all 
situations.  This could pertain to downstream differences beyond extracellular receptor 
oligomerisation.  It has been demonstrated that HLA-Cw*0102VAP-DA induces KIR recruitment of SHP-1 
but fails to induce an inhibitory signal (Borhis et al., 2013; Fadda et al., 2010).  However, in peptide 
mix conditions, HLA-Cw*0102VAP-DA may uncouple inhibitory signalling induced HLA-Cw*0102VAP-FA by 
competing for SHP-1 recruitment, leading to an antagonistic effect.  As CD94 homodimers do not 
possess and intracellular domain, such downstream effects may not be relevant. 
 
In our study, HLA-Gsp increased cell surface HLA-Cw*0102 without inducing inhibition at CD158b
+
 NK 
cells.  In peptide mix experiments, HLA-Gsp was able to relieve CD158b
+
 NK cell inhibition mediated 
by HCV core35-44.  Thus, this pair of peptides which synergise to inhibit NK cells at CD94:NKG2A have 
contrasting interactions at KIR, where antagonism may serve to activate NK cells.  HLA-G has 
recently been found to be upregulated in chronic HCV, where it is associated with lower 
necroinflammatory scores (de Oliveira Crispim et al., 2012).  Additionally, in a high risk population, 
polymorphisms associated with potentially higher levels of HLA-G are found more frequently in 
exposed uninfected individuals compared to those with chronic HCV (Cordero et al., 2009).  This may 
be surprising given that HLA-G is regarded to promote NK cell tolerance, through interaction with 
LILRB-1.  We propose that HLA-Gsp, a by-product of HLA-G expression, could contribute to this 
protective effect and represent a protective host response to viral infection.  Increased HLA-Gsp 
expression could activate CD158b
+
 NK cells by functioning as an altered peptide ligand leading to 
antagonism of other HLA-Cw*0102 bound peptides.   
 
While this may represent a plausible mechanism, as with all of our peptide work, one must consider 
peptide abundance and affinity.  Antagonism of HCV core35-44 mediated inhibition required relatively 
high (>25 μM) concentrations of HLA-Gsp.  In our assays, we used external peptide loading of an 
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MHC deficient cell line.  It is possible that the intracellular loading pathway is more efficient at 
presenting peptides and therefore requires smaller quantities.  This could be assessed by measuring 
HLA-Cw*0102 expression in cell line transfected with HLA-G and HLA-Cw*0102.  Furthermore, HLA-
Gsp appears to have lower affinity for HLA-Cw*0102 than TIMP-1 derived peptides (TIMP-1 being the 
most abundant indentified peptide eluted from HLA-Cw*0102 expressing 721.221 cells) (Barber et al., 
1996; Fadda et al., 2010).  The same reasoning may be applied to HLA-E bound peptides.  It is 
possible that abundance of MHC-Isp may limit the range of peptides presented by HLA-E.  This may 
be true under physiological conditions; however, in cases of viral infection downregulation of MHC-
class I, particularly –A and –B, have been described.  In our MHC class I stabilisation assays, HLA-
B7sp and HLA-A2sp have a higher affinity for HLA-E compared to our virus derived peptides and 
hsp60sp.  Down-regulation of these MHC class I molecules may enable HLA-E to bind and present 
peptides derived from other sources.  Indeed, cell surface HLA-E expression has been demonstrated 
to be increased on hepatocytes that are HCV core positive compared to those that are HCV core 
negative, and is also upregulated on lymphocytes that are HIV p24 positive compared to those that 
are HIV p24 negative (Nattermann et al., 2005a; Nattermann et al., 2005b).  To establish the 
physiological relevance of our findings, future experiments looking at cells transfected with various 
viruses could be performed. 
 
Our finding that viral peptides can synergise with endogenous peptides to increase inhibition is novel 
and has implications for viral evasion.  Based on our experiments, one could speculate that viruses 
may be better adapted to escape CD94:NKG2A mediated surveillance.  Given that changes in 
peptide repertoire at HLA/ KIR can favour activation of NK cells, this system may offer a selective 
advantage in fighting infection.  This theory if further supported by our finding that MHC class I 
polymorphisms that could affect peptide repertoires of HLA-C influence the outcome of HCV infection, 
whereas those that affect HLA-E/ CD94:NKG2A do not. This would lend support to current opinion 
that the evolution of KIR/HLA is driven by pathogen mediated selection. 
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Chapter 7. Conclusion 
 
In this thesis, we have examined the peptide selectivity of inhibitory NK cell receptors that interact 
with MHC class I to regulate NK cell activity.  Using a TAP-deficient cell line we have loaded 
exogenous peptides to enhance cell surface MHC class I expression.  Certain non-inhibitory viral and 
host derived peptides that bind HLA-E can synergise to inhibit NKG2A
+
 NK cells when combined with 
an inhibitory self-peptide.  Confocal microscopy showed these synergistic peptides promote the 
selective recruitment and clustering of CD94, but not NKG2A at the immune synapse in both an NKL 
cell line and primary NK cells.  Using a CD94 transfected/ NKG2A negative cell line we confirmed that 
HLA-E bound synergistic peptides induce clustering of CD94.   Although synergy is seen for several 
peptides, there remain features of peptide selectivity.  Position 5 lysine substitution abrogated the 
synergistic effect of these peptides in degranulation assays, accompanied by a loss of CD94 
clustering.    
These findings provide new insight into the participation of HLA-E-binding peptides to CD94-mediated 
inhibition of NK cells.  Although cell surface CD94 homodimers have previously been described, no 
biological role independent of NKG2 molecules has been identified.  This study reveals a novel 
mechanism for NK cell regulation by demonstrating that in the absence of direct signalling capacity, 
CD94 molecules can contribute to the inhibition of NKG2A
+
 cells.  CD94:NKG2A is upregulated in 
several viral infections, such as HIV and HCV.  Therefore, viruses could be better adapted evade NK 
cells through this receptor ligand system. 
 
Important directions for future studies would aim to determine the biological relevance of our findings.  
Cell lines could be transfected with HLA-E, along with HCV core and other MHC class I, to determine 
whether peptide synergy occurs in an endogenous peptide loading model.  All of the PBMC/ primary 
NK cell experiments presented in this thesis were derived from uninfected (healthy control) donors.  It 
would be interesting to investigate how NK cells from individuals with chronic HCV compare to healthy 
control NK cells in their response to peptide combinations.  The higher level of CD94:NKG2A found 
on HCV-NK cells may mean that they are calibrated differently.  These experiments could lead to 
greater understanding of how viruses can modulate NK cell activity.     
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Chapter 9.  Appendix 
 
 
 
 
 
 
Figure 9.1. Predicated bindng of HLA-Gsp peptide to HLA-C alleles  
HLA-Gsp (VMAPRTLFL) was assigned either a positive (lighter green boxes)  or negative (darker 
green boxes)  binding potential for binding to each individual HLA-C allele according to the 
NetMHCpan prediction tool (Hoof et al., 2009).  nM IC 50 binding  affinities shown for binders. 
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Figure 9.3. Comparison between the number of HLA-C1 and HLA-C2 group alleles predicted to 
bind MHC class I signal peptides 
Data derived from Figure 9.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
